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Idiopathic pulmonary fibrosis (IPF) is a severe lung disease with a poor survival 
rate and it currently has no known cure. In this thesis, the signs and symptoms, diagnosis 
and epidemiology of IPF are discussed. Existing therapies for IPF are highlighted herein 
as well as new small molecule targets such as acylidene oxindoles, isatins and natural 
products such as febrifugine. These novel compounds can potentially be used for 
polypharmacology approaches for IPF treatment. 
The preparation of isatin analogues has been explored with the motivation to 
screen them as potential treatments for IPF. Several types of biological and 
pharmacological activities are also associated with isatin derivatives which highlight their 
potential as novel drugs for the treatment of a number of diseases. Various methods for 
the synthesis of isatin have been reported which include early protocols involving aniline 
derivatives, the oxidation of indole, as well as more modern procedures employing 
transition metal catalysis. Previously reported strategies suffer from many disadvantages 
such as low yielding multi-step approaches and use of harsh conditions and toxic 
reagents which warrants a novel and much improved strategy. 
In this research, a palladium-catalyzed cyclization of o-alkynylnitrobenzenes has 
been employed for the synthesis of different isatin analogues. An alternative strategy 
was developed in which a copper-catalyzed cycloisomerization of o-
alkynylnitrobenzenes afforded 2-iodoisatogens in good yields. The corresponding isatins 
were then obtained via the reduction of the novel 2-iodoisatogens in a very efficient 
manner. In addition, alternative nitrogen-containing heterocycles have been prepared 
from 2-iodoisatogens to demonstrate the versatility of these substrates. 
Finally, the preparation of febrifugine analogues has been explored with the 
incentive to identify polypharmacological mixtures of molecules which could potentially 
be combined into a single molecule. Using the reported model for the binding of 
febrifugine with its target receptor site, different analogues were designed to interrogate 
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Chapter 1: Idiopathic Pulmonary Fibrosis 
Introduction 
Idiopathic Pulmonary Fibrosis (IPF), also known as cryptogenic fibrosing 
alveolitis (CFA) is a clinical disease that belongs to a group of acute and chronic lung 
disorders referred to as interstitial lung diseases (ILDs). These interstitial pneumonias 
have varying degrees of pulmonary inflammation and scarring of lung tissue and IPF is 
one of a few cases where the origin of the disease is unknown, hence it is referred to as 
‘idiopathic’. Whilst major progress has been achieved over the past few years in our 
understanding of the pathogenesis of lung fibrosis, the diagnosis and treatment of 
patients with IPF remain significantly challenging and the cure for IPF continues to evade 
researchers. Hence, in 1999 a joint effort by the American Thoracic Society (ATS), 
European Respiratory Society (ERS) and the American College of Chest Physicians 
(ACCP), resulted to an international consensus statement to define the epidemiology, 
diagnosis and management of IPF.1  
According to the released statement, the definition of IPF is the chronic scarring 
of lung tissue in the interstitium which refers to the collection of support tissues within 
the lung surrounding the air sacs. Upon lung biopsy, a characteristic histopathological 
appearance of usual interstitial pneumonia (UIP) will be observed, although the etiology 
or cause remains unknown. IPF can only be diagnosed if UIP is evident from a high 
resolution CT scan or surgical lung biopsy and all the other known causes of interstitial 
lung diseases have been excluded. This includes usual recognised causes such as drug 
induced toxicities, environmental exposure to substances (e.g. asbestos) and finally, 
connective tissue disease.1 
Common signs and symptoms associated with IPF include progressive exertional 
dyspnea which is shortness of breath when physically active. A persistent, dry and non-
productive cough is observed in patients and there is an increased risk of developing 




sound of Velcro being torn apart slowly is also characteristic and is used for the early 
diagnosis of IPF. Finally, chronic deficiency of oxygen in the blood may also lead to 
thickening and hardening of tissue at the base of finger and toe nails which causes 
disfigurement or clubbing of the digits.2  
Patients diagnosed with IPF tend to be over the age of 50 although this is not a 
major criterion for diagnosis. Studies show that IPF is more prevalent with males than 
females and is more common with middle aged patients than children where diagnosis 
is very rare. In terms of geographical location or ethnicity, there is no general trend 
although variation is manifested by occupational or environmental exposures. The 
mortality rate for IPF is estimated to be 5-7 per 100,000 people and the length of survival 
from the time of diagnosis is 3-5 years.1 
 
Current Treatments 
The scarring of the lung tissue referred to as fibrosis is as a result of the 
production of fibroblasts going out of control as the body’s response to repair damaged 
and inflamed alveolar epithelial cells. Since the cause of the initial inflammation is not 
known to begin with, strategies to treat IPF have been based on supressing the 
inflammation since there is currently no evidence that the fibrotic process can be 
reversed.3 Realistically, existing treatments for IPF only involve reducing the symptoms, 
preventing acute exacerbations and essentially prolonging survival. Nonetheless, a few 
existing anti-inflammatory and antifibrotic drugs have been used for therapy over the 
years.  
Initially, corticosteroids such as Prednisolone have been considered for therapy 
due to their anti-inflammatory effects but studies carried out as recently as 2010 have 
revealed that they have no beneficial effects in patients with IPF.4 Similarly, the initial 
potential of immunosuppressant drugs such as Azathioprine and Cyclophosphamide to 




acetylcysteine have also been studied based on the hypothesis that oxidant-induced 
epithelial cell injury could be repaired but placebo-controlled studies conducted in 2014 
revealed “no significant benefit”.5 Moreover, Etanercept, which is a type of antagonist for 
Tumour Necrosis Factor (TNF), has been used as an anti-inflammatory for arthritis and 
psoriasis but proved to be ineffective for IPF treatment.4  
Anticoagulants such as Warfarin and Heparin have been tested to determine 
whether anticoagulant therapy with Prednisolone increases survival time of IPF patients 
but the trials had to be terminated due to increased mortality rates during the study.6 
Bosentan, a dual antagonist of endothelin 1A and B receptors, was also tested due to its 
known effectiveness in treating pulmonary artery hypertension but proved to be 
ineffective for IPF treatment.7 A phosphodiesterase-5 inhibitor, Sildenafil, was 
hypothesised to improve gas exchange and reduce shortness of breath with IPF patients 
due to its ability to induce pulmonary vasodilation but again, showed negative results.8 
Moreover, Imatinib mesylate, which is a tyrosine kinase inhibitor demonstrated good 




Nintedanib 1, another tyrosine kinase inhibitor, targets vascular endothelial 
growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet 
derived growth factor receptor (PDGFR). Formerly known as BIBF 1120, it was a clinical 
candidate for the treatment of nonsmall cell lung cancer alongside a similar analogue 
named BIBF 1000.10 Nintedanib is a 6-substituted indolinone and its synthesis has been 




inhibitors.11 Tyrosine kinases have previously been associated with the pathogenesis of 
IPF since they mediate fibroblast proliferation and differentiation therefore inhibitors such 
as Nintedanib are useful targets for IPF treatment.12 Preliminary tests with mouse models 
of lung fibrosis indicated antifibrotic and anti-inflammatory activity of Nintedanib as a 
result of reduced levels of cytokines in the lung tissue.12 Phase III clinical trials showed 
that there was a reduced decline in lung function in the Nintedanib group by around 50% 
compared to the placebo group which led to its approval by the FDA in 2014.12 
Initial studies have shown that Pirfenidone 2 demonstrates antifibrotic effects in 
animal models in addition to its anti-inflammatory and antioxidant properties. In these 
preliminary studies, it has been revealed that Pirfenidone inhibits transforming growth 
factor-β which is one of the several growth factors and cytokeins that initiate the migration 
and proliferation of fibroblasts.13 Two subsequent phase III clinical trials then showed 
that Pirfenidone reduced disease progression by significantly decreasing the decline in 
Forced Vital Capacity (FVC) which was associated with decreased mortality.14 This led 
to the drug being approved in Japan in 2008 but a third phase III clinical trial in 2011 
failed to demonstrate a reduction in the deterioration of lung function and the FDA 
required further studies before approval.15 In 2014, results of a randomized, double-blind, 
placebo-controlled trial were reported wherein 48% of the Pirfenidone group exhibited 
decrease in FVC decline compared to the placebo group. Although minor skin-related 
and gastrointestinal side-effects were reported with the Pirfenidone group, these seldom 
required treatment discontinuation therefore Pirfenidone was finally approved by the 
FDA for IPF treatment.16 
Other Potential Targets 
Various potential IPF treatments with different hypothesized mechanisms of 
action are still undergoing phase II or III clinical trials and results are expected by 2018. 
For instance, FG-3019 (FibroGen) is being investigated for its effectiveness in inhibiting 
Connective Tissue Growth Factor (CTGF) which plays roles in proliferation and 




Lysophosphatidic Acid Receptor-1 (LPA1) which is known to promote fibroblast 
migration and activation among other profibrotic effects.3 Finally, Simtuzumab is 
undergoing phase II trials to test inhibition of lysyl oxidase-like 2 (LOXL2) which is a 
promoter of myofibroblast differentiation that can lead to fibrosis progression.3 
Klock recently reported the new roles of 3-acylidene-2-oxindoles 3 as potential 
inhibitors of human transglutaminase 2 (TG2).17 TG2 is a multifunctional enzyme that 
has been implicated in the pathogenesis of multiple disorders including cystic fibrosis.18 
Moreover, Klock described the potential of isatin (indoline-2,3-dione) 4 as a candidate 
TG2 inhibitor due to the presence of the cyclic α-keto amide that could mimic the γ-
carboxamide moiety of TG2 inhibitors.17 Although TG2 has not been directly associated 
as a target for idiopathic pulmonary fibrosis, analogues of 3-acylidene-2-oxindoles and 
isatins could be interesting compounds to test for activity as potential IPF treatment. 
 
Figure 2 
Finally, febrifugine 5 and the related analogue halofuginone 6 have been primarily 
considered as treatments for malaria and they have been shown to target human prolyl-
transfer RNA synthetase (ProRS), an important enzyme for protein synthesis. 
Febrifugine and halofuginone have demonstrated potential therapeutic applications in 







Chapter 2: Synthesis of Azaisatins 
Introduction 
Isatin (1H-indole-2,3-dione) is an indole derivative discovered independently by 
Erdman19 and Laurent20 in 1841 via the oxidation of indigo dye with nitric acid or chromic 
acids. The ring system of isatin comprises a pyrrole fused with benzene and it contains 
both the keto and lactam moiety which is significant for its biological activity.21 In 1882, 
Baeyer distinguished two tautomers of isatin either as the lactam 4 or the lactim structure 
7 (Figure 4).22 At room temperature, isatin exists as a yellowish-red crystalline solid that 




In Nature, the compound exists in plants such as Isatis tinctoria (Asp of 
Jerusalem),23 in the orchid Calanthe discolour,24 and in Couroupita guianensis 
(Cannonball tree).25 Substituted isatins have also been found in plants and fungi such as 
the methoxy phenylpentyl isatins from Melochia tomentosa26 and the methylbutenyl 
isatins isolated from Streptomyces albus27 and Chaetomium globosum.28 Furthermore, 
isatin can be found in the animal kingdom as a component of the parotin gland secretion 
from some species of Bufo frogs.29 In addition, isatin has been found in humans as a 
metabolic derivative of adrenaline.30 
Isatin and its metabolites are components of naturally occurring substances and 
as endogenous compounds, they have a wide spectrum of behavioural and metabolic 
effects. In the human body, they have a variety of biological targets and they have 
potential roles as functional agonists or antagonists.31 As well as endogenous isatin, 




effects such as antimicrobial, antifungal, antiviral, anti-inflammatory, antidepressant and 
antianxiety. Moreover, the isatin moiety has been found in a range of compounds which 
are potential treatments for tuberculosis, HIV and cancer. 
Isatins are known to be synthetically versatile substrates utilized as starting 
materials for the synthesis of a broad range of heterocyclic compounds such as indoles 
and quinolones.21 In addition, the biological and pharmacological properties of some of 
their derivatives make them ideal substrates for the synthesis of potential new drugs. As 
a consequence of their synthetic versatility and their manifold significance in the field of 
medicinal chemistry, extensive research has been carried out to develop methods for the 
synthesis of this class of compound.21 Since classical methods suffer from a few 
limitations including multistep sequences, toxic reagents, low reaction scope and harsh 















Synthetic Routes to Isatin 
Early Methods 
A review, published in 1944, by Sumpter summarizes early methodologies for the 
synthesis of isatin from the late 19th century when it was first discovered, up until the 





In 1869, Kekule proposed that isatic acid was o-aminobenzoylformic acid and 
that the corresponding lactam was isatin, hence instigating the idea for the synthesis of 
isatin from o-aminophenylacetic acid 8 (Scheme 1).32 Over a decade later, Baeyer 
confirmed Kekule’s suggestion by synthesizing isatin from oxindole 9 which was in turn 
made via the reduction of o-nitrophenylacetic acid 10 (Scheme 2).33 Furthermore, 
Claisen and Shadwell reported the preparation of isatin from o-nitrobenzoyl chloride 11 
in 1879 which also confirmed Kekule’s suggested structure (Scheme 3).34 In 1884, Forrer 







Sandmeyer’s route, published in 1919, is commonly regarded as the oldest 
method for the synthesis of isatin.22 However, an earlier procedure by Sandmeyer was 
actually reported in 1903 which involves thiocarbanilide 12 as the starting material and 
isatin-α-anilide 13 as an intermediate (Scheme 4).36 A year later, Reissert developed a 
method which depends on heating thiooxanilide 14 with concentrated sulfuric acid 
(Scheme 5).37 Bauer also utilized sulfuric acid for his synthesis which involves substituted 





Heating o-hydroxylaminomandelonitrile 15 with hydrochloric acid was the basis 
for Heller’s synthesis of isatin in 1906 (Scheme 6).39 Succharda then obtained isatin-7-
sulfonic acid via the oxidation of quinoline-8-sulfonic acid with alkaline potassium 
permanganate.22 Burton and Stoves’ methodology in 1937 also used alkali for the 
reaction with the azalactones of certain o-nitrobenzaldehydes.40 Finally, in 1939, 







Sandmeyer’s second, more well-known methodology for the synthesis of isatin is 
the most frequently used and has been employed for nearly a whole century (Scheme 
7).21 First reported in 1919, it is based on the reaction of aniline 16 with chloral hydrate 
and hydroxylamine hydrochloride in the presence of aqueous sodium sulfate.42 The 
intermediate isonitrosoacetanilide 17 is then treated with concentrated sulfuric acid to 
afford isatin in yields usually greater than 75%. This method can be applied effectively 
with anilines containing electron-withdrawing substituents as well as a few heterocyclic 
amines such as 2-aminophenoxathine. 
 
Scheme 7 
Whilst this method is attractive from an economic point of view due to inexpensive 
and readily available starting materials, over the years a few modifications of the 
Sandmeyer route proved necessary. For example, in cases where the aniline starting 
material was insoluble using the conventional reaction conditions, ethanol was 
incorporated as a co-solvent.43 The usefulness of this modification is most evident in the 
synthesis of 4,6-dibromoisatin in which a 700% enhancement in yield over the existing 
procedure was reported. This particular isatin derivative is a key intermediate for the 
synthesis of the marine natural product convolutamydine A.44 Other significant 
modifications include using alternative reagents for the cyclization of the 
isonitrosoacetanilide other than concentrated sulfuric acid. Lackey’s synthesis of benzo-
oxygenated isatin derivatives as intermediates for the preparation of camptothecin 







Another difficulty associated with the Sandmeyer methodology is the 
ineffectiveness of this route with ortho-hydroxy or ortho-alkoxyanilines. A modified 
procedure was reported which involves reacting the alkoxyaniline 18 with chloroacetyl 
chloride followed by reaction with N,N-dimethyl-4-nitroaniline to eventually obtain the 
isonitroso-acetanilide 19 (Scheme 8).46 Cyclization is then conducted under the same 
conditions using concentrated sulfuric acid to afford the corresponding isatins in 87-99% 
yield.  Furthermore, meta-substituted anilines are known to yield two isomers, e.g. 3-
bromo-4-methoxyaniline 20 gives 6-bromo-5-methoxyisatin 21 and 4-bromo-5-
methoxyisatin 22 in a 2:1 ratio.47 Separating these two isomers involves conversion to 
the corresponding sodium isatinates followed by acidification of the reaction medium. 
Controlled acidification will result in the cyclization of the two isomers at different pH 
values hence generating the corresponding isatins at different rates as they precipitate 
from the reaction mixture (Scheme 9). Lastly, nitroacetanilides have also been employed 
in another modified strategy which involves cyclization using sulfuric acid or 
trifluoromethanesulfonic acid.48 The nitroacetanilides are obtained via the alkaline 








The use of chloral as a starting material in the Sandmeyer methodology can be 
problematic, and may lead to the formation of the extremely poisonous gas hydrogen 
cyanide. Goodwin first detected this colourless liquid via the formation of Prussian blue 
on addition of ferrous sulfate and sodium hydroxide to the reaction mixture.49 Gandy and 
Hill then reported a measured concentration of hydrogen cyanide in the mother liquors 
from the Sandmeyer reaction which was found to vary from 100 to 200 ppm.49  A 
proposed mechanism for the formation of HCN is the addition of water to the 




decompose to water and HCN (Scheme 11).50 Another reported mechanism is the 
decomposition of the nitrosoalkene via the formation of an oxazete 27 and subsequent 
retro-cyclization to yield carbonyl chloride and HCN (Scheme 12).51 It is, therefore, highly 
recommended to take reasonable precautions when using the Sandmeyer procedure in 






A convenient methodology for the preparation of isatin derivatives was reported 
by Stolle and is regarded as the most important alternative to Sandmeyer’s route. This 
synthesis involves the treatment of N-substituted anilines 28 with oxalyl chlorides 
resulting in a chlorooxalylanilide intermediate 29 which cyclizes to the isatin by treatment 
with anhydrous aluminium chloride (Scheme 13).52 Other Lewis acids have also been 
employed in this reaction such as boron trifluoride diethyl ether complex53 and titanium 
tetrachloride.54 In some cases, spontaneous cyclization has also been observed in the 
absence of a Lewis acid; for example in the reaction of 2,3-dimethoxyaniline to afford the 
2,3-dimethoxyisatin, albeit this transformation occurs in a diminished yield.26 Using 
Stolle’s method, the synthesis of polycyclic isatins has been accomplished from 
phenoxazine 30, phenothiazine 32 and dibenzazepine 34 as reported by Silva.55 
Furthermore, Welstead has also reported a synthesis of isatin derived from indoline 36 










Martinet’s original procedure for the synthesis of isatin derivatives involved aniline 
but is now applied to any substituted aromatic amine and their reaction with either the 
ethyl or the methyl ester of oxomalonic acid.57 The condensation reaction proceeds in 
the presence of an acid to yield a 3-(3-hydroxy-2-oxindole)carboxylic acid derivative 38 
which in turn yields a dioxindole on treatment with alkali in the absence of oxygen. 
However, on treatment with alkali in the presence of air, oxidative decarboxylation takes 
place hence affording the isatin (Scheme 15). Examples of using Martinet’s procedure 
include the synthesis of 5,6-dimethoxyisatin 39 from 4-aminoveratrole 40 (Scheme 16)58 













The formation of 3-methylthio-2-oxindoles and their subsequent oxidation is the 
basis of Gassman’s procedure for the synthesis of substituted isatins.59 In this method, 
the advantage of not utilizing a strong acid is emphasized which allows tolerance of a 
wide spectrum of electron-withdrawing and electron-donating substituents. Two 
corresponding methods for the preparation of the 3-methylthio-2-oxindole intermediate 
were developed initially and both allow the one-pot conversion of aniline to the required 
precursor. The procedure used depends on the electronic properties of the aniline 
substituents. 
In the presence of electron-withdrawing substituents, the oxindole precursor 44 
can be derived via an N-chloroaniline intermediate which is subsequently converted to 




with electron-donating groups present, destabilization of the N-chloro intermediate is 
observed and it becomes necessary to use a chlorosulfonium salt to react with the 
appropriate aniline (Scheme 18). To convert the oxindole intermediate to the required 
isatin, 3-chloro-3-methylthio-2-oxindoles 45 were first synthesized by reaction of the 
oxindole with N-chlorosuccinimide. The hydrolysis step was then achieved in the 
presence of red mercuric oxide and BF3.Et2O in aqueous THF to afford the isatin from 





The hydrolysis was also attempted without the presence of the sulfur scavenging 
red mercuric oxide and boron trifluoride, which resulted in a mixture of the desired isatin 
and the 3,3-dimethylthio-2-oxindole ketal byproduct 46.59 It was presumed that the 
formation of this dithioketal is due to the reaction of either the isatin or the 3-chloro-3-
methylthio-2-oxindole intermediate 45 with the methanethiol generated during the 







The synthesis of isatin via the oxidation of the closely related indole is a 
methodology first reported by Parrick in 1989.60 Previously, Noland and Rieke disclosed 
a method using chromium trioxide in acetic acid but these conditions gave poor yields in 
addition to causing modification of certain substituents.61 Consequently, Parrick pursued 
a methodology which employs milder conditions that are applicable to a wider range of 
indoles. This procedure involves the bromination of either 3-bromoindoles or indoles in 




When 1 equivalent of N-bromosuccinimide was used in aqueous t-butyl alcohol, 
the indole 47 was readily oxidized to the corresponding oxindole 48. Remarkably, the 
use of 2 equivalents of NBS under mild conditions afforded the 3-bromo-oxindole 49 as 
the oxindole was brominated in situ. It was then conceived that the use of 3 equivalents 
of NBS would convert indole into 3,3-dibromooxindole 50 in a one-pot process (Scheme 
21). 
With the 3,3-dibromooxindole intermediate 50 in hand, the subsequent hydrolysis 
in aqueous methanol proceeded uneventfully producing the required isatin derivatives in 
excellent yields. However, an attempt to oxidize an azaindole system to the 
corresponding azaisatin proved to be ineffective using this bromination and hydrolysis 
sequence. Mild hydrolysis of 3,3-dibromo-7-azaoxindole 52 in aqueous methanol gave 




characterize the compound were unsuccessful. Nevertheless, Parrick claimed to have 
made the 7-azaisatin 53 by firstly converting the dibromo-oxindole 52 into its oxime 54 
and subsequently converting the oxime into the isatin via the amine 55 in 42% overall 




Gribble’s synthesis of isatin, reported in 2001, involves the preparation of 2- and 
3-haloindoles and their subsequent oxidation using a ruthenium catalyst.62 Khan 
previously disclosed the conversion of vicinal dihaloalkenes to α-diketones via a 




Initially, Gribble described the preparation of 2,3-dibromo-1-methylindole from 
indole by employing the Katritzky indole C-2 lithiation protocol followed by Bergman’s 




and a similar procedure was used in the synthesis of 2-iodoindole 56 which was 
subsequently iodinated and methylated to yield 2,3-diiodo-N-methylindole 57. This 
intermediate was then treated with a ruthenium trichloride catalyst in aqueous acetonitrile 
in the presence of sodium periodate as a co-oxidant to afford the desired N-methylisatin 
58 in 96% yield (Scheme 23). Beauchard employed Gribble’s procedure for the oxidation 
of 6-nitroindole to the corresponding isatin which was a key intermediate for the synthesis 
of substituted indigoids.65 
 
Yadav’s Method 
Yadav’s procedure, published in 2007, is one of the most recently reported 
method involving the oxidation of indole to furnish isatin derivatives.66 In this protocol, 
indole and azaindoles are oxidized using 2-iodoxybenzoic acid 59 (IBX) in the presence 
of indium (III) chloride at 80 °C (Scheme 24). The reaction takes place in aqueous media 
and provides a direct preparation of isatins from indoles in one step. Beauchard also took 
advantage of this procedure, in addition to Gribble’s method, for the synthesis of 6-










Mamun’s microwave assisted synthesis of isatin is claimed to follow the Green 
Chemistry protocol.67 Oximinoacetanilides 60 were prepared from primary aromatic 
amines under microwave irradiation using minimal amount of solvent. The cyclization 
was then carried out in concentrated H2SO4 under microwave irradiation for two 5 second 
pulses to furnish isatin (Scheme 25). The minimal use of solvent and toxic reagents, very 
short reaction times and increased yields make this procedure advantageous over 




A recently published method for the synthesis of isatins involves an H-β Zeolite 
catalyst and a one-pot procedure.68 Commercially available anilines are treated with the 
acylating reagent oxalyl chloride in the presence of the reusable catalyst under 
heterogeneous conditions (Scheme 26). Absence of the H-β Zeolite catalyst resulted in 
no reaction while a 10% wt loading proved to be the optimum amount required for the 
transformation. A wide range of anilines were employed and it was discovered that 
substrates containing electron withdrawing substituents required longer reaction times 






The solvent of choice for the reaction was 1,2-dichloroethane while other solvents 
such as acetonitrile and nitrobenzene proved to be ineffective. After the reaction, the 
catalyst was recovered by simple filtration and calcinated at 823 K in air flow for 6 hours 
before being used for the next reaction. With aniline as the substrate, the catalyst was 
found to be active for a minimum of 5 reaction cycles without substantial loss of activity. 
This procedure is therefore more attractive than using homogeneous Lewis acid 
catalysts such as SnCl4 and BF3.Et2O.68 
 
Larock’s Method 
First published in 2011, Larock’s methodology involves the synthesis of N-
arylisatins by the reaction of arynes with methyl oxamates.69 Aryne methodologies have 
been particularly useful not only in the synthesis of isatin but also in the preparation of a 
wide variety of heteroatom containing structures. Larock has previously disclosed related 
procedures where nucleophilic heteroatoms attack arynes to afford acridones, 
xanthones, thioxanthones and indoloindolones.70 For the synthesis of N-aryl isatins, 
various methyl 2-oxo-2-(arylamino)acetates 60 were reacted with 2-(trimethylsilyl) 
phenyl trifluoromethanesulfonate 61 (Scheme 27). 
 
Scheme 27 
For the required transformation, 6 equivalents of CsF were needed as well as 2 
equivalents of NaHCO3. Acetonitrile proved to be the best solvent while ambient 
temperatures were found to be more effective than higher temperatures due to the 
avoidance of unidentified side reactions. A wide range of oxamates were used including 




yields. Other benzyne precursors were also examined including unsymmetrical 
precursors which afforded a single regioisomer 62 in excellent yields, as well as using a 
symmetrical dimethoxybenzene precursor which produced the corresponding product 63 
in an 86% yield (Figure 5).69 
 
Figure 5 
Two mechanistic pathways were suggested for this process with both routes 
sharing a common first step and both eventually leading to the desired isatin (Scheme 
28). Firstly, an aryl carbanion results from the nucleophilic attack by the nitrogen of 2-
oxo-2-(arylamino)acetate 64 on the benzyne. From there, the first possible route involves 
the attack of the aryl carbanion on the distal ester carbonyl which displaces a methoxy 
group. The alternative pathway involves attack onto the nearer amide carbonyl group 
forming a strained four-membered ring which fragments into a keto ester structure where 











Söderberg’s procedure reported in 2009 offers a unique method for the synthesis 
of isatins in which a palladium catalyst is used for the annulation of 1-(2-haloethynyl)-2-
nitrobenzenes.71 Initially, 1-(2-bromoethynyl)-2-nitrobenzene 65 was reacted with carbon 
monoxide in the presence of a palladium catalyst to synthesize indole but instead, a new 
product was observed and this was identified to be isatin (Scheme 29). The conditions 




the solvent system and the halogen on the haloethynyl nitrobenzene. Heating 1-(2-
iodoethynyl)-2-nitrobenzene 65 to 60 °C with bis(triphenylphosphine) palladium chloride 




The first step of this synthesis involves the Sonogashira coupling of 1-halo-2-
nitrobenzene 66 with trimethylsilylacetylene to afford 1-[2-(trimethylsilyl)ethynyl] 
benzene 67 (Scheme 30). The TMS-alkynes were successfully iodinated using N-
iodosuccinimide in the presence of a silver nitrate catalyst in N,N-dimethylformamide as 
the solvent. In one case, isatin was unexpectedly formed in very low yields from the 
iodination step in the presence of silver nitrate and NBS which also brominated at the 5 
position. To furnish the isatin in good yields, the prepared iodoalkyne 68 was subjected 
to cyclization either as the crude product or immediately after purification due to the 









Results and Discussion 
Investigations into the Synthesis of Azaisatins 
The initial objective of the project was to synthesise azaisatins which are the 
nitrogen containing analogues of isatin. Although the preparation of isatin has been 
extensively studied, there are far fewer methods reported for the synthesis of the aza-
equivalents. The first attempted preparation of 7-azaisatin was reported by Parrick as 
described previously. However, this procedure was unsuccessful in generating the 
expected 7-azaisatin, and a revised 5-step method was necessary to obtain the product 
in a 42% overall yield (Scheme 22). 
A modification of Parrick’s method was reported by Robinson and Donahue in 
their effort to synthesize 5-azaoxindoles via the bromination of 5-azaindoles 69.72 Their 
initial attempt to prepare 5-azaoxindole involved treating 5-azaindole with a minimum of 
3 equivalents of pyridinium bromide perbromide in t-butyl alcohol, but this afforded only 
the hydrobromide of 3-bromo-5-azaindole. Altering the solvent system produced small 
quantities of the 3,3-dibromo-5-azaoxindole 70 which is an intermediate for the synthesis 
of 5-azaisatin although the sample proved to be amorphous and unstable. To alleviate 
the problem, 4 equivalents of bromine in aqueous t-butyl alcohol were used to 
tribrominate 5-azaindole into 3,3,7-tribromo-5-azaoxindole 71 which is a possible 






Tatsugi has also developed a procedure similar to Parrick’s method of oxidizing 
indoles to synthesize isatin derivatives (Scheme 32).73 Firstly, alkyl-7-azaindoles 73 were 
obtained by treating the sodium salt of 7-azaindole 74 with appropriate alkyl halides in 
dimethylacetamide. The 1-alkylated indoles were then oxidized using NBS in anhydrous 
DMSO at above 80 °C for 20 hours. When the reaction was performed at above 80 °C 
under normal pressure, hydrogen bromide was generated which subsequently led to the 
decomposition of DMSO. In order to prevent the acid-catalyzed DMSO decomposition, 
it became necessary to carry out the reaction under reduced pressure when 
temperatures above 80 °C were employed. However, in some cases, excellent yields 
could still be obtained when performing the reaction at 60 °C for 6 hours under normal 




Whilst Tatsugi’s method gives excellent yields for the preparation of 1-substituted 
7-azaisatins, it does not apply to the corresponding unsubstituted azaisatin. Kritsanida’s 
attempt to synthesise 7-azaisatin by brominating 7-azaindole resulted to a mixture of the 
desired product and a dibrominated by-product 76 (Scheme 33).74 The by-product was 
resubjected to the reaction conditions to obtain the desired 7-azaisatin albeit in a poor 
yield. Moreover, Cheng’s attempt to apply this azaisatin synthesis in their effort to 
prepare 7-azaindirubin proved unsuccessful.75 Cheng, therefore, reported a 4-step 
synthesis of 7-azaisatin starting from 2-amino-3-picoline 77 (Scheme 34). The final key 
step involved a bromination of 7-aza-2-indolinone 80 using NBS and DMSO under 









Rivalle reported a preparation of 5-azaisatin 81 via ethyl 4-acyl-
aminopyridineglyoxylate 82.76 The desired 5-azaisatin was obtained in a 68% yield via 
the cyclization of the keto-ester carbamate 83 (Scheme 35). Sӧderberg attempted the 
first synthesis of 4-azaisatin 87 through the Pd-catalyzed cyclization of 2-(2-iodoethynyl)-
3-nitropyridine 86 (Scheme 36).71 This proved to be unsuccessful as no identifiable 








A series of isatin analogues were used in the synthesis of tryptanthrin compounds 
as immunotherapeutics in the treatment of infectious diseases.77 These analogues 
included azaisatins and their synthesis starting from azaisatoic anhydrides was reported. 
The N-protected azaisatoic anhydride 88 was transformed to the N-allyl azaisatin 89 via 
the reaction with potassium cyanide followed by acid hydrolysis (Scheme 37). The allyl 
group was removed by using Wilkinson’s catalyst followed by treatment with acid to 
afford the desired azaisatin. 
  
Scheme 37 
Finally, the most recently reported synthesis of azaisatins involves a sulphur 
ylide-mediated carbonyl homologation as described by Lippert.78 The required 
anthranillic acid was reacted with sulfonium salt 91 to make the sulfur ylide intermediate 
92 which was then transformed to the azaisatin in the presence of oxone (Scheme 38).  
 
Scheme 38 
With these different approaches to azaisatins available from the literature, the 
investigation commenced by choosing Parrick’s method involving the bromination and 
oxidation of indoles. As azaindoles are relatively difficult to obtain commercially, efforts 






Approach 1: Via Oxidation of Azaindoles 
Synthesis of Azaindoles 
Initial efforts to synthesise azaindoles focused on the transition-metal catalysed 
cycloisomerizations of 2-alkynyl anilines which has been extensively investigated for the 
construction of benzoheterocycles.79 A wide range of transition metal catalysts have 
been used for the -activation of the alkyne which forms an electrophilic species that can 
undergo nucleophilic attack by the pendant amine (Scheme 39). 
 
Scheme 39 
Before investigating the transition metal catalysed cyclization, the synthesis of 
the aromatic alkynylamine intermediate was required. Accordingly, the Sonogashira 
reaction of 3-bromo-4-aminopyridine 93 with trimethylsilylacetylene was examined using 
a variety of conditions reported in literature (Table 1). Initially, using 1 mol% of 
PdCl2(PPh3)2 and 2 mol% of CuI did not give any of the desired product whilst increasing 
the loading of both catalysts to 10 mol% each still proved ineffective, even after heating. 
Changing the catalyst to Pd(OAc)2 and adding triphenylphosphine ligand with 
tetrabutylammonium acetate did not aid the reaction. Finally, the use of diisopropylamine 
base was attempted, but again without success. 
 
Entry Conditions Yield 
1 1 mol% PdCl2(PPh3)2, 2 mol% CuI, Et3N, 24 h rt 0% 
2 10 mol% PdCl2(PPh3)2, 10 mol% CuI, Et3N, 2 h Δ 0% 
3 2 mol% Pd(OAc)2, 20 mol % PPh3, 3 eq Bu4NOAc, 24 h, rt 0% 





The failure of the aminopyridine towards Sonogashira coupling prompted us to 
acylate the free amine in the hope that this would aid reactivity. Therefore, 3-bromo-4-
aminopyridine 93 was reacted with ethyl chloroformate in the presence of excess 
pyridine to give ethyl carbanilate 95 in a 48% yield. The yield improved to 78% when 
triethylamine was used as the base in the presence of catalytic DMAP (Scheme 40). 




Treating acetanilide 95 with 1.5 eq. TMSA, 5 mol% PdCl2(PPh3)2 and 10 mol% of 
CuI resulted in the recovery of starting material, and so an additional 2.5 eq. of TMSA 
and 5 mol% PdCl2(PPh3)2 were added. Pleasingly, this afforded the alkyne product in 
50% yield. Repeating the reaction with 4 eq. of TMSA and 10 mol% Pd catalyst at an 
elevated temperature of 100 °C gave the product in a 63% yield, while the product was 
generated in 71% if the CuI and TMSA were premixed before adding to the reaction 
mixture (Scheme 41). 
 
Scheme 41 
Yamanaka reported the cyclization of ethyl 2-(trimethylsilylethynyl)carbanilate 96 
into 5-azaindole when treated with NaOEt, which eliminates the need to deprotect the 
carbanilate prior to cyclization (Scheme 42).80 Interestingly, when the corresponding 2-
(trimethylsilylethynyl)acetanilide was treated with NaOEt, the major product obtained is 




resubjected to NaOEt in EtOH, no indole was detected which suggested that the indole 
was formed via the acylindole 99. Yamanaka’s method was therefore used for the 
cyclization which gave the desired 5-azaindole 97 in a 56% yield (Scheme42). 
 
Scheme 42 
Overall, a 3-step method was developed for the synthesis of 5-azaindole in good 
yields and from commercially available starting materials. 
 
Bromination/Oxidation of Indoles 
Before attempting to oxidise 5-azaindole 97, we began by applying Parrick’s 
conditions to the parent indole. Treatment of 47 with 3 equivalents of N-
bromosuccinimide in tert-butanol gave the 3,3-dibromo-2-oxindole intermediate 50 which 




Encouraged by this promising result, the method was applied on the azaindole 
but treatment of 97 with 3 equivalents of NBS only gave the dibromo intermediate 100 in 




tert-butanol provided 3,3-dibromo-5-aza-2-oxindole in a quantitative yield (Scheme 44).81 
The subsequent hydrolysis was then attempted by refluxing in aqueous methanol for 24 
h but this resulted in a complex mixture which included the starting dibromide. Likewise, 
when the reaction mixture was heated at 140 °C under microwave irradiation for 30 min, 
a complex mixture was obtained. 
 
Scheme 44 
It was then hypothesised that the reaction mechanism for the hydrolysis involves 
the deprotonation of the oxindole as the first step which would require a base (Scheme 
45). Accordingly, the hydrolysis of oxindole 100 in methanol was attempted with the 
addition of an excess amount of NaOH at room temperature. After 1 h, full consumption 
of starting material was observed but the expected azaisatin was not detected. Instead, 
the isolated product was discovered to be 3,3-dimethoxy-5-aza-2-oxindole 101 (Scheme 
46). Moreover, leaving the reaction for 16 h also formed a different product in addition to 
the acetal which was envisioned to be the corresponding oxalic acid 102. However, 








In an endeavour to prevent the formation of the acetal during the hydrolysis 
reaction, the methanol solvent was changed to tert-butanol. In addition, acetonitrile was 
also employed as an alternative solvent. Disappointingly, both sets of conditions resulted 
in a complex mixture with no indication of the expected product. Efforts were then turned 
to trying to convert the acetal to the required azaisatin. Initially, it was envisaged that the 
hydrolysis of the acetal could be achieved by acidifying the reaction mixture after the 
acetal formation. Regrettably, addition of 1 M HCl with further stirring for 1 h proved 
unsuccessful and gave a complex mixture which included the unreacted acetal (Scheme 
47). The acetal was therefore isolated before treatment with acid but eventually, this 
proved to be ineffective as the acetal remained unreacted even after the application of 
heat. Furthermore, during the hydrolysis reaction using base in aqueous methanol, it was 
discovered that a different product was being formed after 5 minutes of reaction time 
which was not the acetal. It was anticipated to be the expected azaisatin but 
characterization of the obtained solid was unconvincing. 
 
Scheme 47 
With the conversion of the acetal to the isatin proving to be challenging, the idea 
of exploiting microwave irradiation was considered. Firstly, the dibromide 100 was 
subjected to microwave irradiation at 150 °C for 5 mins in the presence of acid (Scheme 




obtained. Moreover, the dibromide was subjected to microwave irradiation at 140 °C for 
30 min using aqueous methanol as a solvent but the expected product was not observed. 
 
Scheme 48 
In order to compare the results achieved for the oxidation of azaindole with that 
of the parent indole, the required dibromide intermediate 50 was prepared via the 
bromination of indole using literature conditions. The dibromide was then subjected to 
microwave irradiation at 150 °C for 5 mins in the presence of acid which gave the 
expected isatin in 64% yield (Scheme 49). The hydrolysis reaction in the presence of 
base was then performed in which the corresponding acetal was obtained in a 61% yield. 
The acetal was subsequently treated with acid in order to obtain the desired isatin but 
the acetal proved to be unreactive (Scheme 50). This mirrors the result obtained when 
3,3-dimethoxy-5-aza-2-oxindole 101 was treated with acid, therefore suggesting that 








Since Parrick’s bromination method had proved to be ineffective in the oxidation 
of azaindole, we turned our attention to Tatsugi’s modification of Parrick’s strategy. 
Although Tatsugi’s method has not been successfully applied for the oxidation of 
unsubstituted indoles, it was anticipated that a removable protecting group on the amide 
might provide a solution. Before attempting the oxidation of 5-azaindole, we decided to 
reproduce Tatsugi’s results using 7-azaindole to obtain 7-azaisatin.73 Consequently, 7-
azaindole 74 was benzylated to obtain 1-benzyl 7-azaindole in a 91% yield which was 
easily scaled up to 3 g. Using the reported conditions of heating at 80 °C for 24 h with 2 
equivalents of NBS, 1-benzyl 7-azaisatin was obtained in a disappointing yield of 34%. 
Also observed in the LC-MS of the crude mixture was the 3-bromo indole 104a and the 
dibromo oxindole intermediate 104b (Scheme 51). The amount of NBS was therefore 
increased to 3 equivalents. This is to ensure complete conversion of the 
monobrominated indole to the oxindole intermediate and subsequently, the conversion 
of the oxindole intermediate into the isatin. 
 
Scheme 51 
Conducting the reaction with 3 equivalents of NBS at 80 °C resulted in complete 
consumption of the starting indole after 4 h according to TLC analysis. However, as other 
compounds were evident we decided to continue the reaction for another 1 h in the hope 
that these would converge to the product. Unfortunately, the reaction mixture started to 
become more complex so the reaction was stopped at that point. The expected isatin 
104 was isolated in a 43% yield and was scaled up to 500 mg where the yield improved 






With 1-benzyl 7-azaisatin in hand, efforts were turned towards the deprotection 
of the benzyl group to obtain 7-azaisatin. Remarkably, attempts to hydrogenate with 
Pd/C proved ineffective as only starting material was recovered. The protected isatin was 
also treated with boron trichloride in dichloromethane for 24 h but this also turned out to 
be unsuccessful. Rombouts reported the decomposition of 1-benzyl isatin during their 
debenzylation attempts, leading them to conclude that the benzyl group is not the most 
suitable protecting group to use.82 
Scheme 53 
Finally, 7-azaindole was methylated using iodomethane in the presence of 
sodium hydride which gave 1-methyl 7-azaindole 105 in a 94% yield. Unfortunately, 
attempts to brominate and oxidize this compound only gave the isatin 106 in a poor 
optimised yield of 37% (Scheme 53). 
 
Other Oxidation Methods 
After multiple failed attempts at oxidizing azaindole using the bromination 
method, efforts were turned towards alternative approaches involving other oxidizing 
agents. Krishna reported a preparation of 1-substituted 7-azaindoles using Yadav’s 
method involving IBX as the oxidizing agent.66 In the presence of catalytic InCl3, the 




The previously prepared benzylated 7-azaindole was therefore subjected to Krishna’s 
conditions. Disappointingly, when the oxidation was attempted, complex crude mixtures 
were observed and the desired isatin was only obtained in a 22% yield (Scheme 54). 
 
Scheme 54 
We next attempted to apply this method for the synthesis of 5-azaisatins starting 
from the corresponding 1-substituted 5-azaindole. Accordingly, 5-azaindole was reacted 
with benzyl bromide and sodium hydride to obtain 1-benzyl 5-azaindole 107 in a 56% 
yield (Scheme 55). Disappointingly, the oxidation was unsuccessful when both this 
substrate and the free azaindole were employed, and only starting material was 





Yang reported an oxidative cleavage of olefins to aldehydes using a ruthenium 
catalyst in the presence of an oxidant such as Oxone or NaIO4.83 Beauchard then 
investigated the suitability of this method for the oxidation of 6-nitroindole into 6-
nitroisatin. In the event, RuCl3.2H2O and NaIO4 converted the substrate into the expected 
isatin, albeit in a low yield.65 A proposed reaction mechanism for the transformation is 
depicted in Scheme 57. Firstly, the ruthenium catalyst and the oxidant forms RuO4 which 
reacts with the indole. Instead of the expected oxidative cleavage, the presence of water 






Before we attempted this approach on our azaindole substrates, it was decided 
to try the chemistry on the parent indole first. Indole was therefore treated with RuCl3 and 
NaIO4 at ambient temperature for 24 h but a complex mixture was obtained. Likewise, 
using Yang’s alternative conditions of RuCl3 and Oxone in the presence of NaHCO3 was 
ineffective (Scheme 58).83 It was speculated that a more labile trimethylsilyl group at the 
2-position would help the oxidation of indole, and therefore 2-trimethylsilylindole was 
treated with RuCl3 and NaIO4 at ambient temperature for 24 h (Scheme 59). Eventually, 
a complex mixture was obtained and therefore this approach was not applied in the 








Approach 2: Via Isatoic Anhydride 
Synthesis of Azaisatoic Anhydride 
The next strategy explored for the synthesis of azaisatin was the homologation 
of azaisatoic anhydride with cyanide, using the method previously described (Scheme 
37). This approach was reported to allow the preparation of different analogues of isatin, 
including all four isomers of azaisatin. Whilst the patent suggested preparing the starting 
azaisatoic anhydride from azaphthalic anhydride or the corresponding anthranilic acid,77 
there appeared to be an opportunity to develop a new methodology to make the key 
azaisatoic anhydrides. Efforts were turned to developing a C-H activation strategy to 
these compounds. This novel approach would be efficient, and this area of research has 
received wide interest in organic synthesis in recent years. 
Yu reported a carboxylate-directed amidation of benzoic acids using a palladium 
catalyst to afford anthranilic acids, which are important building blocks in heterocycle 
synthesis.84 This C-H activation method employed ethyl N-mesityloxycarbamate as the 
amidation reagent while the carboxylic acid was used as the corresponding Li-
carboxylate (Scheme 60). More recently, Yu also disclosed a Rh-catalyzed amidation of 
benzoic acids using N-chlorocarbamates as the amidating reagent (Scheme 61).85 Not 
only is this a more convenient way to prepare functionalized anthranilic acids, but it was 








We decided to investigate the Pd-catalyzed amidation first and this involved 
preparing the amidating reagent ethyl N-mesitoxycarbamate using the reported two-step 
method (Scheme 62).84 Next, the pyridine carboxylic acid lithium salts were prepared by 
treating nicotinic acid and isonicotinic acid with lithium hydroxide. The C-H amidation 
was then attempted using Yu’s conditions but none of the expected anthranilic acid 
products were observed in either case (Scheme 63). Some of the starting pyridine 
carboxylic acid starting materials were recovered but most of the material remained in 





The Rh-catalyzed amidation was then investigated which firstly required the 
synthesis of the N-chlorocarbamate as the amidating reagent.85 Equimolar amounts of 
urethane 114 and N,N-dichlorourethane 115 were mixed in the dark for 24 h to afford 
ethyl N-monochlorocarbamate 116 after a disproportionation reaction (Scheme 64).86 
However, employing Yu’s amidation procedure with nicotinic acid 117 only resulted in 








Whilst the Rh-catalyzed amidation works well for benzoic acids, and appears to 
be more general than the Pd-catalyzed variant, carboxylic acids containing heteroaryl 
motifs are evidently not applicable for this method. In light of this, efforts were turned 
towards preparing azaisatoic anhydrides using more established methods. 
Traditionally, isatoic anhydride is obtained via the oxidation of isatin by chromic 
acid or m-CPBA. In fact, the name isatoic acid was coined by Kolbe in 1884 when isatoic 
anhydride was first discovered because it was thought to be an acid product from the 
oxidation of isatin.87 Coppola published a review surveying traditional methods to make 
isatoic anhydride including the aza-derivatives.88 The two most useful strategies are the 
ring closure of anthranilic acid (Scheme 66) and the reaction of phthalic anhydride with 








Commercially available 2-amino nicotinic acid 119 was initially treated with 
triphosgene in the presence of sodium carbonate in water at room temperature for 16 h 
(Scheme 68). Under these conditions however, only traces of product were observed 
and most of the unreacted starting material remained in the aqueous layer after work-
up. The reaction was repeated in THF but in this case the starting material was fully 
recovered. Running the reaction at reflux resulted in about 50% conversion of starting 




Triphosgene was substituted for ethyl chloroformate, which was the reagent used 
for one of the earliest reported syntheses of isatoic anhydride. Due to the poor recovery 
of mass balance when using water as the reaction solvent, an organic solvent was used 
for subsequent reactions. Accordingly, 2-amino nicotinic acid 119 was treated with ethyl 
chloroformate in toluene and then heated to 100 °C in the presence of triethylamine 
(Scheme 69). Whilst the product was indeed observed, unfortunately, removing the 
solvent directly to avoid aqueous work-up did not remove the triethylamine salt 121 from 
the reaction mixture. In an effort to avoid formation of the triethylamine salt, potassium 







To summarise, attempts to form the azaisatoic anhydride from all the aza-
derivatives of the anthranilic acids were generally unsuccessful. Only one from the series 
was isolated cleanly, albeit in a low yield of 24%. In order to improve access to this class 




The reaction of phthalic anhydride with azides involves an overall insertion of an 
N-H moiety between the carbonyl and the benzene ring. Initial addition of the azide forms 
an acyl azide intermediate which undergoes a Curtius rearrangement to produce an 
isocyanate. Subsequent ring closure gives the isatoic anhydride in a 91% yield according 
to the initial report by Coppola.88 However, based on literature precedent, 3,4-
pyridinedicarboxylic anhydride 125 would give an almost 1:1 mixture of both azaisatoic 
anhydride products 122 and 123 (Scheme 71). In contrast, it has been reported that the 
2,3-pyridinedicarboxylic anhydride 125 gives one isomer as the major product, and this 








With an optimal route to azaisatoic anhydride established, investigation of the 
transformation to azaisatin commenced. Firstly, 5-azaisatoic anhydride 120 was treated 
with allyl bromide in the presence of sodium hydride to obtain 1-allyl-5-azaisatoic 
anhydride in a 68% yield. This transformation could be performed on a multi-gram scale. 
This intermediate was then treated with potassium cyanide in DMF at 100 °C for 10 mins 
to obtain the imine intermediate 127. The crude mixture observed after the reaction was 
complex but attempts to purify the imine via column chromatography were unsuccessful. 
Consequently, the crude material was used in the next step without further purification 





On further investigation of the reaction involving the addition of potassium 
cyanide to the azaisatoic anhydride, it was discovered that the reaction is time sensitive 
and running the reaction for longer than 10 mins led to decomposition. It was envisaged 
that performing the reaction at elevated temperatures might be detrimental and so it was 




potassium cyanide was performed at room temperature and run for 24 h but this still led 
to a complex mixture. Nevertheless, the crude mixture was still subjected to the acid 
hydrolysis step but unfortunately, this resulted to unidentified products with none of the 
expected azaisatin observed.  
Whilst a viable route to azaisatin was developed, it was far from ideal and multiple 
problems arose that needed to be addressed. For instance, the initial reaction with 
potassium cyanide to form the imine intermediate was difficult to control and always led 
to complex mixtures. Moreover, after multiple attempts, the acid hydrolysis step 
remained challenging and the yields obtained were always below 20%. Consequently, 
scaling up the reaction to make multi-grams of azaisatin would require large quantities 
















Approach 3: Via Sulfur Ylide 
The next strategy investigated for the synthesis of azaisatin was Lippert’s method 
involving the sulfur ylide mediated carbonyl homologation previously described (Scheme 
38).78 They claimed to have synthesised 7-azaisatin in a 56% yield using their 
methodology and so the initial aim was to try to reproduce this result. The preparation of 
the required sulfonium bromide salt 91 via the reaction of dimethyl sulfide and 
bromoacetonitrile was quite convenient and the salt was found to be stable if stored at 0 
°C, thereby allowing its preparation on multigram scale (Scheme 75).  The synthesis of 
the sulfur ylide 92 from 2-amino nicotinic acid 90 was based on Lippert’s conditions with 





The sulfur ylide was not purified as it was reported that it is susceptible to forming 
fluorescent oxidation products via a spontaneous oxidation on silica gel. The crude ylide 
was therefore treated with 3 equivalents of oxone in THF/H2O at room temperature for 
10 mins and then the product was extracted. Low mass balance was obtained after the 
aqueous workup, however basifying the reaction mixture improved mass balance but at 
the expense of incorporating impurities obtained from HATU. Notwithstanding the report 
that the ylide intermediate decomposes on silica gel, the sulfur ylide was prepared again 
and purified by flash column chromatography to obtain pure product in an 81% yield. We 




observed in the NMR spectrum of the crude mixture, all attempts to purify it by column 
chromatography were unsuccessful. The product appeared to be unstable on silica gel 
as no desired azaisatin was isolated from chromatographic purification. Trituration of the 
crude mixture with ethanol gave the clean product in a very poor yield of 4%. 
 
Scheme 77 
We speculated that an impurity in the crude mixture of the ylide from the previous 
step could be aiding the oxidation step which enabled Lippert to obtain the azaisatin in a 
56% yield. Therefore, the preparation of the sulfur ylide was performed again using 
precisely the reported conditions where HATU was replaced with HBTU. The crude ylide 
was used directly for the oxidation step but after three separate attempts, the product 
was only obtained in a 15% yield on average. Efforts to identify what else may be in the 
crude mixture by analysing the LC-MS proved challenging and none of the expected by-
products were observed. For instance, none of the pyridine N-oxide products which could 
have resulted from the oxidation of the pyridine moiety were detected and none of the 
starting anthranilic acid was observed.  
Having failed to obtain the azaisatin in useful amounts, the stability of azaisatin 
was scrutinized in order to identify whether its decomposition was the main problem. 
Remarkably, it was discovered that when the isolated solid was stirred in methanol in the 
presence of a base (triethylamine), a new product was obtained in a 70% yield which 
was identified to be the methyl ester of the anthranilic acid 129 (Scheme 78). This was 
very surprising since there is no precedent for isatin ring opening under this set of 
conditions, and this transformation normally requires an oxidant such as oxone or 
hydrogen peroxide.89 At this point, the results reported by Lippert appeared highly 




After searching for ways of preparing methyl anthranilate, we found a report that 
treating isatoic anhydride with base such as triethylamine, sodium hydride or sodium 
methoxide in methanol gives methyl anthranilate (Scheme 78).90 Moreover, isatins are 
readily oxidized into isatoic anhydrides and this transformation has been shown to 
proceed using oxone.91 We therefore concluded that the isatin being formed from the 
oxidation of the sulfur ylide is also being oxidized further to isatoic anhydride which 





Taking this new evidence into consideration, the spectroscopic data reported by 
Lippert was scrutinized in more detail. Firstly, the 1H NMR spectrum published by the 
authors was performed in d4-methanol and matched that of anthranilic acid ester 129. 
However, the 1H NMR spectrum of our product sample run in d6-DMSO was found to 
match the data obtained for azaisatoic anhydride, which was synthesised earlier via a 
different method. Furthermore, the melting point and 13C NMR spectrum obtained for this 
sample matched with literature data for azaisatoic anhydride. We therefore concluded 
that the compound isolated and reported by Lippert was in fact the azaisatoic anhydride, 
and that this has been erroneously identified as the azaisatin. 
Returning to the oxidation of the sulfur ylide, and conducting a trituration of the 




liquor. This material was purified by flash column chromatography and the azaisatin was 
isolated in a 26% yield. We next decided to carry out an optimization of the ylide oxidation 
reaction. Assuming that the isatin formation happens before oxidation to isatoic 
anhydride, it was envisaged that decreasing the equivalents of oxone used and reducing 
the reaction time might increase the yield of the isatin. Accordingly, the sulfur ylide was 
treated with 1.5 equivalents of oxone for 10 mins which stopped the formation of 
azaisatoic anhydride but only 17% of azaisatin was isolated and some unreacted starting 
material was observed. Increasing to 2 equivalents of oxone marginally increased the 
yield of azaisatin to 22% but the formation of small amounts of azaisatoic anhydride were 
noted. Increasing to 3 equivalents of oxone added in a portionwise manner was also 
ineffective. Finally, increasing the oxone equivalents to 4 but reducing the time to 5 mins 
resulted in complete consumption of starting material but only azaisatoic anhydride was 
observed. Evidently, it appears that the use of 3 equivalents of oxone over a 10 min 
reaction time offers the best conditions to obtain the azaisatin. As this yield was rather 
poor, a more efficient strategy to prepare azaisatin was sought and efforts were turned 














1 10 min 3 26% 16% 0% 
2 10 min 1.5 17% 0% 36% 
3 10 min 2 22% 13% 36% 
4 10 min 3a 13% 10% 15% 
5 5 min 4 0% 32% 0% 
Table 2 




Approach 4: Via Palladium-Catalysed Cyclization of Iodoacetylenes 
Based on the substantial interest in transition-metal catalysts for a variety of 
organic transformations, Sӧderberg’s method was explored for the synthesis of 5-
azaisatin and the novel 6-azaisatin. Although Sӧderberg was unsuccessful in their 
attempt to react the pyridine derivative, it was felt that there was an opportunity to further 




The first objective was to develop an efficient starting material synthesis and our 
results are shown in Scheme 80. Starting from 4-chloro-3-nitropyridine 131, a 
Sonogashira reaction was attempted to furnish the desired substrate 133 however the 
chloride coupling partner proved to be unreactive. The iodide counterpart was obtained 
via a Finkelstein reaction and the Sonogashira coupling of the resulting 4-iodo-3-
nitropyridine 132 proceeded uneventfully giving the TMS-acetylene product 133 in a 73% 
yield. Finally, iodination of 133 furnished the iodoacetylene substrate 134 in a 63% yield 
(Scheme 80). 
With the iodoacetylene precursor in hand, the cyclization was attempted using 
Sӧderberg’s conditions (Table 3). The reaction proved to be slower than expected using 
5 mol% of the palladium catalyst with most of the starting material recovered and only 
24% of product 81 isolated after 4 h. Moreover, leaving the reaction for 24 h at room 




was observed and no identifiable product was isolated. We suggested that the low yield 
might be due to decomposition of the starting material since the iodoacetylene substrates 
are known to be relatively unstable. Doubling the loading of the catalyst to improve 
reaction rates however did not improve the yield and most of the starting material was 
still recovered. Further cyclization attempts were then performed using a different metal 
catalyst. 
 
Entry Conditions Yield 
1 5 mol% cat., 60 °C, 4 h 24% 
2 5 mol% cat., rt, 24 h 0% 
3 5 mol% cat., 60 °C, 24 h 36% 
4 10 mol% cat., 60 °C, 48 h 10% 
Table 3 
As a substitute for palladium, it was speculated that copper salts could be used 
to catalyze the cyclization which would represent a cheaper alternative. A number of 
copper catalysts were tested and copper (II) chloride was found to be promising, giving 
the product in a 15% yield when 10 mol% of the catalyst was used (Table 3). However, 
most of the starting material was still recovered and leaving the reaction for longer only 
led to decomposition. Increasing the loading to 50 mol% only marginally increased the 
yield to 20% while using a stoichiometric amount of copper salt provided a 31% yield of 
product. Employing copper (I) iodide failed to promote the cyclisation, while adding zinc 
powder as a co-catalyst proved to be unsuccessful. It was then hypothesized that the 
copper or palladium catalyst might be coordinating to the nitrogen atom of the pyridine 





Entry Conditions Isolated Yield 
1 10 mol% CuCl2, 60 °C, 24 h 15% 
2 50 mol% CuCl2, 60 °C, 24 h 20% 
3 1.5 eq. CuCl2, 60 °C, 24 h 31% 
4 1.5 eq. CuI, 60 °C, 24 h 0% 
5 1.5 eq. CuI, 1.5 eq. Zn, 60 °C, 48 h 0% 
Table 4 
Attention was then turned to the synthesis of isomeric 5-azaisatin. Investigation 
began with the preparation of the 3-iodo-4-nitro pyridine 136 (Scheme 81). The oxidation 
of the commercially available 3-iodo-4-aminopyridine 135 was attempted using hydrogen 
peroxide in the presence of sulfuric acid at 0 °C to rt. This proved to be a sluggish reaction 
with only traces of product observed after 48 h. Reported oxidations of aminopyridines 
to nitropyridines involved using harsher conditions at higher temperatures.92 Other 
oxidizing agents were considered such as m-CPBA but this resulted to a complex 
mixture. Moreover, obtaining the 3-iodo-4-nitropyridine from 3-iodopyridine was also 
envisioned but there is no precedent for the direct nitration of 3-halopyridines. 
 
Scheme 81 
A different approach was employed which involved the initial oxidation of 3-
bromopyridine 138 to obtain 3-bromopyridine N-oxide 139. The direct nitration of this 
substrate has been previously achieved93 and protecting the nitrogen atom of the 




as the oxidant in the presence of acetic acid gave the product in less than 10% yield 
however, most of the starting material was recovered even after heating under reflux 
(Scheme 82). Fortunately, replacing H2O2 with m-CPBA effected the reaction at room 
temperature after 1 h providing 3-bromopyridine N-oxide 139 in a quantitative yield 
(Scheme 83). 
Scheme 82       Scheme 83 
 
With the 3-bromopyridine N-oxide in hand, the nitration was performed using 
fuming nitric acid and concentrated sulfuric acid at 90 °C (Scheme 84). Conducting the 
reaction for 16 h gave 4-nitro-3-bromopyridine N-oxide 140 in a 33% yield. It appeared 
that the reaction was incomplete even after leaving for 48 h, and so it was speculated 
that the active reagent was decomposing. Therefore, nitric acid was added portion-wise 
over 16 h but unfortunately, this only improved the yield to 47%. 
Scheme 84 
The Sonogashira reaction with the bromide then proceeded uneventfully to give 
the desired TMS-acetylene 141 in a 70% yield. However, the subsequent iodination 
proved to be more difficult using silver nitrate and 1.5 equivalents of N-iodosuccinimide 
in DMF. The high water solubility of the product made the aqueous work-up problematic 
and in addition, the succinimide by-product was difficult to separate from the desired 
substrate. Silver fluoride was then used with 1 eq. of NIS in acetonitrile which avoided 
an aqueous work-up and decreased the succinimide by-product to give the precursor 





Entry Conditions Yield 
1 5 mol% AgNO3, 1.5 eq NIS, DMF >5% 
2 5 mol% AgNO3, 3 eq NIS, MeCN 10% 
3 1 eq AgF, 1 eq NIS, MeCN 65% 
Table 5 
 
With the N-protected iodo-acetylene substrate 142 in hand, the cyclization was 
attempted with 5 mol% of PdCl2(PPh3)2 over 24 h (Table 6). Disappointingly, the reaction 
did not proceed even when the catalyst loading was increased to 10 mol%. Likewise, 
using 10 mol% CuCl2 did not afford any product and using stoichiometric amounts of 
copper salt led to a complex mixture. Furthermore, it was discovered that as the 
cyclization progresses, the pH drops considerably which signifies the generation of 
hydrogen iodide. The presence of this acid is also evident from the formation of diacetone 
alcohol and isobutenyl methyl ketone resulting from the acid-catalyzed self-condensation 
of acetone. The presence of acid is potentially one of the factors leading to the poor 
yields obtained in this work, and that of Sӧderberg. 
 
Entry Conditions Result 
1 PdCl2(PPh3)2 (5 mol%), 24 h No Reaction 
2 PdCl2(PPh3)2 (10 mol%), 24 h No Reaction 








Cyclization of 4-(iodoethynyl)-3-nitropyridine 134 using Pd(OAc)2 in the presence 
of benzoquinone gave a different product in trace amounts which was identified as the 
iodoisatogen 144 based on the 1H NMR spectrum and LCMS (Scheme 85). Although the 
actual mechanism of forming isatin was ambiguous, Sӧderberg proposed that it is likely 
formed via this isatogen intermediate in accordance with Yamamoto’s reported gold-
catalyzed cyclization.94 We then hypothesized that the efficient synthesis of this isatogen 
could lead to a better overall route to the corresponding isatin after reducing this 
intermediate. Accordingly, efforts were focused on finding conditions to prepare isatogen 
















Isatin and its derivatives are versatile substrates which are important in the field 
of medicinal chemistry due to their biological and pharmacological properties. Since it 
was first discovered, the synthesis of isatin has been extensively investigated and 
reported methodologies have been modified over the years. Earlier routes to isatin have 
involved aniline and its derivatives as starting materials while more recently, the oxidation 
of indole to obtain isatin has been explored. Other modern procedures include the use 
of transition metal catalysts while innovative methods have also focused on following the 
Green Chemistry protocol. 
Traditional methods to prepare isatins suffer from a few limitations including 
multistep sequences, toxic reagents, low reaction scope and harsh conditions. In this 
investigation, a 3-step method was developed for the synthesis of 5-azaindole but the 
subsequent oxidation to the azaisatin proved unsuccessful or limited to the N-substituted 
isatins. The homologation of azaisatoic anhydride with cyanide provided N-allyl azaisatin 
but only in poor yields. Finally, the sulfur-ylide mediated carbonyl homologation gave 
azaisatin in poor yields due to the formation of azaisatoic anhydride which is a competing 
side reaction. 
A transition-metal catalyzed cyclization of iodoacetylenes also resulted in 
unsatisfactory yields of azaisatins. However, a 2-iodoisatogen intermediate was isolated 






Chapter 3: Synthesis of 2-Iodoisatogens 
Introduction 
Isatogens or 3-oxo-3H-indole 1-oxides 145 are interesting compounds that do not 
occur naturally and were first synthesised by Baeyer in 1881 in line with his research 
involving the synthesis of indigo and isatin.95 2-Substituted isatogens were prepared via 
the cyclization of 2-nitrophenylacetylene derivatives in the presence of concentrated 
sulfuric acid at room temperature. Further work by Pfeiffer demonstrated that the 
cyclization could also be effected by refluxing in pyridine, whilst Ruggli reported 
irradiation with a mercury lamp as an alternative.96 Moreover, it has been shown that the 
cyclization proceeds by refluxing with nitrosobenzene in an inert solvent such as 
chloroform. 
 
Entry Conditions R1 R2 Yield 
1 conc. H2SO4, rt, 10-15 mins CO2Et H 44% 
2 pyridine, Δ, 3 mins Ph NO2 75% 
3 pyridine, hV, 21 days 2-Py H 30% 
4 nitrosobenzene, chloroform, Δ, 72 h 1-Naph H 70% 
Table 7 
Bond and Hooper reported the synthesis of 2-arylisatogens via the reaction of 
copper o-nitrophenylacetylides 146 with aryliodides in pyridine (Scheme 86).97 It has 
been proposed that the cyclization involves the tolan (diphenylacetylene) intermediate 
147 although this is not isolated from the reaction. Another way to synthesise 2-
arylisatogens involves exposing 2-nitrostilbene dichlorides 149 in sunlight with pyridine 
for a long period of time.98 This process could be accelerated by irradiation with a 




monochlorostilbenes 151 react faster when exposed to sunlight in the presence of 







Krohnke reported the synthesis of 2-arylisatogens using o-nitrostyrylpyridinium 
salts 153 and treating them with base such as pyridine, sodium carbonate or 
diethylamine (Scheme 89).96 The related acetoxy compound 155 has also been 
converted to an 2-arylisatogen using the same conditions (Scheme 90). For the 
corresponding alcohols, o-nitrophenylpyridinium ethanols 156 were transformed to the 
isatogens by exposing them to sunlight in 50% aq. AcOH (Scheme 91).100 A pyridine 
derivative has also been successfully prepared using these conditions albeit with a 










A unique strategy for the synthesis of isatogen derivatives that does not require 
a cyclization method was reported by Sakamoto.102 This involved the oxidation of 2-
substituted indoles with 3 equivalents of oxodiperoxomolybdenum (VI) to afford 2-aryl 
isatogens (Scheme 92). Whilst this transformation is not possible using peracids, 
MoO5.HMPA was able to oxidize 2-phenylindole 158 to obtain 2-hydroxyindoxyl 160 
which could undergo spontaneous dehydration to form indolone 161 (Scheme 93). 
Further oxidation of the indolone intermediate by MoO5.HMPA gives the isatogen 
whereas using a peracid for the oxidation results in a Baeyer-Villiger-type rearrangement 










Bergman recently reported the use of m-CPBA and indoles to prepare 2-
substituted isatogens but with 2,3-dihydroindoles 164 as the intermediates to avoid the 
unwanted Baeyer-Villiger rearrangement observed with the indolone 162.103 2-
Arylindoles were prepared via Fischer indole synthesis and then reduced to indoline 
derivatives 164 by treatment with hydrochloric acid, ethanol and an excess of tin. The 
indolines were oxidized with 3 equivalents of m-CPBA in methanol to obtain the 2-
substituted isatogens in good yields (Scheme 95). Previously, Hooper reported the 
oxidation of 2-alkyl indolines 165 via the N-hydroxy indoline intermediate 166 to obtain 
the 2-alkylisatogens 167, the first report of such compounds (Scheme 96).104 Moreover, 
in a separate report, Hooper also described the oxidation of 2-substituted 1-
hydroxyindoles 168 with 4-nitrobenzoperoxoic acid to afford isatogens which suggests 
that the hydroxyindole could be an intermediate in the oxidation of indolines to isatogens 










With the emergence of transition metal catalysis as an important tool for many 
organic transformations, strategies to synthesise isatogens using transition metal 
catalysts started to appear more recently. Rosen reported what is effectively Bond and 
Hooper’s method but applying a Sonogashira reaction to couple iodonitrobenzene with 
the aryl acetylide 169.106 The initial idea was to use Pd catalyst to prepare the 
diarylacetylene intermediate 170 and then cyclize it to the isatogen using previously 
reported methods. Remarkably, after running the reaction at prolonged times, the desired 






Cikotiene also attempted a similar approach involving a diarylacetylene 
intermediate to synthesise isatogens containing pyrimidines.107 Whilst the Pd-catalyzed 
coupling of the aryl acetylene with the o-nitro chloropyrimidine 171 proceeded 
uneventfully, the subsequent cyclization was not observed under the reaction conditions. 
The diarylacetylene intermediates were isolated and traditional conditions were explored 
for the required cyclization to the isatogen. Eventually, the cyclization was effected using 
pyridine in ethanol to obtain the isatogens in excellent yields (Scheme 99). 
 
Scheme 99 
In their attempt to prepare a small library of isatogen derivatives, Nepveu 
employed three different strategies based on transition-metal catalysed reactions.108 One 
method involved Rosen’s approach where the Sonogashira coupling of the ortho-nitro 
arenes with terminal alkynes was followed by the cyclization of the diarylacetylene 
intermediate to obtain the isatogens in a one-pot procedure. The second method was 
applied for the cases where the concomitant cyclization did not occur therefore the 
diarylacetylene intermediates were treated with pyridine and DMAP at 140 °C to afford 
the isatogens (Scheme 100). Finally, the third strategy involved 1,2-diketone 
intermediates 174 which were treated with Zn and NH4Cl to effect a reduction of the nitro 








Gold catalysis has also been employed for the preparation of various 2-
substituted isatogens. Yamamoto described the AuBr3-catalyzed cyclization of ortho-
substituted nitrobenzene precursors which either resulted in isatogen formation or the 
generation of anthranils 175, depending on the substrate.94 With the alkyl substituted 
alkynes, anthranils are obtained selectively whilst analogues bearing aryl substituents 
gave the isatogens (Scheme 102). Employing more common Lewis acids such as 
BF3.OEt2 and TiCl4 were ineffective for the cyclization whilst the complete absence of a 
Lewis acid led to the corresponding products in moderate yields over prolonged times 
and elevated temperatures. 
 
Scheme 102 
Verniest reported the gold-catalyzed cyclization of o-nitrophenyl-propiolamides 
176 followed by an intramolecular dipolar cycloaddition to obtain 2-spiropseudoindoxyls 




cycloaddition is an isatogen therefore efforts were focused on finding suitable conditions 
to prepare the required isatogens. The major problem encountered was the formation of 
both the desired isatogen 178 and the anthranil derivative 179 using Au (I) catalysis 
(Scheme 104). Fortunately, Au (III) catalysts were more effective for the transformation 
in which selectivity towards the isatogen was observed with AuBr3 or an Au (III) catalyst 





Ramana carried out extensive investigations to understand the mechanism of the 
cyclization of o-alkynylnitrobenzenes to obtain both the isatogen and the anthranil 
derivatives.110 Using DFT calculations, it has been shown that anthranil formation 
proceeds via a 6-endo-dig cyclization in the presence of the gold catalyst. On the other 
hand, Ramana also demonstrated that using Pd catalyst afforded the isatogen product 
exclusively via a 5-exo-dig cyclization. Consequently, a wide range of 2-substituted 
isatogens bearing alkyl and aryl substituents were prepared in moderate to excellent 






Finally, Söderberg first reported the preparation of an isatogen bearing a 
substituent at the 2-position other than an aryl or an alkyl group.71 During their 
investigation to cyclize 1-(2-haloethynyl)-2-nitrobenzenes to the corresponding isatins 
using palladium catalysis, 2-bromoisatogen 181 was isolated in an 87% yield (Scheme 
106). Simultaneously, 2-iodoisatogen 184 was also observed when trimethylsilyl-alkyne 
182 was treated with AgNO3 alongside the expected iodo-alkyne product 183 (Scheme 
107). These 2-halogenated isatogens have not been previously reported and their 





Although the mechanism of isatin formation remains ambiguous, Söderberg 
proposed that the cyclization proceeds via 2-haloisatogens. It was then envisaged that 
developing an efficient methodology for the synthesis of 2-iodoisatogens and their 
subsequent reduction could provide a novel and innovative way to access isatins. 
Moreover, there was an opportunity to develop an alternative protocol involving a catalyst 
cheaper than palladium such as copper salts. Even more enticing was the prospect to 
investigate the unexplored chemistry of 2-iodoisatogens and unlock their potential as 





Results and Discussion 
Investigations into the Synthesis of Trimethylsilylacetylene Precursors  
Our unsuccessful attempts to prepare azaisatin derivatives prompted us to target 
alternative benzene fused substrates, with a particular emphasis on establishing the 
scope of isatin formation with a range of electron withdrawing and donating groups. To 
begin with, methods to synthesize the required TMS-acetylene precursors were 
explored. 
 







































































































































































Table 9        *ca. 80% purity 
 
A range of o-halo nitrobenzenes were used for Sonogashira coupling reactions 
to prepare the desired TMS-acetylene substrates. For the iodide coupling partners, the 
reaction proceeded uneventfully using PdCl2(PPh3)2 (5 mol%) and CuI (10 mol%) in the 
presence of DIPA at 0 °C. The TMS-acetylene products were obtained in excellent yields 
as summarized in Table 8. In contrast, the bromide coupling partners did not react 
effectively using the same conditions employed for the iodide counterparts. 
Subsequently, the conditions were varied by increasing the Pd catalyst loading to 10 
mol% and by heating the reaction under reflux in triethylamine. However, in the presence 
of 10 mol% CuI as a co-catalyst, Glaser coupling was observed which diminished the 
product yields. The reaction was therefore performed without CuI which generated the 
TMS-acetylene substrates in good yields as summarized in Table 9. Finally, a fluoride 
precursor 196 was used in a nucleophilic aromatic substitution reaction to obtain the 
corresponding TMS-acetylene. Yoakim reported a SNAr reaction between aryl 
nitrofluorides and triethylsilylacetylene in the presence of NaHMDS.111 Unfortunately, 
using these conditions only gave the expected TMS-acetylene 187 in a 20% yield 
(Scheme 108) therefore the iodide precursor was used for the Sonogashira reaction to 






























































































































































Investigations into the Synthesis of Iodoacetylene Precursors 
With the TMS-acetylene precursors in hand, the iodination reactions were 
performed using N-iodosuccinimide in the presence of silver nitrate. Most of the reactions 
proceeded uneventfully with the iodoacetylene substrates obtained in moderate to good 
yields as summarized in Table 10. However, it was observed that the iodoacetylene 
intermediates are relatively unstable to air and light with decomposition apparent upon 
standing at room temperature. It was then investigated whether the more stable TMS-
acetylene precursors could undergo cyclization to generate TMS-isatogens, with the 
objective of transforming these compounds into the corresponding iodoisatogens at a 
later stage. 
 
Investigations into the Synthesis of Trimethylsilyl-isatogens 
As described earlier, Ramana reported a general synthesis of alkyl and aryl 
isatogens via the palladium catalyzed cycloisomerization of o-alkynylnitrobenzenes.110 
Previously, Yamamoto reported that this nitro-alkyne cyclization proceeded in the 
presence of gold (III) bromide or an iridium hydride complex, although a mixture of the 
desired isatogen and anthranil was obtained.94 Huisgen proposed a mechanism leading 
to the formation of isatogens (Scheme 109)112 while Crabtree suggested a different 
mechanism to access anthranils (Scheme 110).113 Ramana then investigated the 









Whilst PdCl2(PPh3)2 and Pd(OAc)2 were found to be ineffective, the cyclization 
proceeded uneventfully using PdCl2 or PdBr2. The yields were further improved by 
employing the acetonitrile and benzonitrile complexes of these Pd catalysts. A wide 
range of o-alkynylnitrobenzenes were subjected to the reaction conditions, highlighting 
the compatibility of substituents such as free alcohols, alkenes, and electron-rich and 
electron-poor aryl groups.110 However, the synthesis of trimethylsilyl-isatogen 208 had 
not been described in their investigation and it was decided to explore the 
cycloisomerization of TMS-alkynylnitrobenzene using Ramana’s conditions.  
 
Entry Cat. loading Temp. Time Result 
1 10 mol% 25 °C 4 h No reaction 
2 10 mol% Reflux 24 h No reaction 
3 50 mol% Reflux 24 h No reaction 





Treatment of TMS-alkynylnitrobenzene 67 with 10 mol% of Pd(CH3CN)2Cl2 at rt 
for 4 h showed no reaction while heating the reaction at reflux for 24 h proved to be 
ineffective (Table 11). Increasing the catalyst loading to 50 mol% and subsequently using 
stoichiometric amounts of transition metal catalyst also gave no reaction. With efforts to 
synthesise the TMS-isatogen proving to be futile, attention was turned to the 
cycloisomerization of the iodoacetylene precursors to obtain iodoisatogens. Efforts were 
also focused on whether a cheaper copper catalyst can be employed to achieve the 
desired cyclization. 
 
Investigations into the Copper-catalyzed Synthesis of Iodoisatogens 
Using 1-(iodoethynyl)-2-nitrobenzene 68 as the model substrate, the viability of 
the cyclization was investigated using a number of palladium and copper catalysts (Table 
12). Initially employing Söderberg’s conditions did result to the isatin but only with a 
moderate yield of 46%. 
 





1 PdCl2(PPh3)2 5 mol% acetone 0% 46% 
2 CuI 10 mol% acetone 0% 27% 
3 CuCl2 10 mol% acetone 0% 22% 
4 PdCl2(PPh3)2 5 mol% CH2Cl2 0% 30% 
5 PdCl2(PPh3)2 5 mol% THF 0% 55% 
6 CuBr.DMS 50 mol% THF 73% 13% 
7 CuBr.DMS 25 mol% THF 89% 8% 





Substituting the Pd catalyst with copper salts resulted to poor yields of isatin with 
no isatogen detected. Changing the solvent from acetone to THF to enable use of 
anhydrous conditions only resulted to a marginal improvement of the isatin yield. 
Remarkably however, using 50 mol% of CuBr.DMS in THF afforded the desired 
iodoisatogen in a 73% yield with only 13% of isatin isolated. The selectivity for the 
isatogen further improved by decreasing the loading to 25 mol%. However, increasing 
the loading to 1 equivalent gave the isatin exclusively with a moderate yield of 60%. It 
was then hypothesised that the copper salt not only catalyzes the cycloisomerization to 
the iodoisatogen but it also effects the transformation of iodoisatogen to isatin. 
 
Entry Cat. loading Time Isatogen Yield Isatin Yield 
1 25 mol% 16 h 63% 23% 
2 25 mol% 1.5 h 91% 0% 
3 10 mol% 5 h 70% 16% 
Table 13 
 
Entry Cat. loading Time Isatogen Yield Isatin Yield 
1 25 mol% 16 h 56% 44% 
2 25 mol% 0.5 h 99% 0% 






With an effective copper-catalyzed cyclization in hand, the cycloisomerizations of 
a range of electron-rich and electon-poor iodoacetylenes were attempted. Starting with 
iodo-acetylene 197, the desired isatogen 210 was obtained in a 63% yield and the 
corresponding isatin 211 in a 23% yield after running the reaction for 16 h (Table 13). 
Similar results were observed with the cyclization of iodoacetylene 183 which furnished 
the isatogen 184 in a 56% yield and the isatin 212 in a 44% yield after a reaction time of 
16 h (Table 14). It was then discovered that the reactions with the electron-rich 
substrates proceeded much faster compared to the electron-neutral aryl iodoacetylenes, 
with the cyclizations found to be complete within 2 h. The desired 6-methyl-2-iodo-
isatogen 210 and 5-methoxy-2-iodo-isatogen 184 were then obtained in excellent yields 
with only traces of the corresponding isatin observed after 0.5-2 h. As expected, running 
the reaction for longer times led to the formation of the corresponding isatins. 
The subsequent cyclizations were then carefully monitored by TLC analysis in 
order to stop the reaction as soon as complete consumption of the starting material was 
observed. The reaction was also attempted using 10 mol% of the catalyst but this led to 
longer reaction times which resulted to the formation of isatin. Further examples of 
electron-rich analogues were explored and pleasingly, the iodoisatogens were 
synthesized in excellent yields as summarized in Table 15. In all cases, the cyclizations 
are reproducible on a gram scale and the isatogen products are stable for a few weeks 
if stored below ambient temperature in the absence of light. Problems were encountered 
when the cyclization of the aniline substrate 201 was attempted which could be as a 
result of the copper catalyst coordinating to the free amine. Accordingly, the 
corresponding acetanilide 215 was prepared and the cyclization proceeded to obtain the 



















































With these promising results, the cyclizations were then attempted with the 
electron-poor iodoacetylenes using the same conditions. Unfortunately, treating the 
nitro- substituent 200 with 25 mol% of CuBr.DMS gave no reaction (Scheme 112). 
Doubling the catalyst loading to 50 mol% also returned starting material whereas using 
a stoichiometric amount of Cu-salt and running the reaction for long times led to a 
complex mixture. Similarly, with the trifluoromethyl-substituent 207, performing the 
reaction for long times with 25 mol% of catalyst led to no reaction and decomposition of 
starting material (Table 16). Increasing the catalyst loading to 50 mol% and then using 
stoichiometric amounts did not show improvement. Moreover, using microwave 








 Conditions Time Result 
1 25 mol% CuBr.DMS, THF, reflux 24 h Complex mixture 
2 50-100 mol% CuBr.DMS, THF, reflux 6 h Complex mixture 
3 1 eq. CuBr.DMS, DMF, µw:200W, 150 °C 1 h Complex mixture 
4 1 eq. CuBr.DMS, DMF, µw:200W, 100 °C 3 min Glaser coupled product 
Table 16 
 
Efforts were therefore turned to finding a more active copper catalyst to achieve 
the cyclization more efficiently. Treatment of the bromo-substituent 202 with 25 mol% of 
copper (I) iodide, a more electrophilic copper source, for 24 h gave no reaction. 
Fortunately, employing 25% of [Cu(MeCN)4][BF4] after 8 h gave the desired isatogen 219 
albeit as a mixture with isatin and starting material (Table 17). Increasing the catalyst 
loading to 50 mol% gave the same results while running the reaction for 24 h with 
catalytic [Cu(MeCN)4][BF4] resulted to a mixture of isatin and starting material. These 
results suggested that the isatogen being formed is converted to the corresponding isatin 
if left for a long period of time and even if the starting iodoacetylene is not fully converted 
to isatogen. It is therefore essential to ensure that the isatogen-forming reaction is fast 
and that the reaction is stopped before conversion to the isatin is observed. 
 
 Conditions Time Result* 
1 25 mol% [Cu(MeCN)4][BF4] 8 h 
Isatogen + isatin + starting 
material 
2 50 mol% [Cu(MeCN)4][BF4] 24 h Isatin + starting material 




Gratifyingly, the use of 1 eq. of the copper complex led to full conversion of the 
starting iodoacetylene after 30 min. and furnished the isatogen 219 in a 64% yield. 
However, the cyclization of the nitro-substituted analogue led to complete disappearance 
of starting material but with no identifiable product isolated. Nonetheless, the reaction of 
the other electron-poor substrates proceeded reasonably well, delivering the 
corresponding isatogens in moderate yields as summarized in Table 18. 
 





























































Finally, the cycloisomerization of the pyridine analogues was reinvestigated using 
these conditions. Treating 4-(iodoethynyl)-3-nitropyridine 134 with 25 mol% of 
CuBr.DMS after 8 h gave the corresponding isatogen albeit in less than 10% yield 
(Scheme 113). Running the reaction for 24 h and using super-stoichiometric amounts of 
CuBr.DMS (1.2 eq.) resulted in a complex mixture. The cyclization of 3-(iodoethynyl)-4-
nitropyridine 1-oxide 142 was also attempted using 25 mol% of CuBr.DMS with the 
anticipation that the N-oxide would act as an electron-donating substituent hence making 




h and running the reaction for more than 24 h led to decomposition of starting material. 
Moreover, the same problems were encountered when the substrates were treated with 







Sӧderberg proposed a mechanism for the formation of isatogen based on the 







According to the proposed mechanism, a metal complex undergoes protonolysis, 
followed by hydrolysis to form a nitrosobenzene derivative 226 which can cyclize and 
undergo dehydration to yield the isatogen. On the other hand, Ramana suggested a 
different mechanism involving the addition of nitro oxygen to the alkyne in a 5-exo-dig 




Based on both hypotheses, the reactivities of the electron-rich and electron-poor 
iodoacetylene precursors can be explained by considering the first step of the 
mechanism involving the attack of the nitro group to the metal-alkyne complex. By 
incorporating an electron donating substituent into the aryl ring, the nucleophilicity of the 
nitro group is enhanced hence enabling a more facile nucleophilic attack. Moreover, 
increasing electron density on the aromatic ring may also promote binding of Cu-to the 
alkyne. On the other hand, the incorporation of electron-withdrawing groups would retard 
these processes (but would nevertheless enhance electrophilicity of the alkyne). It is 
worth bearing in mind that electron deficient substrates do react, but don’t provide clean 




competing isatin-forming reaction remains a significant factor which influences the yield 
of the desired isatogens. 
 
Investigations into the Reduction of Isatogen to Isatin 
There are no established protocols in the literature for the direct conversion of 
isatogen to isatin. Sӧderberg suggested that their Pd-catalyzed synthesis of isatin most 
likely proceeds via the isatogen, although a mechanism was not proposed.71 
Nonetheless, 5-methoxy-2-iodoisatogen, the most reactive substrate in this 
investigation, was subjected to Sӧderberg’s conditions to see whether this would convert 
the substrate to the corresponding isatin. Unsurprisingly, treatment of the isatogen 184 






Analysis of the reaction mixture obtained after reduction of the isatogen with 
PdCl2(PPh3)2 provided evidence for the formation of triphenylphosphine oxide (1H NMR 
spectrum of the crude material). This led to the hypothesis that triphenylphosphine might 
be acting as a reducing agent in the same way that it reduces aromatic N-oxides to the 
corresponding amines. Accordingly, 5-methoxy-2-iodoisatogen was treated with 3 eq. of 




However, the resulting triphenylphosphine oxide by-product proved to be very difficult to 
separate from the desired product by flash column chromatography. 
 
Scheme 119 
In an endeavour to avoid the triphenylphosphine oxide which proved to be 
problematic, the reducing agent was replaced with triethylphosphite (Scheme 119). The 
resulting by-product, triethylphosphate, is a liquid which is easier to remove hence 
isolation of the desired isatin would be more facile. Unfortunately, although all the starting 
material was consumed after 5 h, no isatin was detected after treatment of the isatogen 
with excess triethylphosphite. The crude mixture contained a number of intensely 
coloured compounds and we have speculated that indigo related products114-116 could be 
formed (Figure 6) although no compounds have been isolated and characterized. 
 
Figure 6 
Using sodium thiosulfate as an alternative reducing agent was also ineffective 






A wide variety of metals were then explored for the reduction of the isatogens, in 
which reagents used for the deoxygenation of amine N-oxides were focused on. 
Reported conditions involving ruthenium,117 cerium,118 copper,119 zinc120 and titanium121 
were all ineffective for the required transformation (Table 19). More promising results 
were obtained using Mo(CO)6122 and InCl3117 in which the desired isatin was isolated in 
moderate yields. It was then decided to optimize the reaction conditions using InCl3. 
 
Entry Conditions Yield 
1 RuCl3.xH2O (1 eq.), MeCN, Δ, 24 h 0% 
2 CeCl3.7H2O (2 eq.), Zn (4 eq.), MeOH, rt, 18 h 0% 
3 CuI (1 eq.), Zn (1 eq.), EtOH, Δ, 18 h 0% 
4 TiCl4 (1 eq.), NaI (3 eq.), MeCN, rt, 2 min. 34% 
5 Mo(CO)6 (1 eq.), EtOH Δ, 3 h 38% 
6 InCl3 (1 eq.), MeCN, Δ, 30 h 47% 
Table 19 
 
Entry InCl3 Solvent Time Yield 
1 1 eq. MeCN 30 h 47% 
2 2 eq. MeCN 24 h 58% 
3 2 eq. MeCN:H2O (10:1) 18 h 73% 
Table 20 
Whilst InCl3 effectively transforms the iodoisatogen to isatin, it was observed that 
most of the starting material was still present even after heating for 30 h. Doubling the 
equivalents only marginally improved the yield and unconverted isatogen was still 
detected after 24 h. It was then envisaged that the reaction mechanism involves the initial 




Accordingly, water was added to the reaction mixture which converted all the starting 




With effective conditions to reduce the isatogens to the corresponding isatin, two 
more examples were studied to obtain isatin analogues in good yields. Using this new 
strategy, a number of isatins which are either not commercially available or very 
expensive can be obtained in reasonable quantities. Moreover, this new approach avoids 
the use of expensive palladium catalyst for the cyclization to isatogens and the 
subsequent reduction to isatins. This efficient synthetic methodology was performed with 
easily accessible starting materials and relatively non-toxic reagents making it an 










Investigations into the Functionalization of 2-Iodoisatogen 
Having developed an efficient method to synthesise 2-iodoisatogens and to 
reduce them to the corresponding isatins, efforts were turned to functionalizing these 
novel substrates to access new heterocyclic products other than isatins. Specifically, we 
decided to concentrate efforts on elaborating the C-I bond and finding suitable 
nucleophiles to displace the iodide and form novel heterocyclic products. The first 
strategy proposed was employing Pd-catalyzed cross coupling reactions although the 
tendency of Pd to reduce 2-iodosatogens to isatins was an anticipated problem.  
 
Scheme 123 
In an effort to avoid this potential drawback, initial Pd-catalyzed cross coupling 
reactions were attempted at room temperature in order to slow down the reduction to 
isatin. However, it was disappointing to find that Suzuki reactions employing Fu’s 
conditions123 failed to give any of the desired cross-coupled products at room 
temperature and application of heat only led to isatin products. Nevertheless, a 
Sonogashira reaction was attempted at 0 °C to room temperature and pleasingly, this 
resulted in the desired cross-coupled product, albeit at a moderate yield of 35%. 
Fortunately, increasing the equivalents of the acetylene coupling partner to 3 lead to a 
more promising yield of 68% (Table 21). Buoyed by these encouraging results, it was 
decided to explore the scope of this cross-coupling reaction which was not previously 
reported. However, the reaction with phenylacetylene gave the expected product in a 






Entry TMS-acetylene Time Yield 
1 1.5 eq. 5 h 35% 
2 1.5 eq. 24 h 36% 
3 2 eq. 1 h 68% 
Table 21 
 
Entry phenyl-acetylene Pd. cat Cu cat. Time Yield 
1 3 eq. 5 mol% 5 mol% 1 h 44% 
2 3 eq. 5 mol% 0 mol% 24 h 0% 
3 3 eq. 5 mol% 5 mol% 1 h 0% 
4 0 eq. 5 mol% 5 mol% 24 h 0% 
5 3 eq. 10 mol% 2.5 mol% 0.5 h 51% 
Table 22 
As the reaction in the presence of 5 mol% of CuI led to Glaser coupled product, 
which is common in Sonogashira cross-coupling reactions, the copper catalyst was 
removed but this completely shut down the reaction (Table 22). Adding phenylacetylene 
portion wise to alleviate the homocoupling problem did not help either as this resulted in 
a complex mixture. Finally, doubling the loading of Pd catalyst to 10 mol% and 
decreasing the amount of Cu catalyst improved the yield to 51%. 
Using other acetylene cross-coupling partners gave the desired products in 
moderate yields (Table 23). Interestingly, one by-product isolated in the reaction with 1-
hexyne was the rearranged product 233 which was previously reported by Ibrahim 




catalyst; in this case the base employed acted as a nucleophile and added to the 
isatogen product (Scheme 125). Since this unusual reaction has not been previously 
reported, the addition of different amines were next investigated. 
 









































Preliminary experiments focused on replacing the diisopropylamine base with 
piperidine and pyrrolidine, however these generated complex mixtures when 2-
iodoisatogen 184 was used as the starting material. It was then speculated that the 




Accordingly, the 2-alkynylisatogen 230 was subjected to the reaction conditions but 
again, this resulted to complex mixtures (Scheme 127). Moreover, the reaction of 
allylamine without the presence of any copper catalyst resulted in the recovery of starting 






With the endeavours to add amines to 2-iodoisatogens proving futile, the addition 
of alcohols was next investigated. Treating 2-iodoisatogen 184 with 3 equivalents of allyl 
alcohol led to recovery of starting material (Scheme 129). Adding sodium hydride to the 
reaction led to full consumption of starting material after 5 mins but only the double 
addition product 239 was isolated in a 28% yield (Scheme 130). In an effort to obtain 
only the mono-addition product, only 1 equivalent of allyl alcohol was added and the 
reaction was performed at 0 °C but only the double addition product was obtained in an 








Inspired by Ramana’s report of adding indoles to 2-phenylisatogens in the 
presence of an indium catalyst,125 the same reaction with 2-iodoisatogens was explored 
next. Treating isatogen 184 with 20 mol% of InCl3 and 1.1 equivalents of indole gave the 
desired product 240 in a poor yield of 18%. Replacing the indium catalyst with In(OTf)3 
afforded the product in an improved yield of 52% (Scheme 131). Unfortunately, all 











With the addition of various nitrogen and oxygen based nucleophiles to 2-
iodoisatogens giving only moderate yields at best, focus was shifted back to Pd-
catalyzed cross coupling reactions. After the success of the Sonogashira reactions, 
Negishi couplings were next explored in the effort to prepare 2-arylisatogens. Whilst 
these compounds are quite well known in the literature already, the established routes 
towards these intermediates incorporate the aryl group at an early stage of the synthesis. 
An opportunity to develop a new aryl coupling strategy with 2-iodoisatogens to obtain the 
corresponding 2-aryl analogues was, therefore, advantageous. 
 
Entry PhZnCl Pd. cat ligand Time Yield 
1 3 eq. PdCl2(dppf)2 10 mol% - 24 h 28% 
2 3 eq. Pd2(dba)3 2.5 mol% SPhos 5 mol% 4 h 45% 
3 3 eq. Pd2(dba)3 2.5 mol% RuPhos 5 mol% 24 h 25% 
4 3 eq. Pd2(dba)3 2.5 mol% XPhos 5 mol% 24 h 21% 
5 5 eq. Pd2(dba)3 2.5 mol% SPhos 2.5 mol% 24 h 30% 
6 5 eq.* Pd2(dba)3 2.5 mol% SPhos 2.5 mol% 24 h 22% 
Table 24   *added portion wise 
To begin the investigation for the Negishi couplings, 2-iodoisatogen 184 was 
treated with 3 equivalents of phenylzinc iodide in the presence of 10 mol% of 
PdCl2(dppf)2. The organozinc reagent was prepared in situ by the addition of zinc 
chloride to the corresponding aryl Grignard reagent and pre-mixing before addition to the 
reaction mixture. This initial reaction gave the desired 2-phenylisatogen 229 in a 28% 
yield with some starting material recovered. The Pd catalyst was replaced with Pd2(dba)3 
and a variety of Buchwald phosphine ligands were explored. SPhos proved to be the 
best ligand which afforded the product in a 45% yield but some starting material was still 




mixture started to become more complex and the product was only obtained in a 30% 
yield. Adding the organozinc reagent portion wise was not beneficial and only resulted in 
a 22% yield of desired product. It was observed that the reaction mixtures tended to be 
very complex with the presence of homo-coupled by-product evident in the NMR spectra 
of the crude mixtures. 
 
Scheme 133 
Attempts to vary the electronic properties of the arylzinc chloride coupling partner 
involved using p-trifluoromethylphenylzinc chloride but this only favoured homocoupling 
of the organozinc reagent (Scheme 133).  Remarkably, when a control experiment was 
performed where the 2-iodoisatogen was treated with 5 equivalents of arylzinc chloride 
in the absence of Pd catalyst, the desired product was obtained in a 68% yield. Using 
Rieke organozinc reagent phenylzinc iodide did not yield any product whatsoever which 
suggests that preparing the organozinc reagent from the corresponding Grignard 
reagent is crucial. It is possible that excess Mg salts present in the reaction mixture aid 
the cross-coupling since using less than 5 equivalents of Grignard gave the product in 
inferior yields. 
The scope of this aryl coupling was then explored by treating 2-iodoisatogen 184 
with a selection of arylzinc chlorides, and these were all found to react smoothly. 
Electron-withdrawing and electron-donating substituents on the arylzinc chloride can be 
tolerated which afforded the 2-arylisatogens in good yields (Table 25). The chemistry 
can also be applied to the halogenated analogues of 2-iodoisatogens but the inherent 
instability of these compounds led to the 2-arylisatogen products in modest yields. 
Moreover, the 7-chloro substituted isatogen 247 was also obtained but this compound 















































































Finally, with the displacement of the iodide observed already, it was envisaged 
that 2-iodoisatogens could also be used as intermediates to prepare 2-acylidene 3-
oxindoles 248 which are the isomers of the initially targeted 3-acylidene 2-oxindoles 3 
(Figure 7). Whilst the synthesis and chemistry of the 2-oxindole isomers are well 
established, strategies to prepare the 3-oxindole counterparts are quite limited. As well 
as bearing useful biological properties,126,127 these compounds have also been proven to 
be useful intermediates in organic synthesis.128 For instance, these oxindoles have been 







The initial strategy devised to prepare these 2-acylidene 3-oxindoles involved the 
use of α-arylacetic acid t-butyl esters. It was envisaged that displacing the iodide with 
dicarbonyl 249 would give intermediate 250 which could be acidified to obtain the desired 
oxindole (Scheme 134).  
 
Scheme 134 
Unfortunately, after trying a variety of bases to aid the reaction, the displacement 
proved to be difficult and no desired product was obtained (Table 26). Remarkably, both 
unreacted keto ester and isatogen were recovered from the reaction mixture which 
suggests that the deprotonation step might not be taking place due to steric hindrance 
from the t-butyl group. 
 
Entry R1 base solvent Temp. Yield 
1 phenyl NaH (2 eq.) THF Δ 0% 
2 4-chlorophenyl LiHMDS (1 eq.) THF -78 °C to rt 0% 






Entry ketone additive time Yield 
1 1 eq. - 15 mins 12% 
2 1 eq. - 1 h 20% 
3 1 eq. NaI 1 h 18% 
4 4 eq. - 4 h 9% 
Table 27 
The next strategy explored is much simplified in which aryl ketones where 
envisaged to displace the iodide and obtain the corresponding acylidene oxindoles in 
one step. Accordingly, 2-iodoisatogen 184 was treated with acetophenone and sodium 
hydride which led to full consumption of starting material after 15 mins but only gave 
product 251 in a poor yield of 12% (Table 27). Changing the base to LiHMDS only 
marginally improved the yield and using sodium iodide as an additive to aid the 
displacement did not prove beneficial. Moreover, adding an excess of the ketone was 
ineffective and product was only generated in less than 10% yield. It was then decided 
to form the silyl enol ether of the ketone and react with the 2-iodoisatogen 184 in the 
presence of TMSOTf as the Lewis acid. This proved to be ineffective as the starting 
isatogen decomposed under the reaction conditions. 
 
Scheme 135 
We returned to the initial idea of using a β-keto ester nucleophile, but a substrate 




intention of performing a decarboxylation-reduction sequence to generate the desired 
acylidene oxindole (Scheme 136). Hence, isatogen 184 was treated with β-keto ester 
253 in the presence of sodium hydride to obtain isatogen 254 in an 89% yield. 
Remarkably, it was discovered that upon treatment with 3 equivalents of lithium iodide 
at 180 °C, the isatogen underwent decarboxylation with concomitant reduction of the N-
O bond to generate 2-acylidene 3-oxindole 251 (Scheme 137). Since the product was 






Since the traditional mechanism proposed for the Krapcho decarboxylation 
involves an SN2 reaction where the iodide attacks the alkyl group of the ester,130 it was 
envisaged that having the less sterically hindered methyl group will aid the 
decarboxylation. Accordingly, β-keto ester 255 which is not easy to obtain commercially 
was prepared by treating the corresponding ethyl ester 253 with acid in methanol. The 
resulting methyl ester was reacted with isatogen 184 which gave the product 256 in an 
86% yield. Pleasingly, the decarboxylation-reduction sequence proceeded to generate 






The displacement reaction was then applied to different iodoisatogens and β-keto 
esters to obtain 3 more examples of the isatogen intermediate required for 
decarboxylation (Table 28). Unfortunately, applying the subsequent decarboxylation-
reduction sequence with the other substrates only gave the acylidene oxindoles in 
modest yields (Table 29). One by-product in the crude reaction mixture which was 
detected by LC-MS was the deoxygenated starting material 263 that could be derived 
via iodide addition at the N-O bond rather than the ester C-O bond (Scheme 138). In 
addition, when the reaction was run over longer times, the deoxygenated compound 
failed to convert to the acylidene oxindole and could still be detected in the reaction 
mixture, which suggests that 263 is not an intermediate in the 2-acylidene 3-oxindole 
forming pathway. Regardless, it was necessary to find a different reagent to effect the 












































































Murphree reported the use of microwave conditions for the Krapcho 
decarboxylation of alkyl malonate derivatives.131 A new mechanism was also proposed 
in which water is required to generate a hydroxide ion that can attack the carbonyl 
(Scheme 139). Hence, isatogen 256 was treated with a variety of lithium salts in aqueous 
microwave conditions. Unfortunately, the product could only be obtained in around 25% 
yield and the crude mixtures were always rather complex. Moreover, acetophenone was 
observed in the crude mixture which could arise from an isatogen 256 hydrolysis-
decarboxylation pathway (Scheme 140). With these observations in mind, it was 










We next screened a series of salt additives under anhydrous conditions. From 
the salts employed for the reaction, sodium iodide gave the best results providing the 
acylidene oxindole with a 62% yield (Table 30). Only traces of the deoxygenated starting 
material was observed, possibly because of the low Lewis acidity of the sodium cation. 
With these new conditions, the decarboxylation was applied to the other substrates to 
obtain 4 examples of 2-acylidene 3-oxindoles in improved yields (Table 31). 
 
Entry salt Yield 
1 LiI 56% 
2 LiCl 44% 
3 NaI 62% 


































The 2-acylidene 3-oxindoles were isolated as single olefin isomers and 
compound 262 was determined to have the Z-configuration by X-ray crystallography 
(Figure 8). By analogy, the remaining analogues were tentatively assigned as the Z-
isomers as well. This can be attributed to the potential H-bond formed between the 
carbonyl and the amine proton. Moreover, with the Z-configuration, dipole-dipole 








Isatogens are interesting compounds that are traditionally prepared via the 
cyclization of 2-nitrophenylacetylenes under acidic or basic conditions or via the 
oxidation of 2-substitued indoles. In this investigation, novel 2-iodoisatogens were 
prepared via the copper-promoted cycloisomerization of 2-nitrophenyl iodoacetylenes in 
moderate to excellent yields. These isatogens have been transformed to the 
corresponding isatin analogues effectively by treatment with indium chloride or 
molybdenum hexacarbonyl. This represents a cheaper and more efficient protocol to 
synthesise isatins without the use of toxic reagents and harsh conditions which have 
hampered previously reported strategies. 
The versatility of 2-iodoisatogens has also been highlighted in which a wide range 
of novel nitrogen-containing heterocycles have been prepared via the elaboration of the 
C–I bond. Sonogashira reactions have been performed to couple 2-iodoisatogens with a 
variety of acetylenes to obtain novel 2-alkynylisatogens. 2-Arylisatogens were furnished 
via the substitution of 2-iodoisatogens with arylzinc chlorides in the absence of Pd 
catalyst. Notably, this provides a new aryl coupling strategy since established routes 
towards 2-arylisatogens incorporate the aryl group at an early stage of the synthesis. 
Finally, a two-step displacement-decarboxylation sequence has been devised to 
prepare 3-acylidene-2-oxindoles. These intermediates are isomers of 2-acylidene-3-
oxindoles which are biologically important and potential treatment for Idiopathic 
Pulmonary Fibrosis. Further research would be useful to determine what other 
transformations could be carried out on 2-iodoisatogens by exploiting the reactivity of the 
C–I bond. This would unlock the potential of these versatile compounds as useful 
intermediates in organic synthesis. 
 




Chapter 4: Synthesis of Febrifugine Analogues 
Introduction 
Febrifugine 5 is an alkaloid that exists in the leaves and roots of the Chinese herb 
Dichroa Febrifuga of the Saxifragaceae family.132 For centuries, the Chinese have been 
using this medicinal plant as a treatment for symptoms of fever but it wasn’t until 1943 
when Chou disclosed that a crude extract from the roots (Chang Shan) could be applied 
in clinical cases of tertian malaria.133 The first reported isolation of febrifugine and the 
related compound isofebrifugine was in 1946 when Chou extracted two alkaloids from 
Chang Shan which were initially termed ‘dichroine A’ and ‘dichroine B’.134 Koepfli named 
the two alkaloids as febrifugine and isofebrifugine in 1947, after the empirical formula of 
dichroine B was calculated to be C16H19O3N3.135  
 
Figure 9 
Further progress towards elucidating the structure of febrifugine emerged in 1948 
when Chou disclosed that the dichroine alkaloids were in fact isomers that interconverted 
under acidic and basic conditions, and with the application of heat.136 Later that year, in 
a chemical degradation study, quinazolinone was isolated by Chou which was a 
structural motif prevalent in many reported alkaloids during the time. Accordingly, Koepfli 
proposed structures for febrifugine and isofebrifugine with the quinazolinone core and a 
hemiketal motif with different configurations at the hemiacetal carbon atom for both 
diastereoisomers (Figure 9).137 However, the emergence of a new alkaloid similar to the 
pair of isomers in 1952 led to the proposed structures of febrifugine and isofebrifugine to 
be modified. 
Extracts from the plant Hydrangea umbellata which also comes from the 




Baker, Hutchings and Williams then synthesised analogues of febrifugine and compared 
them to the naturally occurring substance. Hence it was concluded that febrifugine and 
the hydrangea alkaloid were identical and a new structure 266 was proposed which 
contained a hydroxy group on the piperidine and a keto linker.139 Finally, after efforts to 
synthesise febrifugine and isofebrifugine by different groups such as Kobayashi140 and 
Takeuchi,141 the ambiguity surrounding their structures was finally clarified which 
eventually led to the verification of the structures as 5 for febrifugine and 263 for 
isofebrifugine (Figure 10). 
 
Figure 10 
Whilst Dichroa Febrifuga has been used in East Asia to treat various ailments for 
over 2,000 years, the mechanism of action of the active components remained unknown. 
Studies in the 1970’s however identified key structural features of febrifugine which are 
essential for its biological activity. The preparation and assessment of febrifugine 
analogues as potential antimalarial drugs revealed that the amino and hydroxyl group of 
the piperidine ring as well as the quinazolinone core were crucial for activity.142 Moreover, 
the discovery that the unnatural enantiomer possessed very modest activity showed that 
the absolute configuration was also important.143 
 
Figure 11 
The emergence of halofuginone 6 in the late 1960’s as a useful synthetic 




compounds. Halofuginone has been shown to be more active as an antimalarial drug 
than febrifugine itself and it reduces the side-effects observed in humans such as nausea 
and vomiting. As a result, interest in halofuginone has increased in the past few decades 
and it has progressed to phase 2 clinical trials as a potential cancer treatment.144 It has 
also been demonstrated to be an effective antifibrotic agent among other useful 
biological properties.139 
Recently, it has been established that febrifugine and halofuginone are inhibitors 
for the differentiation of proinflammatory TH17 cells via the activation of the amino acid 
response (AAR) pathway.145 This could be triggered by the inhibition of aminoacyl-tRNA 
synthetases which results in the intracellular accumulation of uncharged tRNAs. The 
activity of aminoacyl-tRNA synthetases is crucial as they are responsible for the 
aminoacylation of tRNAs which entails the attachment of amino acids to specific 
tRNAs.146 This particular role in protein synthesis is so vital that when it is inhibited, the 
viability of all cell types is suppressed and hence, cell growth is also arrested. 
 
Figure 12 (Reproduced with kind permission by Nature Reviews) 
Human prolyl-transfer RNA synthetase or ProRS is the specific target of 
febrifugine and this enzyme is responsible for the formation of aminoacyl adenylates 
(AA-AMP) which transfer activated amino acids to tRNAs (Figure 12).147 This process 




the active site to block ATP and the incoming tRNA. However, it has been shown that 
ATP is actually essential for the binding of febrifugine/halofuginone to the active site.148 
This observation suggests that febrifugine/halofuginone are not mimics of AA-AMP and 
could instead be binding to ProRS via a different mechanism altogether. 
To explain the inhibition of ProRS by halofuginone, a crystal structure of the 
binding site has been reported by Zhou and Schimmel which reveals the vital interactions 
between halofuginone, ProRS and ATP (Figure 13).147 Hydrophobic stacking and 
hydrogen bonding interactions of ProRS and the adenosine group of ATP, in addition to 
the hydrogen bonding of ProRS and the ribose of ATP, allow ATP to form a cap over the 
binding pocket. As a consequence of these numerous interactions, the ATP sits in a bent 
conformation which allows the α-phosphate to form hydrogen bonds with the ketone and 
the hydroxy group of halofuginone. The ATP therefore orientates halofuginone to form 
further hydrogen bonds with the ProRS binding site. These further interactions with 
ProRS allow halofuginone to occupy two pockets of the binding site hence acting as a 
dual site inhibitor. Whilst the quinazolinone moiety blocks the pocket where tRNA 
normally binds, the hydroxypiperidine part of halofuginone also mimics proline and 
prevents the binding of proline to ProRS (Figure 14). 
 





Figure 14 (Reproduced with kind permission by Zhou and Schimmel) 
The reported crystal structure of the binding site showing the interactions with 
halofuginone suggests an analogous mode of action for febrifugine. Whilst the template 
used to determine the binding with halofuginone was the Thermus thermophilus ProRS, 
it has been shown that febrifugine binds similarly with Plasmodium falciparum ProRS 
which is highly similar to that of human ProRS (Figure 15).147 
 




With the existing model as a reference, it was then possible to design febrifugine 
analogues for synthesis with the incentive to test them as potential therapy for IPF. The 
first strategy was to simplify the febrifugine structure and interrogate the binding at the 
southeast polar region. This entailed replacing the piperidine ring with different amine 
groups to introduce potential new hydrogen bonding interactions. Furthermore, the 
importance of the keto linker was also examined by incorporating other groups that could 
hydrogen-bond with the phosphate of ATP, or by varying the carbon chain length 





Results and Discussion 
Synthesis of Quinazolinone Epoxide 
Initial efforts to synthesise different analogues of febrifugine focused on exploring 
the binding in the southeast polar region while keeping the quinazolinone core 
unchanged. The early strategy to prepare the desired analogues involved the use of 
different nucleophiles to attack epoxide 267 regioselectively (Scheme 142). The 
secondary alcohol 268 could then be oxidized at a later stage to obtain the ketone 269. 
Accordingly, efforts were focused on developing an efficient and scalable method to 






Existing methods to synthesise the required epoxide involved the alkylation of 
quinazolinone using epichlorohydrin (Scheme 143).149 However, the alkylating agent is 
employed as a solvent and removed by evaporation at the end of the reaction which is 
not desirable. We therefore endeavoured to find “greener conditions” which minimised 
the quantities of highly toxic alkylating agent. Consequently, the reaction was attempted 
with 2 equivalents of epichlorohydrin in the presence of a base, and a solvent screen 
was performed. 
N,N-Dimethylformamide (DMF) was the first solvent chosen for the reaction due 




base which was expected to be removed quite easily after the reaction. Using 2 
equivalents of base and heating at 60 °C after 18 h resulted in complete conversion of 
the quinazolinone (Scheme 144). However, removal of the DMF solvent proved to be 
problematic and a low mass balance was observed after aqueous work-up. After 
recrystallization, the expected quinazolinone epoxide 267 was obtained in a 20% yield. 
The use of sodium hydride as an alternative base gave a complex mixture after heating 




Repeating the reaction with DMF as a solvent and potassium carbonate as a 
base on a gram scale gave the desired product in a yield of 25%. One side-product 
isolated was the dimer 268 resulting from the addition of the product to the starting 
epoxide (Scheme 144). Another identified side-product was the carbonate ester 269 
derived from the reaction of the potassium carbonate base with the epoxide. A minor 
byproduct observed in the crude LCMS that was not isolated was the diol 270, the result 
of water adding to the epoxide which highlighted the importance of ensuring anhydrous 




A method for the alkylation of 6,8-dibromoquinazolinone was reported which 
involved the use of acetone as the solvent.150 These conditions also used potassium 
carbonate as the base, and were applied for the alkylation of quinazolinone (Scheme 




epoxide in a 62% yield after recrystallization. The reaction afforded gram quantities of 
material without the use of chromatography which is highly convenient. Furthermore, the 
acetone solvent is considered a much greener solvent than DMF which has a very high 
boiling point and therefore can be difficult to remove. Finally, the use of lower quantities 




Addition of Amines to the Epoxide 
With the quinazolinone epoxide in hand, various nucleophiles were envisaged for 
the epoxide opening to afford different febrifugine analogues. Initial efforts were focused 
on the addition of primary amines which could mimic the piperidine part of the molecule. 
Accordingly, a selection of primary amines were chosen and conditions were sought to 
achieve the nucleophilic addition. Naturally, the use of green conditions were borne in 
mind when the optimisation studies began. 
Kochetkov recently published the use of aqueous media to afford the 
regioselective ring opening of oxiranes with various amines to synthesise amino 
alcohols.151 These conditions were applied in this investigation and a variety of aliphatic 
amines were chosen for the ring opening. Pleasingly, this method was successful and 
gave the desired amino alcohols in moderate yields. A number of these compounds 
precipitated from the reaction mixture and were easily isolated by filtration, hence 






A side reaction observed in the epoxide opening reactions involved the addition 
of the secondary alcohol product to the starting material, hence affording the dimer 271 
(Figure 17). It was, therefore, important to monitor the reaction in order to stop it after all 
the starting material has been consumed. Furthermore, in one case, the other 
regioisomer was also observed in which the amine had added onto the more hindered 
part of the epoxide. It is worth noting that the two regioisomers were difficult to separate 
by chromatography. In cases where chiral amines were used, diastereoisomers were 
generated and these were difficult to separate. Our results are summarized in Table 32. 
 




































Whilst the reaction of most amines proceeded uneventfully, the reaction with the 
less reactive aniline proved to be more difficult and running the reaction for 18 h led to 
significant decomposition of starting material. Nonetheless, the desired amino alcohol 
276 was still isolated albeit in a low yield of 20%. 
In addition to the reaction of primary amines to the quinazolinone epoxide, the 
aminolysis using secondary amines was also investigated. A variety of dialkylamines 
were reacted with the epoxides to obtain the analogues summarized in Table 33. 
 





































Addition of Amino Acids to the Epoxide 
After the success of adding different amines to the epoxide, we then investigated 
whether the ring-opening would also proceed with amino acids. L-Proline was the first 
choice of amino acid as it was reported that proline binds to the ProRS active site as 
described earlier. The methyl-ester of the amino acid was used in order to avoid potential 
side reactions with the carboxylic acid. L-Proline methyl ester hydrochloride was reacted 
with the quinazolinone epoxide in the presence of base in methanol (Scheme 146). The 
starting material was fully consumed after 1 hour, and a mixture of the desired methyl 
ester product 284, the corresponding acid 285, as well as the resulting lactone 286 was 
generated (Figure 17). Instead of isolating the three products, the entire mixture was 








After stirring the mixture in 2 M NaOH solution for 18 h at room temperature, the 
reaction was carefully acidified and a single product was isolated. However, the expected 




opening of the quinazolinone core had taken place which resulted in the aniline product 
287 (Scheme 147). To summarise, the addition of amino acids to the epoxide may not 
be as straightforward as anticipated, and none of the desired product was isolated in the 
case of proline. Consequently, we considered whether the corresponding amino alcohols 
would be more suitable nucleophiles for the ring opening of the epoxide. 
 
Addition of Amino Alcohols to the Epoxide 
Prolinol was chosen as the next nucleophile to be used after our problematic 
attempts to react the corresponding amino acid. Both L- and D-prolinol were reacted with 
the racemic quinazolinone epoxide resulting in four different diastereoisomeric products 
(Scheme 148, 149). Gratifyingly, the four products were successfully separated during 
chromatographic purification, allowing their isolation in good yields. The optical rotations 











L- and D-leucinol were also used as nucleophiles to give the expected products in 
moderate to good yields (Scheme 150, 151). Unfortunately, the products gave a mixture 







Synthesis of Homologues 
A different set of febrifugine analogues were envisaged whereby an extra 
methylene is introduced in between the secondary alcohol and the quinazolinone core. 
To synthesise these homologues, the corresponding epoxide 294 had to be generated 




The initial proposed route to the epoxide was via the alkylation of quinazolinone 
using 4-bromobut-1-ene followed by epoxidation. A reported competing reaction for the 
N-alkylation of quinazolinone is the O-alkylation152 but gratifyingly, the N-alkylated 




observed (Scheme 153). With the desired alkene in hand, the epoxidation was attempted 
using m-CPBA and replacing the conventional dichloromethane solvent used in 
epoxidation reactions to a greener alternative, ethyl acetate. Surprisingly, in the presence 
of 2 equivalents of m-CPBA and running the reaction for 72 h, only traces of the expected 
epoxide was observed. Heating the reaction to 80 °C did not help the conversion of 
starting material and adding 3 more equivalents of m-CPBA and running for another 72 
h proved unsuccessful. We therefore decided to perform the epoxidation of 4-bromobut-






Pleasingly, the epoxidation proceeded uneventfully providing the desired 2-(2-
bromoethyl)oxirane 297 in a quantitative yield (Scheme 155). This bromoepoxide was 
then successfully coupled with the quinazolinone to give the expected product 294 in a 









A number of secondary amines were then reacted with the epoxide 284 using the 
conditions employed for the synthesis of the earlier series of analogues. The desired 
amino alcohol products were obtained in generally excellent yields with only the very 
hindered diisopropylamine analogue 300 giving a low yield (Table 34). 
 

































Incidentally, the reaction with both L- and D-prolinol also proceeded uneventfully 
and the resulting 4 diastereoisomers were successfully separated using Mass Directed 
Auto Preparative HPLC (Scheme 157,158). The optical rotations for all four products 









Addition of Amines to Oxetane 
In order to access the complementary homologous series, we next targeted 
analogues with an extra methylene incorporated between amino group and the ketone. 
We envisaged that this could be achieved by a regioselective ring opening of oxetanes 
with amines, which has been accomplished before in the presence of different Lewis 




To make the oxetane starting material, the alkylation of quinazolinone using a 
pre-formed oxetane was considered. However, these oxetanes are not readily available 
and are generally expensive to purchase. However, the synthesis of the corresponding 
quinazolinone epoxide 267 is easier and can be performed on a large scale. A way to 




pursued. Recently, a Corey-Chaykovsky type reaction was reported in which 
dimethylsulfoxonium methylide was used to achieve the ring expansion of epoxides to 
oxetanes. This reported consecutive oxacycle ring expansion involves a high degree of 
regioselectivity and stereospecificity which provides a novel preparation of optically 
active cyclic ethers.153 However, the reported scope did not involve epoxides appended 
to heterocycles.  
The reaction was attempted by deprotonating dimethylsulfoxonium iodide using 
sodium hydride in DMSO followed by addition of the epoxide. After stirring at 60 °C for 
18 h, the epoxide was fully consumed and three products were observed in the LCMS 
analysis (Scheme 160). The first product appeared to be the sulfoxide 312 which hadn’t 
cyclised to the desired oxetane. The second and third products were the desired oxetane 




Repeating the reaction using potassium tert-butoxide as the base and tert-
butanol as the solvent gave similar results in which an inseparable mixture of oxetane 
and alkene was obtained. Furthermore, another product observed in the NMR spectrum 
of the crude mixtures was the aniline resulting from ring-opening of the quinazolinone. 
The heterocycle core seems to be prone to ring opening under strong basic conditions 




that the oxetane product could not be separated from the olefin, a different approach was 
investigated which involved introducing the oxetane as an alkylating agent.  
A new strategy was devised to make the desired quinazolinone oxetane starting 
material in which the oxetane 314 was prepared and then reacted with quinazolinone in 
an alkylation procedure (Scheme 161). We planned to prepare the oxetane via the 





Firstly, the epoxide alcohol had to be protected, and so glycidol was reacted with 
benzyl bromide to afford the benzyl protected alcohol 316 in a moderate yield. The ring 
expansion using trimethylsulfoxonium iodide in the presence of potassium tert-butoxide 
was performed over 24 hours giving the desired oxetane 317 in a 53% yield. However, 
although the starting material was fully consumed after this time, the uncyclized 
intermediate 318 was still observed in the crude NMR spectrum (Figure 18). Related 
Corey-Chaykovsky reactions in literature were reported in which the reaction is 
performed over 3-5 days to obtain high yields.153 Disappointingly, running the reaction 
over these extended times did not improve the yield for the oxetane significantly and so 






Efforts were then turned to the deprotection of the benzyl group to obtain the 
desired alcohol 319 but attempts to perform the hydrogenation using the H-cube reactor 
under standard conditions proved unsuccessful. Alternatively, employing a more 
traditional method involving the use of a hydrogen balloon did not result in debenzylation, 
even after 48 h (Scheme 163). Ultimately, the use of methanol or acetic acid as solvents 
with relatively high boiling points was also deemed to be problematic for the work-up 
especially with the expected high volatility of the product. For this reason, and due to the 
unreactive nature of the benzyl-protected alcohol under the hydrogenation conditions, a 




The preparation of simple oxetanes containing reactive 2-substituents was 
reported starting from glycidol, and also using trimethylsulfoxonium iodide as the 
methylene transfer agent. In this method, the alcohol was reacted with vinyl ethyl ether 
to afford the acetal 320. After the ring expansion, the protecting group was removed via 
treatment with acid to give 2-hydroxymethyloxetane in excellent yields. This sequence 
was therefore applied for this investigation which gratifyingly, provided the protected 






Despite the ability to prepare the desired protected alcohol in multiple grams, the 
acid hydrolysis step proved to be more difficult than expected. Treating the acetal 321 
with 10% acetic acid in water for 18 h and then basifying afterwards resulted in poor 
mass balance after extraction with diethyl ether. Although the selected solvent was not 
ideal for efficiently extracting the product from the aqueous layer, it was anticipated that 
using solvents with higher boiling points such as ethyl acetate would be problematic 
when it came to evaporation of the extract due to the expected volatility of the product. 
In an attempt to omit the solvent removal stage after extraction, the solution was used 
directly in the subsequent tosylation step.  
 
Scheme 165 
Unfortunately, no product was observed after treatment of the crude extract with 
tosyl chloride and triethylamine in the presence of catalytic DMAP. Almost as a last 
resort, the extraction step was eliminated altogether and the tosylation was performed 
directly after basifying the reaction mixture. Unfortunately however, the main compound 







To address the problem of the volatility of the product, removal of the solvent 
after extraction via short-path distillation was considered. After basifying the acidic 
reaction mixture using excess solid sodium bicarbonate, the reaction mixture was 
distilled to remove the ethanol by-product. The resulting residue was further basified by 
the addition of an excess of solid potassium carbonate and then the product was 
extracted with diethyl ether. Removal of the solvent via short path distillation delivered 
the product 319 in a 44% yield. Gratifyingly, switching the extraction solvent from diethyl 
ether to dichloromethane improved the yield to 56%. The reaction was also shown to be 
efficient on large scale with up to 5 grams of the desired alcohol obtained without 
reduction in yield. 
 
Scheme 167 
With the free alcohol 319 in hand, the tosylation was performed using 
triethylamine as the base and in the presence of DMAP to afford the product 322 in a 
40% yield (Scheme 168). Changing the base to pyridine (used neat) did not improve the 
yield any further. Fortunately, performing a mesylation with mesyl chloride and 
triethylamine gave the mesylate in an 86% yield. The change in reactivity could be 







The final step to prepare the quinazolinone oxetane starting material involved the 
alkylation of quinazolinone using the tosylate or mesylate of the oxetane. The conditions 
developed in this investigation to alkylate quinazolinone with epichlorohydrin were 
employed in which potassium carbonate was employed as the base and with acetone as 
the solvent. Under these conditions, the tosylate 322 afforded the desired product in a 
modest yield of 56% after 18 h of reaction time. In an effort to decrease the reaction time, 
the temperature was increased to 120 °C with sodium hydride as the base and the 
solvent was changed to DMF, which solubilises the starting material better. 
Unfortunately, this resulted in a complex mixture with only 15% of the desired product 
isolated. The base was reverted back to potassium carbonate but the DMF solvent was 
maintained and this provided the product in better yields. Due to the inferior yields 
obtained when preparing the tosylate in comparison to the mesylate 324, the latter 
alkylating agent was preferred. Furthermore, the crude mixture of the reaction using the 
mesylate tended to be cleaner (as judged by crude NMR analysis), eliminating the need 
to purify the product by column chromatography. 
 
Entry R base solvent temp. time yield 
1 Ts K2CO3 (1.5 eq) acetone 60 °C 18 h 55% 
2 Ms NaH (2 eq) DMF 120 °C 2 h 15% 
3 Ms K2CO3 (1.5 eq) acetone 60 °C 18 h 19% 
4 Ms K2CO3 (1.5 eq) DMF 60 °C 18 h 67% 
Table 35 
With the quinazolinone oxetane in hand, we then investigated the ring opening of 
the oxetane with different amines. Firstly, a range of different Lewis acids were screened. 
Although the ring opening of epoxides with a variety of nucleophiles has been well 




reactivity of the 4-membered cycle compared with their 3-membered counterparts. This 
could be attributed to the fact that there is a lower degree of strain in oxetanes although 
the oxygen in the ring has greater basicity.155 
Although existing methodologies for the aminolysis of oxetanes are very limited, 
a number of examples exist where hard Lewis acids have been successfully employed. 
Papini described the use of aluminium (III) chloride to open up epoxides using 
aminosilanes or aminostannanes and this method was also extended for use on lactones 
and oxetanes.156 Three examples of β-amino alcohols have been synthesised via the 
cleavage of oxetanes using catalytic AlCl3. The main advantages highlighted in this 
method were the complete regioselectivity observed as well as the absence of competing 
β-elimination. 
More recently, Mojtahedi reported an efficient solvent-free aminolysis of epoxides 
which can be applied to oxetanes as well.157 In this method, magnesium bromide diethyl 
etherate was employed as the catalyst and two examples of amines were added to an 
unsubstituted oxetane. In addition to the solvent-less strategy, this preparation of amino 
alcohols is performed at room temperature with quick reaction times. It has also been 
reported that the catalyst can be separated from the products by simple filtration which 
normally obviates the need to purify by column chromatography.  
Finally, Crotti disclosed the aminolysis of oxetanes using milder catalysts and 
avoiding the use of harsh conditions.158  In an effort to find a more practical method to 
prepare γ-amino alcohols, a number of readily available metal salts were tried for the 
addition of primary and secondary amines to unhindered oxetanes. In their investigation, 
it was found that the reaction could be performed at room temperature in the presence 
of lithium tetrafluoroborate to give the products in moderate to good yields. However, 
alternative Lewis acids such as lithium perchlorate and zinc (II) triflate resulted only in 
unreacted starting material although both catalysts worked for the aminolysis of the 




Some of these Lewis acids were employed in this investigation with morpholine 
as the model amine substrate. The reactions were performed at room temperature and 
the consumption of starting material was monitored by TLC analysis. Disappointingly, 
only traces of product were observed and majority of the starting material remained 
unreacted even after prolonged times. Warming the reaction did not help and no product 
was isolated after heating at 80 °C for 72 h (Table 36). 
 
Entry Lewis Acid eq. solvent temp result 
1 AlCl3 0.1 DCM RT RSM 
2 MgBr.OEt2 0.1 MeCN RT RSM 
3 LiBF4 0.5 DCM RT RSM 
4 LiBF4 0.5 DCM 40 °C RSM 
5 LiBF4 0.5 MeCN 80 °C RSM 
Table 36 
Whilst there are no reported methods to open up oxetanes using soft Lewis acids, 
the use of borderline Lewis acids has been described by Crotti as well.158 Extraordinarily, 
employing rare-earth metal triflates was successful in promoting the ring opening of 
oxetanes. Although literature-known compounds for a long time, it wasn’t until 1991 that 
the first use of lanthanide triflates in organic synthesis emerged.159 These exceptional 
Lewis acids offer a few advantages over traditional ones which include improved stability 
in water. Furthermore, they are known to be recoverable after the reaction and they can 
be re-used without significant loss of activity.160 Crotti exploited some of these unique 
lanthanide compounds, in particular ytterbium (III) triflate, neodymium (III) triflate and 





Entry Lewis Acid eq. result 
1 Gd(OTf)3 0.5 36% 
2 Gd(OTf)3 1 56% 
3 Yb(OTf)3 1 46% 
4 Sc(OTf)3 1 49% 
Table 37 
Satisfyingly, using Crotti’s conditions of 0.5 eq. of Gd(OTf)3 at 80 °C in MeCN, 
the desired amino alcohol was obtained in a moderate yield of 36%. Some of the starting 
material was recovered after a reaction time of 24 h so the catalyst loading was doubled 
to 1 equivalent. This improved the yield to 56% but the reaction still failed to reach 
completion after 24 h. Yb(OTf)3 also gave the product in a 46% yield while another rare-
earth metal triflate, Sc(OTf)3 provided the product in a slightly improved yield of 49% 
(Table 37). 
With Gd(OTf)3 proving to be the most effective Lewis acid, the reaction conditions 
were optimized further. The catalyst loading was increased to 1.2 equivalents in the hope 
that the reaction would reach full conversion but starting material was still observed after 
24 h. Disappointingly, running the reaction over a much more prolonged reaction time 
(72 h) resulted in a complex mixture which didn’t lead to any desired product. In an effort 
to reduce the reaction time and possibly decrease the loading of the catalyst as well, 
microwave conditions were also attempted. Running the reaction at 80 °C under 
microwave irradiation for 1 h only resulted in recovered starting material with no product 
observable. Increasing the temperature to 120 °C and running for 10 mins resulted to full 





Entry Gd(OTf)3 temp time result 
1 1.2 eq. 80 °C 72 h Complex mixture 
2 1.0 eq. 80 °C (microwave) 5 min NO REACTION 
3 1.0 eq. 80 °C (microwave) 1 h NO REACTION 
4 1.0 eq. 120 °C (microwave) 10 min 41% 
Table 38 
With these results in hand, the reactivity of other amines were evaluated. 
Diethylamine and piperidine were reacted with the oxetane using one equivalent of 
Gd(OTf)3 and 3 equivalents of the amine. Inconveniently, the main by-product of the 
reaction which is the corresponding amine triflate salt which proved to be difficult to 
separate from the product by column chromatography. Reducing the amine equivalents 
to 1.2 proved to be detrimental to the reaction with no product obtained after 24 h. 
Performing a base wash and then an extraction with dichloromethane was unsuccessful 
due to the high water solubility of the amino alcohol products. After discovering that the 
products were not very soluble in dichloromethane, the extraction was performed with 
ethyl acetate and then purification by column chromatography afforded the desired 



























Oxidation of Amino Alcohols 
With the synthesised amino alcohols in hand, we then investigated their oxidation 
to obtain the corresponding amino ketone analogues. An efficient oxidation method that 








The oxidation of selected amino alcohols from the first two series proceeded 
using Swern conditions to give the corresponding amino ketones with moderate to good 
yields. The amino alcohols were premixed with trifluoroacetic acid to ensure that the 
amine was protected as an ammonium salt in order to prevent oxidation. Unfortunately, 
both analogues containing the diisopropylamine unit did not react under the conditions 
with starting material recovered in both cases. The results are summarized in table 40. 
 
 






























































 Obtaining the ketones for the third series proved to be difficult starting from the 
corresponding amino alcohols since these intermediates are challenging to obtain in 




aminolysis of the quinazolinone oxetanes in which typically ~20 mg of material is 
obtained. Not only are the yields for the reactions poor to moderate, the use of 
stoichiometric amounts of Gd(OTf)3 is not practical as this reagent is expensive. Indeed, 
using our current conditions, obtaining 100 mg of product would require more than 1 g 
of gadolinium catalyst. Furthermore, the lengthy procedure to synthesise the 
quinazolinone oxetane starting material justified the need to develop a new strategy to 
obtain the required amino alcohols from the third series. 
 
Synthesis of γ-amino alcohols 
A new approach was envisioned for the synthesis of the γ-amino alcohols in 
which the quinazolinone is used to open up an epoxide already containing the amine 
moiety (Scheme 170). Bromo epoxide 297 would be employed to alkylate various amines 
to obtain the desired amino oxirane 340 which could be opened regioselectively by the 
quinazolinone with the aid of a base. 
 
Scheme 170 
Accordingly, different examples of amino oxiranes were prepared starting from 4-
bromo-but-1-ene which was epoxidised with m-CPBA to obtain the epoxyalkyl bromide 
297 in a 99% yield. Various amines were then added which remarkably reacted 
chemoselectively with the alkyl bromide with no observed opening of the epoxide to give 




























Entry Base Solvent Temp. Result 
1 K2CO3 (1.5 eq.) Acetone 60 °C RSM 
2 NaH (2 eq.) DMF 80 °C 21% 
3 NaH (5 eq.) DMF 100 °C 25% 
4 LiHMDS (2 eq.) THF 0 to 70 °C RSM 
5 KHMDS (2 eq.) THF 0 to 70 °C RSM 
6 EtMgBr (2 eq.) THF 0 to 70 °C RSM 
7 Et3N (2 eq.) EtOH 60 °C 86% 
Table 42 
With the amino oxiranes in hand, the epoxide opening with quinazolinone was 
explored by performing a base screening with the morpholinyl epoxide as the model 
substrate. Amongst the bases employed, K2CO3, LiHMDS, KHMDS and EtMgBr were 
ineffective, and only starting material was recovered in all cases (Table 42). Using 
sodium hydride was more promising where product was obtained in a 21% yield when 2 




equivalents of sodium hydride only marginally increased the yield with most of the 
unreacted quinazolinone still recovered. Two previously reported aminolysis of epoxides 
with quinazolinones by Mai involved the use of an organic base (e.g. triethylamine, 
pyridine) in combination with an alcohol as a solvent (e.g. ethanol, isopropanol). 
Gratifyingly, performing the epoxide opening with Et3N in EtOH gave the desired γ-amino 
alcohol 325 in an 86% yield. 
With optimized conditions in hand, the scope of the protocol was explored by 
performing the reaction with the other prepared amino epoxides. Rather surprisingly, the 
reaction did not proceed when diethylamine or piperidine were used, with unreacted 
quinazolinone being recovered in both cases. A control experiment was performed in 
which a 1:1 mixture of morpholine and piperidine were reacted with the quinazolinone. 
In this case, only the morpholine product was isolated in a 23% yield with most of the 
quinazolinone recovered. It was then speculated if the reaction is just in the verge of 
proceeding and it just needs to be driven harder to completion. 
 
 



























Consequently, the solvent was changed to isopropanol to enable the reaction to 
be run at a higher temperature. Unfortunately, the epoxide opening still did not proceed 
using piperidine and diethylamine with unreacted quinazolinone recovered once again. 
One notable observation in the reaction was the failure to recover the unreacted epoxide, 
even though the quinazolinone was isolated afterwards. We suspected therefore that the 
epoxide is unstable under the reaction conditions, and so a control reaction in which the 
epoxide was subjected to the reaction conditions without the quinazolinone was 
performed. In the event, this resulted in a complex mixture which suggested that the 
epoxide is too reactive, possibly decomposing by polymerisation. The reaction was 
repeated at room temperature to address this issue but unfortunately this only resulted 
in a complex mixture after running the reaction for 24 h. 
Finally, the aminolysis was attempted with the epoxyalkyl bromide 297 with the 
intent to do the alkylation at a later stage. This would require the quinazolinone to 
chemoselectively react with the oxirane ring. Studies on the reactivity of bifunctional 
epoxyalkyl bromides have been carried out by Cruickshank and Fishman and they 
reported that the alkylation is significantly affected by the choice of solvent as well as the 
nature of the nucleophile.142 In theory, using a protic solvent could activate the epoxide 
ring hence allowing the nucleophile to open up the ring and provide hydroxy bromoalkyl 
derivatives. On the other hand, no solvent effects are observed with aprotic solvents 




Unfortunately, attempts to perform the aminolysis of the epoxyalkyl bromide 297 with 
quinazolinone using NaOEt as the base and EtOH as the solvent resulted in a mixture 
of products, which included the undesired epoxyalkyl quinazolinone 294 (Scheme 172). 
 
Scheme 172 
A different approach was proposed which would allow the synthesis of the amino 
ketone without going through the corresponding γ-amino alcohols. This new strategy 
involved the synthesis of bromomethyl aminopropyl ketone 348 which could be used to 
alkylate quinazolinone and provide the desired amino ketones (Scheme 173). Magidson 
has previously reported the synthesis of febrifugine analogues by alkylating 
quinazolinone with bromomethyl aminoethyl ketone 349 in the presence of sodium 





To prepare the starting bromo ketones 349, the corresponding β-amino ketone 
was anticipated to be brominated on the least hindered part of the ketone. The β-amino 
ketone bearing the dimethyl amine substituent 350 was obtained commercially whilst two 




addition of diethylamine and morpholine to enone 351 was performed using silicon 
tetrachloride as the catalyst in the absence of solvent. This afforded two different β-amino 
ketones in excellent yields and in multi-gram amounts (Scheme 175). 
 
Scheme 175 
With the β-amino ketones in hand, the bromination was attempted with the 
dimethylamine substrate. The corresponding silyl enol ether was prepared by treating 
the ketone with Hünig’s base and TMSOTf as the Lewis acid. The silyl enol ether was 
used in the next step directly due to its instability and so the crude was treated with N-
bromosuccinimide. Unfortunately, the desired bromo ketone 355 was not observed, and 




To ensure that the intermediate silyl enol ether was the active reagent, the amino 
ketone was changed to the diethylamine analogue since the enol silane for this substrate 
was already reported and the NMR data could be used for comparison. Using Pratt’s 
optimal reaction conditions, an 8:2 mixture of distal and proximal silanes were generated, 
as determined by crude 1H NMR spectroscopy.163 Disappointingly, after treating the 
crude silanes with NBS, no desired bromo ketone was observed. It was therefore 
decided to change the brominating agent to diatomic bromine, and start with the ketone 






The diethylamine analogue 352 was treated with hydrobromic acid in acetic acid 
before the addition of bromine and heating at 60 °C for 2 h. Disappointingly, this resulted 
in a complex mixture in which the major identifiable product was diethylamine. This result 
suggested that the E1CB elimination of the amine to obtain the enone back which could 
decompose or further react in the reaction mixture. Furthermore, the bromo amino 
ketones are also prone to cyclization so it was concluded that this route was not 
appropriate to obtain the desired quinazolinone amino ketones. 
The final strategy employed for the synthesis of the amino ketones exploited 
bromomethyl vinylketone 358 which could be used to alkylate quinazolinone. We 
envisaged that the resulting enone could then be used for the aza-Michael addition of 
various amines to obtain the target amino ketones without going through the 
corresponding amino alcohols. The preparation of 1-bromo-3-buten-2-one was reported 
by Carlson and starts from the commercially available protected ketone 359.164 Using 
Carlson’s method, the dibrominated acetal 360 was obtained in a quantitative yield and 
then a dehydrobromination was performed with potassium tert-butoxide to obtain 361 in 
good yield. The deprotection step could be accomplished with formic acid either by 
conventional heating for 4 h or under microwave irradiation. Either way, the resulting 







The alkylation of quinazolinone with the bromomethyl vinylketone 358 was 
performed with potassium carbonate as the base and acetone as the solvent. 
Disappointingly however, heating the reaction for 18 h gave a mixture of the desired 
enone 362 and the product 363 arising from the addition of the quinazolinone to the 
alkene. Furthermore, the dimer 364 was also observed in which the quinazolinone added 
to both the alkene and the bromide. Separating the mixture of products by flash column 




We speculated that the addition of tetrabutylammonium iodide could aid the 
reaction by generating the more reactive iodide via an in situ Finkelstein reaction. Proust 
also described the addition of tosylamines to bromomethyl vinylketone at 0 °C to avoid 
the 1,4-addition of the nucleophile and observed only the SN2 reaction at the bromide.165 
Using both ideas, the reaction was performed with catalytic TBAI and at 0 °C to slow 
down the conjugate addition. Disappointingly, the same mixture of products was still 




isolated with minor impurities which was used for the aza-Michael addition of amines. 
Using Tang’s conditions of sodium carbonate as the base in aqueous medium, the 
addition of diethylamine was attempted but only gave traces of the desired amino 
ketone.166 After multiple failed attempts to develop an efficient methodology to prepare 
the amino ketones from the third series, we finally discontinued this aspect of our 
research efforts and moved on to investigate the synthesis of febrifugine analogues with 


















Synthesis of Fluorinated Analogues 
Having synthesised a number of febrifugine analogues with hydroxy and keto-
linkers, we decided to explore the possibility of preparing the corresponding fluorinated 
analogues. Although not very common in natural products, around 20% of existing 
pharmaceuticals on the market incorporate at least one fluorine atom and the estimate 
is even higher with agrochemicals.167 This can be attributed to the significant benefits 
that fluorine has to offer which include improvement in important properties such as 
bioavailability, lipophilicity and metabolic stability. Moreover, these advantages can be 
exploited without too much modification in molecular geometry and shape due to the 
comparative sizes of hydrogen and fluorine. 
Whilst the incorporation of fluorine into organic compounds is indeed highly 
advantageous, the task is by no means straightforward and has proven to be quite 
challenging in the past.26 Firstly, issues with selectivity may arise in the presence of other 
functionalities which often require the introduction of the fluorine or fluorinated moiety at 
a much later stage in the synthesis. A more significant drawback is the use of highly toxic 
and hazardous reagents such as fluorine gas, hydrofluoric acid or sulfur tetrafluoride 
which is not ideal for large-scale synthesis in industry. Fortunately, more stable reagents 
that are relatively non-toxic have been developed over the years allowing for safer and 
more efficient protocols for fluorination reactions. 
Having already obtained the amino ketone analogues from the first series, we 
decided to perform deoxofluorination reactions with the carbonyl groups to obtain the 
gem-difluorides. This transformation is traditionally carried out using sulfur tetrafluoride 
which is a highly toxic and corrosive gas but a safer alternative, diaminosulfurtrifluoride 
(DAST) 366, is now more commonly used.168 Unfortunately, treating amino ketone 329 
with 3 equivalents of DAST led to complete recovery of starting material. Likewise, the 






A more stable version of DAST is the aminodifluorosulfonium tetrafluoroborate 
salt XtalFluor-E 368 which is an easy handled crystalline solid. It is reported to have a 
higher decomposition temperature compared with DAST or Deoxo-Fluor and a lower 
exothermic heat generated which signifies greater thermal stability.169 Disappointingly, 
the deoxofluorination of 329 using XtalFluor-E proved ineffective in our hands and the 
starting material was recovered once again. The addition of an exogenous fluoride 
source such as Et3N.HF or Olah’s reagent (pyridine.HF) to promote the fluorination did 
not aid the reaction and the application of heat was also unsuccessful (Table 44). 
 
Entry Flourinating agent Additive Temperature Result 
1 DAST (3 eq.) None -78 °C to RT RSM 
2 Deoxo-Fluor (3 eq.) None -78 °C to RT RSM 
3 XtalFluor-E (1.5 eq.) None -78 °C to RT RSM 
4 XtalFluor-E (1.5 eq.) Pyridine.HF (1.5 eq.) -78 °C to RT RSM 
5 XtalFluor-E (1.5 eq.) Et3N.HF (1.5 eq.) -78 °C to RT RSM 







We decided to employ a new strategy which involved fluorinating α-bromoketone 
370 and then introducing the amine moiety at a later stage. But before investigating the 
preparation of intermediate 370, we felt it was sensible to try the fluorination of 372 which 
indeed is less hindered than the amino ketone 329. Accordingly, quinazolinone was 
treated with chloroacetone and potassium carbonate to afford 372 which could be 
successfully scaled up to generate gram quantities (Scheme 182). To our 
disappointment, the fluorination did not proceed using various conditions (Table 45) and 







Entry Flourinating agent Additive Temperature Result 
1 DAST (3 eq.) None -78 °C to RT RSM 
2 DAST (3 eq.) Et3N.HF (3 eq.) -78 °C to RT RSM 
3 Deoxo-Fluor None -78 °C to RT RSM 






With our unsuccessful attempts to prepare the gem-difluorinated analogues, we 
finally focused on the fluorination of the alcohols to obtain the mono-fluoride analogues. 
Initial investigation on the preparation of 374 in order to incorporate the amine moiety at 
a later stage showed that the fluorination of bromohydrin 373 is not feasible. Pleasingly, 
treating the amino alcohols with 3 equivalents of Deoxo-Fluor gave a number of the 
desired mono-fluorinated analogues in moderate yields (Table 46). The analogue 
containing the diisopropylamine unit did not react under the conditions but the analogues 








































Febrifugine and the synthetic analogue halofuginone have been shown to inhibit 
human prolyl-transfer RNA synthetase by acting as dual site inhibitors. The 
quinazolinone moiety blocks the binding site of tRNA whilst the hydroxypiperidine part 
inhibits the binding of proline to ProRS. In this investigation, a number of febrifugine 
analogues have been designed and synthesised to interrogate the binding at the 
southeast polar region. The analogues were prepared with the incentive to test them as 
potential therapy for IPF. 
The hydroxypiperidine moiety was replaced with different amine groups to 
introduce potential new hydrogen bonding interactions. This entailed opening an epoxide 
regioselectively with various amines as well as amino alcohols derived from amino acids. 
The carbon chain length between the quinazolinone and the keto linker was also varied 
to obtain a homologous series. This involved the aminolysis of oxetanes catalysed by 
rare-earth metal triflates such as gadolinium triflate. 
Finally, the keto-linker was also investigated by incorporating other groups that 
could hydrogen-bond with ATP in the binding site. The amino alcohol analogues were 
successfully oxidized to obtain the corresponding amino ketones. The deoxofluorination 
of the ketones has been attempted to obtain the gem-difluoride analogues but was 
ineffective. The fluorination of the amino alcohols was successful and furnished the 










Idiopathic Pulmonary Fibrosis continues to be a disease with unsatisfied needs 
for treatment or effective management. At present, Pirfenidone and Nintedanib remain 
as the only useful therapies for patients with IPF. Understanding the polypharmacology 
of both agents might be key to determining their efficacy. Likewise, polypharmacology 
approaches could help in designing an effective treatment for IPF. 
In vitro biological data from testing the synthesised isatin, isatogen and 
febrifugine analogues would be useful in determining which further analogues to design 
to improve the pharmacological properties. By identifying the polypharmacology mixtures 
of compounds required for activity, these could then be combined to a single molecule. 
The property of febrifugine as a dual site inhibitor is important to exploit to design an 
effective drug with multiple targets. Furthermore, it would be useful to find out the 
effectiveness of isatins as TG2 inhibitors and whether they could be developed as 















General Experimental Procedures 
Unless otherwise stated, all melting points (uncorrected) were recorded directly 
from products after chromatography and obtained using a Gallenkamp melting point 
apparatus. Melting points for amorphous solids were not recorded. 
All 1H NMR spectra were recorded on a Bruker AC-250 (250 MHz) or a Bruker 
AMX-400 (400 MHz) instrument supported by an Aspect 3000 data system. The 
chemical shifts are reported in ppm from tetramethylsilane with the solvent resonance 
as the internal standard (CHCl3 in CDCl3: δ 7.27 ppm; DMSO in (CD3)2SO: δ 2.52). Data 
are expressed as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, 
dd = doublet of doublet, td= triplet of doublet, q = quartet, m = multiplet), coupling 
constant (Hz), and integration.  
All 13C NMR spectra were recorded using the JMOD pulse sequence on a Bruker 
AC-250 (62.9 MHz) or AMX-400 (100.6 MHz) with complete proton decoupling. Chemical 
shifts are reported in ppm from tetratmethylsilane with the solvent resonance as the 
internal standard (CDCl3: δ 77.0 ppm; (CD3)2SO: δ 39.7). Relative to CDCl3 or (CD3)2SO, 
(+) denotes CH3 or CH and (–) denotes CH2 or C (or vice versa).  
Infrared (FTIR) spectra were recorded on a Perkin Elmer Paragon 100 FTIR 
spectrophotometer, vmax in cm-1. Low resolution mass spectra (m/z) were recorded on 
either a Kratos MS 25 or MS 80 spectrometer supported by a DS 55 data system, 
operating in EI,CI or FAB mode; or a Perkin-Elmer Turbomass Benchtop GC-MS 
operating in either EI or CI mode,with only molecular ions (M+) and major peaks being 
reported with intensities quoted as percentages of the base peak. High resolution mass 
spectra (HRMS) recorded for accurate mass analysis, were performed on either a 
MicroMass LCT operating in Electrospray mode (TOF ES) or a MicroMass Prospec 




All reactions were conducted in oven or flame-dried glassware under an inert 
atmosphere of nitrogen. Dichloromethane, toluene and acetonitrile were distilled from 
calcium hydride. Tetrahydrofuran was distilled from sodium metal/benzophenone ketyl. 
All reagents were used as received from commercial sources unless otherwise stated.  
Petroleum ether (40-60 petroleum distillate) was distilled prior to use. Flash 
column chromatography was performed on silica gel (Merck Kieselgel 60 F254 230-400 
mesh). Thin layer chromatography (TLC) was performed on aluminium backed plates 
pre-coated with silica (0.2 mm Merck Kieselgel 60 F254) which were developed using 
standard visualizing agents: UV fluorescence (254 and 366 nm), potassium 
permanganate/heat. 
All spectral data (1H NMR, 13C NMR) and m.p. for compounds that have 
previously been described are in accordance with literature values. Silyl enol ether 354 
and bromomethyl vinyl ketone 358 were found to decompose quickly after preparation 














Synthesis of ethyl (3-bromopyridin-4-yl)carbamate (95)80 
 
4-Amino-3-bromopyridine (3.00 g, 17.3 mmol, 1.0 eq.) and DMAP (1.06 g, 8.67 mmol, 
0.5 eq.) were dissolved in dichloromethane (20 mL) and Et3N (4.81 mL, 34.7 mmol, 2.0 
eq.) was added. Ethyl chloroformate (2.48 mL, 26.0 mmol, 1.5 eq.) was added at 0 °C 
and the reaction mixture was stirred at rt under a stream of N2 for 1 h. Water (20 mL) was 
added and the product extracted with dichloromethane (3 x 30 mL). The combined 
organic layers were dried with MgSO4 before filtering and removing the solvent in vacuo. 
The crude product was purified by flash column chromatography (silica gel, 20% 
EtOAc/petrol) to afford the title compound as white crystals (3.25 g, 78%). M.p. 58-60 °C 
(lit: 60-61.5 °C).80 1H NMR (400 MHz, CDCl3) δ 8.62 (s, 1H), 8.42 (d, J = 5.5 Hz, 1H), 
8.18 (d, J = 5.5 Hz, 1H), 7.33 (s, 1H), 4.30 (q, J = 7.0 Hz, 2H), 1.37 (t, J = 7.0 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 152.5 (-), 151.6 (+), 149.5 (+), 142.9 (-), 113.2(+), 109.8 (-
), 62.3 (-), 14.4 (+). 
 
Synthesis of ethyl [3-((trimethylsilyl)ethynyl)pyridin-4-yl]carbamate (96) 80 
 
Copper iodide (0.230 g, 1.22 mmol, 0.1 eq.) and TMSA (6.97 mL, 49.0 mmol, 4.0 eq.) 
were combined in Et3N (10 mL) and stirred at rt for 20 mins. Ethyl (3-bromopyridin-4-
yl)carbamate 95 (3.00 g, 12.2 mmol, 1.0 eq.) and PdCl2(PPh3)2 (0.86 g, 1.22 mmol, 0.1 
eq.) were dissolved in Et3N (20 mL) and then the CuI/TMSA mixture was added. The 
reaction mixture was stirred at 100 °C under a stream of N2 for 3 h. Water (50 mL) was 
added and the product extracted with dichloromethane (3 x 30 mL). The combined 




The crude product was purified by flash column chromatography (Florisil, 20% 
EtOAc/Petrol) to afford the title compound as a light brown solid (2.27 g, 71%). M.p. 130-
132 °C (lit: 133-134 °C).80 1H NMR (400 MHz, CDCl3) δ 8.53 (s, 1H), 8.39 (d, J = 5.0 Hz, 
1H), 8.06 (d, J = 5.0 Hz, 1H), 4.27 (q, J = 7.0 Hz, 2H), 1.34 (t, J = 7.0 Hz, 3H), 0.29 (s, 
9H). 13C NMR (101 MHz, CDCl3) δ 152.6 (+), 152.5 (-), 145.8 (-), 132.2 (-), 132.0 (+), 
128.5 (+), 105.8 (-), 97.0 (-), 62.1 (-), 14.4 (+), -0.50 (+). 
 
Synthesis of 5-azaindole (97)80 
 
Sodium (0.115 g, 5 mmol) was added to absolute EtOH (10 mL) and the mixture heated 
at reflux until all the sodium has disappeared. Ethyl [3-((trimethylsilyl)ethynyl)pyridin-4-
yl]carbamate 96 (0.150 g, 0.57 mmol, 1.0 eq.) was dissolved in the ethanolic sodium 
ethoxide solution and then heated at reflux for 2 h. Water (20 mL) was added and the 
product extracted with dichloromethane (3 x 30 mL). The combined organic layers were 
dried with MgSO4 before filtering and removing the solvent in vacuo. The crude product 
was purified by flash column chromatography (silica gel, 50% EtOAc/petrol) to afford the 
title compound as off-white crystals (0.038 g, 56%). M.p. 110-112 °C (lit: 111.5-112.5 
°C).80 1H NMR (400 MHz, CDCl3) δ 10.41 (br s, 1H), 8.99 (s, 1H), 8.31 (d, J = 6.0 Hz, 
1H), 7.36 (d, J = 6.0 Hz, 1H), 7.33 (d, J = 3.0 Hz, 1H), 6.68 (d, J = 3.0 Hz, 1H). 13C NMR 
(101 MHz, CDCl3) δ 142.8, 139.9, 139.1, 125.7, 124.8, 106.6, 101.1. 
 
Synthesis of 1H-indole-2,3-dione (4)59 
 
Indole (0.117 g, 1.00 mmol, 1.0 eq.) was dissolved in tert-butanol (20 mL) and NBS 




reaction mixture was stirred at rt under a stream of N2 for 3 h. The solution was 
concentrated at rt under high vacuum to precipitate a solid which was removed by 
filtration and washed with cold ether. The combined ethereal and alcoholic solution was 
evaporated to dryness to obtain dibromide 50 which was used in the next step without 
further purification. 
Dibromide 50 was dissolved in MeOH/H2O (1:1, 40 mL) and the reaction mixture was 
heated at reflux with stirring for 5 h. The solution was cooled to rt and the solvent 
removed in vacuo to obtain the title compound as a bright orange solid (0.082 g, 56%). 
M.p. 200 °C (decomp) (lit: 199-200 °C).59 1H NMR (250 MHz, DMSO) δ 11.04 (s, 1H), 
7.57 (t, J = 8.0 Hz, 1H), 7.49 (dd, J = 8.0, 1.0 Hz, 1H), 7.05 (app. t, J = 8.0 Hz, 1H), 6.90 
(dd, J = 8.0 Hz, 1.0 Hz, 1H). 13C NMR (101 MHz, DMSO) δ 184.5 (-), 159.5 (-), 151.0 (-
), 138.5 (+), 124.9 (+), 123.0 (+), 117.8 (-), 112.4 (+). 
 
Synthesis of 3,3-dimethoxy-1,3-dihydro-2H-indol-2-one (102)170 
 
3,3-Dibromo-1,3-dihydro-2H-indol-2-one 50 (0.10 g, 0.34 mmol, 1.0 eq.) was dissolved 
in MeOH (10 mL) and 5 M NaOH solution (1.0 mL) was added. The reaction mixture was 
stirred at rt for 16 h. Anhydrous MgSO4 was added before filtering and removing the 
solvent in vacuo. The product was obtained as a dark red amorphous solid (0.040 g, 
61%). M.p. 80-82 °C (lit: 74.7 °C).170 1H NMR (250 MHz, CDCl3) δ 8.49 (s, 1H), 7.42 (dd, 
J = 7.0, 1.0 Hz, 1H), 7.33 (t, J = 7.0 Hz, 1H), 7.09 (dd, J = 7.0, 1.0 Hz, 1H), 6.91 (t, J = 
7.0 Hz, 1H), 3.59 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 172.8 (-), 140.4 (-), 130.8 (+), 
125.2 (+), 124.8 (-), 122.8 (+), 110.9 (+), 97.3 (-), 50.9 (+). 
 





7-Azaindole (1.18 g, 10 mmol, 1.0 eq.) and NaH (0.480 g, 20 mmol, 2.0 eq.) were 
suspended in DMF (50 mL). The reaction mixture was stirred at rt for 30 min and then 
benzyl bromide (1.30 mL, 11 mmol, 1.1 eq.) was added. The reaction mixture was stirred 
at rt under a stream of N2 for 1 h. Aqueous saturated NH4Cl solution (20 mL) was added 
and the product was extracted with EtOAc (3 x 30 mL). The combined organic layers 
were washed with brine (3 x 100 mL) and then dried with MgSO4 before filtering and 
removing the solvent in vacuo. The title product was obtained as a yellow oil (1.89 g, 
91%). 1H NMR (400 MHz, CDCl3) δ 8.42 (d, J = 1.5 Hz, 1H), 7.97 (d, J = 8.0 Hz, 1H), 
7.37 – 7.28 (m, 3H), 7.25 (d, J = 7.5 Hz, 2H), 7.21 (d, J = 3.5 Hz, 1H), 7.12 (dd, J = 8.0, 
5.0 Hz, 1H), 6.53 (d, J = 3.5 Hz, 1H), 5.55 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 147.8 
(-), 143.1 (+), 137.9 (-), 128.9 (+), 128.7 (+), 127.9 (+), 127.6 (+), 127.5 (+), 120.5 (-), 
115.9 (+), 100.2 (+), 47.8 (-). 
 
Synthesis of 1-benzyl-7-azaisatin (104)73 
 
1-Benzyl-7-azaindole 103 (0.140 g, 0.67 mmol, 1.0 eq) and N-bromosuccinimide (0.240 
g, 1.3 mmol, 2.0 eq) were dissolved in DMSO (7 mL) and then heated at 80 °C for 24 h. 
The reaction mixture was added to water (30 mL) and the product extracted with 
dichloromethane (3 x 30 mL). The combined organic layers were washed with water (3 
x 50 mL) and then dried with MgSO4 before filtering and removing the solvent in vacuo. 
The crude product was purified by flash column chromatography (silica gel, 20% 
EtOAc/petrol) to afford the title compound as a yellow solid (0.055 g, 34%). M.p. 190-
192 °C (lit: 187-188 °C).73 1H NMR (400 MHz, CDCl3) δ 8.48 (dd, J = 5.0, 2.0 Hz, 1H), 
7.83 (dd, J = 7.5, 2.0 Hz, 1H), 7.52 (m, 2H), 7.40 – 7.25 (m, 3H), 7.09 (dd, J = 7.5, 5.0 
Hz, 1H), 5.04 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 181.9 (+), 163.5 (+), 158.1 (+), 155.9 




Synthesis of 1-methyl-7-azaindole (105)73 
 
7-Azaindole (1.18 g, 10 mmol, 1.0 eq.) and NaH (0.480 g, 20 mmol, 2.0 eq.) were 
suspended in DMF (50 mL). The reaction mixture was stirred at rt for 30 min and then 
methyl iodide (0.68 mL, 11 mmol, 1.1 eq.) was added. The reaction mixture was stirred 
at rt under a stream of N2 for 1 h. Aqueous saturated NH4Cl solution (20 mL) was added 
and the product was extracted with EtOAc (3 x 50 mL). The combined organic layers 
were washed with brine (3 x 100 mL) and then dried with MgSO4 before filtering and 
removing the solvent in vacuo. The title product was obtained as a yellow oil (1.24 g, 
94%). 1H NMR (400 MHz, CDCl3) δ 8.36 (dd, J = 4.5, 1.5 Hz, 1H), 7.93 (dd, J = 8.0, 1.5 
Hz, 1H), 7.20 (d, J = 3.5 Hz, 1H), 7.08 (dd, J = 8.0, 4.5 Hz, 1H), 6.47 (d, J = 3.5 Hz, 1H), 
3.92 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 142.9 (+), 129.0 (+), 128.7 (+), 120.5 (-), 
115.5 (+), 99.3 (+), 60.4 (-), 31.3 (+). 
 
Synthesis of 1-methyl-7-azaisatin (106)73 
 
1-Methyl-7-azaindole 105 (0.132 g, 1.0 mmol, 1.0 eq) and N-bromosuccinimide (0.356 
g, 2.0 mmol, 2.0 eq) were dissolved in DMSO (10 mL) and then heated at 80 °C for 20 
h. The reaction mixture was added to water (100 mL) and the product extracted with 
dichloromethane (3 x 50 mL). The combined organic layers were washed with water (3 
x 100 mL) and then dried with MgSO4 before filtering and removing the solvent in vacuo. 
The crude product was purified by flash column chromatography (silica gel, 50% 
EtOAc/petrol) to afford the title compound as a yellow-orange solid (0.038 g, 23%). M.p. 
160-162 °C (lit: 160-161 °C).73 1H NMR (400 MHz, CDCl3) δ 8.48 (dd, J = 5.0, 2.0 Hz, 




(101 MHz, CDCl3) δ 181.9 (+), 163.9 (+), 158.4 (+), 155.9 (–), 132.8 (–), 119.6 (–), 112.1 
(+), 25.1 (–). 
 
Synthesis of 1-benzyl-5-azaindole (107) 171 
 
5-Azaindole (0.354 g, 3.0 mmol, 1.0 eq.) and NaH (0.144 g, 6.0 mmol, 2.0 eq.) were 
suspended in DMF (15 mL). The reaction mixture was stirred at rt for 10 min and then 
benzyl bromide (0.39 mL, 3.3 mmol, 1.1 eq.) was added. The reaction mixture was stirred 
at rt under a stream of N2 for 1 h. Aqueous saturated NH4Cl solution (20 mL) was added 
and the product was extracted with EtOAc (3 x 50 mL). The combined organic layers 
were washed with brine (3 x 100 mL) and then dried with MgSO4 before filtering and 
removing the solvent in vacuo. The title product was obtained as a dark brown solid 
(0.350 g, 56%). M.p. 60-62 °C (lit: 61-62 °C).171 1H NMR (400 MHz, CDCl3) δ 8.97 (s, 
1H), 8.31 (d, J = 6.0 Hz, 1H), 7.37 – 7.28 (m, 3H), 7.22 (d, J = 6.0 Hz, 1H), 7.17 (d, J = 
3.0 Hz, 1H), 7.12 (d, J = 7.5 Hz, 2H), 6.67 (d, J = 3.0 Hz, 1H). 13C NMR (101 MHz, CDCl3) 
δ 146.3 (-), 144.2 (+), 137.1 (-), 128.8 (+), 127.9 (+), 127.7 (+), 126.8 (+), 124.3 (+), 118.4 
(-), 116.4 (+), 100.1 (+), 47.9 (-). 
 
Synthesis of 1-benzyl-7-azaisatin (104) 73 
 
1-Benzyl-7-azaindole (0.208 g, 1.0 mmol, 1.0 eq.), 2-iodoxybenzoic acid (0.700 g, 2.5 
mmol, 2.5 eq.) and InCl3 (0.022 g, 0.1 mmol, 0.1 eq.) were combined in MeCN (18:2, 20 
mL) and then stirred at 80 °C for 2 h. Aqueous saturated NaHCO3 solution (20 mL) was 
added and the product extracted with EtOAc (3 x 30 mL). The combined organic layers 




the solvent in vacuo. The title product was obtained as a yellow solid (0.021g, 22%). See 
page 149 for data.  
 
Synthesis of ethyl (2,4,6-trimethylphenoxy)carbamate (109)84 
 
Hydroxylamine hydrochloride (3.47 g, 50 mmol, 5.0 eq.) was added to an aqueous 
solution of NaOH (1.5 M, 40 mL) and then cooled to 0 °C. Ethyl chloroformate (0.95 mL, 
10 mmol, 1.0 eq.) was added dropwise over 5 mins and the reaction mixture was stirred 
at rt for 2 h. A 1 M HCl solution was added (until pH = 4) and then the product was 
extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine 
(20 mL) and then dried with MgSO4 before filtering and removing the solvent in vacuo. 
The residue was dissolved in diethyl ether (50 mL) and then 2-mesitylene sulfonyl 
chloride (2.40 g, 11 mmol, 1.1 eq.) was added. Et3N (1.5 mL, 11 mmol, 1.1 eq.) was 
added dropwise at 0 °C and the reaction mixture was stirred at rt under a stream of N2 
for 2 h. H2O (50 mL) was added and the product was extracted with dichloromethane (3 
x 30 mL). The combined organic layers were washed with brine (20 mL) and then dried 
with MgSO4 before filtering and removing the solvent in vacuo. The crude product was 
purified by flash column chromatography (SiO2, EtOAc) to afford the title compound as 
a white solid (1.66 g, 58%). M.p. 94-95 °C. (lit: not reported) 1H NMR (400 MHz, DMSO) 
δ 11.47 (s, 1H), 7.14 (s, 2H), 3.97 (q, J = 7.0 Hz, 2H), 2.57 (s, 6H), 2.30 (s, 3H), 1.05 (t, 
J = 7.0 Hz, 3H). 13C NMR (101 MHz, DMSO) δ 156.2, 144.4, 141.0, 131.8, 128.6, 62.1, 









Synthesis of ethyl chlorocarbamate (116)86 
 
Urethane (4.57 g, 51.3 mmol, 1.0 eq.) and N,N-dichlorourethane (6.0 mL, 51.3 mmol, 
1.0 eq.) were combined and stirred at rt in the absence of light for 18 h. The title 
compound was obtained as a yellow/green oil (12.6 g, 99%). 1H NMR (400 MHz, CDCl3) 
δ 6.54 (s, 1H), 4.24 (q, J = 7.0 Hz, 2H), 1.30 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 157.5 (-), 64.2 (-), 14.9 (+).  
 
Synthesis of 3-azaisatoic anhydride (120) 172 
 
2-Aminopyridine-3-carboxylic acid (1.38 g, 10 mmol, 1.0 eq.) was suspended in toluene 
(20 mL) and then Et3N (1.5 mL, 20 mmol, 2.0 eq.) was added. Ethyl chloroformate (1.43 
mmol, 15 mmol, 1.5 eq.) was added dropwise and the reaction mixture was stirred at 
100 °C for 2 h. The reaction mixture was cooled to rt and the resulting precipitate 
removed by filtration. The crude product was triturated with EtOH to afford the title 
product as an off-white solid (0.394 g, 24%). M.p. 198-200 °C (lit: 195 °C).172 1H NMR 
(400 MHz, d6-DMSO) δ 12.30 (s, 1H), 8.66 (dd, J = 5.0, 2.0 Hz, 1H), 8.32 (dd, J = 8.0, 
2.0 Hz, 1H), 7.32 (dd, J = 8.0, 5.0 Hz, 1H). 13C NMR (101 MHz, d6-DMSO) δ 160.0 (–), 
156.4 (+), 153.5 (–), 147.5 (–), 138.8 (+), 120.3 (+), 107.2 (–). 
 





Azidotrimethylsilane (4.4 mL, 33 mmol, 1.1 eq) was added to a solution of 2,3-
pyridinedicarboxylic anhydride (4.47 g, 30 mmol, 1 eq) in 1,2-dichloroethane (50 mL). 
The reaction mixture was stirred at 60 °C under a stream of N2 for 2 h. The solution was 
cooled to rt and then EtOH (5 mL) was added and stirred for 15 mins. The resulting solid 
precipitate was filtered and triturated with cold EtOH to afford the title compound as an 
off-white solid (4.70 g, 97%). See page 153 for data. 
 
Synthesis of N-allyl-3-azaisatoic anhydride (126) 88 
 
To a suspension of 3-azaisatoic anhydride 120 (0.300 g, 1.83 mmol, 1 eq) and sodium 
hydride (0.088 g, 3.66 mmol, 2 eq) in DMF (10 mL) was added allyl bromide (0.17 mL, 
2.01 mmol, 1.1 eq) and the reaction mixture was stirred at rt under a stream of N2 for 16 
h. Ice-cold H2O (50 mL) was added and the product was extracted with diethyl ether (3 
x 30 mL). The combined organic layers were washed with brine (20 mL) and then dried 
with MgSO4 before filtering and removing the solvent in vacuo. The crude solid was 
recrystallized with DCM/petrol to afford the title compound as white crystals (0.254 g, 
68%). M.p. 112-114 °C (lit: 114-117 °C).88 1H NMR (400 MHz, d6-DMSO) δ 8.76 (dd, J = 
5.0, 2.0 Hz, 1H), 8.41 (dd, J = 7.5, 2.0 Hz, 1H), 7.39 (dd, J = 7.5, 5.0 Hz, 1H), 5.92 (ddt, 
J = 17.0, 10.0, 5.0 Hz, 1H), 5.28 (dd, J = 17.0, 1.5 Hz, 1H), 5.14 (dd, J = 10.0, 1.5 Hz, 
1H), 4.75 (dd, J = 5.0, 1.5 Hz, 2H). 13C NMR (101 MHz, d6-DMSO) δ 158.8 (–), 155.8 
(+), 152.2 (–), 147.8 (–), 139.2 (+), 132.2 (+), 120.4 (+), 117.3 (–), 108.6 (–), 45.3 (–). 
 





N-Allyl-3-azaisatoic anhydride 126 (0.120 g, 0.58 mmol, 1.0 eq.) was dissolved in DMF 
(3 mL) and a solution of KCN (0.042 g, 0.65 mmol, 1.1 eq.) in DMF (2 mL) was added. 
The reaction mixture was stirred at 100 °C under a stream of N2 for 10 mins. The reaction 
mixture was poured onto ice-cold H2O (100 mL) and the product extracted with diethyl 
ether (3 x 30 mL). The combined organic layers were washed with brine (30 mL) and 
then dried with MgSO4 before filtering and removing the solvent in vacuo. The residue 
was dissolved in 2 M HCl solution (10 mL) and then stirred at rt for 16 h. Aqueous 
saturated NaHCO3 solution (20 mL) was added and the product extracted with 
dichloromethane (3 x 20 mL). The combined organic layers were washed with brine (20 
mL) and then dried with MgSO4 before filtering and removing the solvent in vacuo. The 
crude product was purified by flash column chromatography (silica gel, 20% 
EtOAc/petrol) to afford the title compound as a yellow oil (0.018 g, 20%). 1H NMR (400 
MHz, CDCl3) δ 8.48 (dd, J = 5.0, 2.0 Hz, 1H), 7.86 (dd, J = 7.5, 2.0 Hz, 1H), 7.12 (dd, J 
= 7.5, 5.0 Hz, 1H), 6.01 – 5.91 (m, 1H), 5.39 – 5.26 (m, 2H), 4.50 (dt, J = 6.0, 1.5 Hz, 
2H). 13C NMR (101 MHz, CDCl3) δ 182.0 (-), 164.8 (-), 162.0 (-), 156.0 (+), 133.0 (+), 
130.4 (+), 119.7 (+), 118.6 (-), 112.1 (-), 41.2 (-).  
 
Synthesis of (cyanomethyl)(dimethyl)sulfonium bromide salt (91) 78 
 
Bromoacetonitrile (0.35 mL, 5.0 mmol, 1.0 eq.) and dimethyl sulfide (0.37 mL, 5.0 mmol, 
1.0 eq.) were combined and stirred at rt for 16 h. The title compound was obtained as a 
white solid (0.910 g, 99%). M.p. 200 °C, decomp. (lit: not reported) 1H NMR (400 MHz, 








oxopropanenitrile (92) 78 
 
HATU (0.837 g, 2.2 mmol, 1.1 eq), (cyanomethyl)dimethylsulfonium bromide salt 91 
(0.874  g, 4.8 mmol, 2.4 eq) and DIPEA (0.98 mL, 5.6 mmol, 2.8 eq) were added to a 
suspension of 2-aminonicotinic acid (0.276 g, 2.0 mmol, 1 eq) in dichloromethane (20 
mL). The solution was stirred vigorously under a stream of N2 for 1 h. A 1 M K2CO3 
solution (20 mL) was added to the reaction mixture and the product extracted with 
dichloromethane (3 x 20 mL). The combined organic layers were dried with MgSO4 
before filtering and removing the solvent in vacuo. The crude product was purified by 
flash column chromatography (silica gel, EtOAc) to afford the title compound as an off-
white solid (0.354 g, 81%). M.p. 198-200 °C. (lit: not reported) 1H NMR (400 MHz, d4-
MeOD) δ 8.07 – 7.91 (m, 2H), 6.67 (t, J = 5.0 Hz, 1H), 2.94 (s, 6H). 13C NMR (101 MHz, 
d6-DMSO) δ 168.1 (–), 152.8 (+), 130.1 (+), 122.2 (+), 116.5 (–), 65.5 (–), 44.4 (–), 42.5 
(–), 29.7 (+). 
 
Synthesis of 3-azaisatoic anhydride and 7-azaisatin (75)78 
 
3-(2-Aminopyridin-3-yl)-2-(dimethyl-44-sulfanylidene)-3-oxopropanenitrile 92 (0.150 g, 
0.68 mmol, 1.0 eq.) was dissolved in THF/H2O (13:6, 19 mL) and then oxone (0.581 g, 
1.90 mmol, 3.0 eq.) was added. The reaction mixture was stirred at rt for 10 mins. 
Aqueous saturated NaHCO3 solution (20 mL) was added and the product extracted with 




mL) and then dried with MgSO4 before filtering and removing the solvent in vacuo. The 
crude solid was triturated with cold EtOH to afford 7-azaisatoic anhydride as an off-white 
solid (0.018 g, 16%). (See page 153 for data). The solvent from the mother liquor was 
removed in vacuo and the residue was purified by flash column chromatography (silica 
gel, 20% EtOAc/petrol) to afford 7-azaisatin as a yellow amorphous solid (0.026 g, 26%). 
M.p. 200 °C, decomp. (lit: 225-230 °C, decomp.).78 1H NMR (400 MHz, DMSO) δ 11.61 
(s, 1H), 8.40 (dd, J = 5.0, 1.5 Hz, 1H), 7.88 (ddd, J = 7.5, 1.5, 0.5 Hz, 1H), 7.11 (dd, J = 
7.5, 5.0 Hz, 1H). 13C NMR (101 MHz, DMSO) δ 181.7 (-), 164.9 (-), 157.6 (-), 155.9 (+), 
133.9 (+), 119.4 (+), 106.8 (-).  
 
Synthesis of 4-iodo-3-nitropyridine (132) 173 
 
4-Chloro-3-nitropyridine (1.59 g, 10 mmol, 1 eq.) and sodium iodide (27.0 g, 180 mmol, 
18 eq.) were dissolved in acetonitrile (85 mL, 0.118 M) and the reaction mixture stirred 
at room temperature under a stream of nitrogen for 1 h. Aqueous saturated NaHCO3 (50 
mL) was added to the reaction mixture and then the product extracted with ethyl acetate 
(3 x 50 mL). The organic phase was dried with anhydrous MgSO4 before filtering and 
removing the solvent under reduced pressure. The title compound was obtained as a 
brown solid (2.46 g, 100%). M.p. 140-142 °C (lit: not reported). 1H NMR (400 MHz, 
CDCl3) δ 9.06 (s, 1H), 8.37 (d, J = 5.0 Hz, 1H), 8.04 (d, J = 5.0 Hz, 1H). 13C NMR (101 
MHz, CDCl3) δ 152.4 (-), 145.9 (-), 136.4 (-), 98.4(+), 65.1 (+). 
 





4-Iodo-3-nitropyridine 132 (5.00 g, 20.0 mmol, 1 eq.), TMSA (3.42 mL, 24.0 mmol, 1.2 
eq.), PdCl2(PPh3)2 (0.702 g, 1.00 mmol, 0.05 eq.), CuI (0.381 g, 2.00 mmol, 0.1 eq.) and 
DIPA (8.43 mL, 60.0 mmol, 3 eq.) were dissolved in THF (100 mL) and the reaction 
mixture was stirred at 0 C under a stream of nitrogen for 1 h. Aqueous saturated sodium 
bicarbonate solution (100 mL) was added and the product extracted with EtOAc (3 x 100 
mL). The combined organic layers were washed with brine (20 mL) and dried with 
MgSO4. The crude product was purified by flash column chromatography (silica gel, 20% 
EtOAc/petrol) to give the title compound as a dark brown oil (3.21 g, 73%). 1H NMR (250 
MHz, CDCl3) δ 9.30 (s, 1H), 8.79 (d, J = 5.0 Hz, 1H), 7.55 (d, J = 5.0 Hz, 1H). 0.30 (9H, 
s). 13C NMR (101 MHz, CDCl3) δ 153.0 (+), 145.9 (+), 132.0 (+), 127.9 (–), 126.3 (–), 
110.8 (–), 96.8 (–), -0.5 (–). IR (FTIR, cm-1) 2960, 2926, 2066, 1746, 1616, 1579, 1537, 
1491, 1345, 1251, 1196, 844. HRMS calcd. mass for C10H12N2O2Si (M+H+) 220.0668, 
found 220.0660. 
 
Synthesis of 4-(iodoethynyl)-3-nitropyridine (134) 
 
3-Nitro-4-[(trimethylsilyl)ethynyl]pyridine 133 (0.500 g, 2.27 mmol, 1 eq.) and silver 
nitrate (0.019 g, 0.114 mmol, 0.05 eq.) were dissolved in DMF (5 mL) in a flask wrapped 
in aluminium foil and the reaction mixture was cooled at 0 C. A solution of N-
iodosuccinimide (0.562 g, 2.50 mmol, 1.1 eq.) in DMF (5 mL) was added and the reaction 
mixture was stirred at room temperature under a stream of nitrogen for 5 h. Ice-cold 
water was added and the product extracted with diethyl ether (3 x 20 mL). The combined 
organic layers were washed with ice-cold water (50 mL) and dried over MgSO4. The 
crude product was purified by flash column chromatography (silica gel, 10% 
EtOAc/petrol) to give the title compound as a yellow solid (0.543 g, 87%). Mp 110-115 
°C; 1H NMR (400 MHz, d6-DMSO) δ 9.28 (s, 1H), 8.86 (d, J = 5.0 Hz, 1H), 7.77 (d, J = 




(–), 87.2 (–), 25.5 (–); IR (FTIR, cm-1) 3093, 2159, 1597, 1536, 1521, 1345, 1179, 1050, 
872, 847, 820, 766; HRMS calcd. mass for C7H4N2O2127I (M+H+) 274.9318, found 
274.9324. 
 
Synthesis of 6-azaisatin (81) 174 
 
4-(Iodoethynyl)-3-nitropyridine 134 (0.100 g, 0.37 mmol. 1.0 eq.) was dissolved in 
acetone (10 mL) and then PdCl2(PPh3)2 (0.013 g, 0.02 mmol, 0.05 eq.) was added. The 
reaction mixture was stirred at 60 °C under a stream of N2 for 24 h. After cooling to rt, 
the solvent was removed in vacuo. The residue was purified by flash column 
chromatography (silica gel, EtOAc) to afford the title compound as a dark red solid (0.020 
g, 36%). M.p. 200 °C (decomp).174 1H NMR (400 MHz, DMSO) δ 9.44 (s, 1H), 9.01 (d, J 
= 5.0 Hz, 1H), 8.05 (d, J = 5.0 Hz, 1H). 13C NMR (101 MHz, DMSO) δ 181.0 (-), 164.1 (-
), 154.7 (+), 153.9 (-), 146.8 (+), 129.3 (+), 123.8 (-). 
 
Synthesis of 6-azaisatin (81) 174 
 
4-(Iodoethynyl)-3-nitropyridine 134 (0.120 g, 0.44 mmol. 1.0 eq.) was dissolved in 
acetone (10 mL) and then PdCl2(PPh3)2 (0.088 g, 0.66 mmol, 1.5 eq.) was added. The 
reaction mixture was stirred at 60 °C under a stream of N2 for 24 h. After cooling to rt, 
the solvent was removed in vacuo. The residue was purified by flash column 
chromatography (silica gel, EtOAc) to afford the title compound as a dark red solid (0.020 






Synthesis of 3-bromopyridine 1-oxide (139)175 
 
3-Bromopyridine (11.6 mL, 120 mmol, 1 eq.) was dissolved in ethyl acetate (200 mL) 
and m-CPBA (33.1 g, 192 mmol, 1.6 eq.) was added portion-wise. The reaction was 
stirred at ambient temperature for 1 h. Solvent was removed under reduced pressure 
and the crude product was purified by flash column chromatography (silica gel, 10% 
MeOH/DCM) to give the title compound as a pale yellow oil (20.7 g, 99%). 1H NMR (400 
MHz, CDCl3) δ 8.32 (1H, s), 8.11 (d, J = 7.0 Hz, 1H), 7.38 (d, J = 8.0 Hz, 1H), 7.14 (dd, 
J = 8.0, 7.0 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 140.9 (-), 138.1 (-), 128.7(-), 126.1 (-
), 120.6 (+). 
 
Synthesis of 3-bromo-4-nitropyridine 1-oxide (140)176 
 
3-Bromopyridine-1-oxide 139 (10 g, 57.8 mmol, 1.0 eq.) was dissolved in conc. H2SO4 
(15 mL). A mixture of conc. H2SO4 (15 mL) and HNO3 (25 mL) was added to the solution 
and then stirred at 90 °C for 1 h. HNO3 (25 mL) was added portion-wise every half an 
hour for 2 h and the reaction was stirred at 90 °C for 16 h. A solution of NaOH (aq. 5 M) 
was slowly added to the cooled reaction mixture until it was basic and then the product 
was extracted with DCM (3 x 100 mL). The combined organic layers were dried with 
MgSO4 and the solvent was removed at reduced pressure. The crude product was 
recrystallized with petrol/DCM to give the title compound as a yellow solid (5.90 g, 47%). 
M.p. 150-152 °C (lit: 152-153 °C).176 1H NMR (400 MHz, DMSO-d6) δ 8.89 (d, J = 2.0 Hz, 
1H), 8.40 (dd, J = 7.0, 2.0 Hz, 1H), 8.18 (d, J = 7.0 Hz, 1H). 13C NMR (101 MHz, DMSO-






Synthesis of 4-nitro-3-[(trimethylsilyl)ethynyl] pyridine 1-oxide (141) 
 
3-Bromo-4-nitropyridine-1-oxide 140 (1.00 g, 4.59 mmol, 1.0 eq.) PdCl2(PPh3)2 (0.161 g, 
0.230 mmol, 0.05 eq.) and copper (I) iodide (0.087 g, 0.460 mmol, 0.1 eq.) were 
dissolved in tetrahydrofuran (20 mL). Trimethylsilylacetylene (0.980 mL, 6.89 mmol, 1.5 
eq.) and diisopropylamine (1.94 mL, 13.8 mmol, 3 eq.) were added and the reaction 
stirred at ambient temperature under a stream of nitrogen for 1 h. Aqueous saturated 
NaHCO3 (20 mL) was added to the reaction mixture and the product  extracted with ethyl 
acetate (3 x 30 mL). The combined organic layers were washed with brine (20 mL) and 
dried with MgSO4. The crude product was purified by flash column chromatography 
(silica gel, 20% EtOAc/petrol) to give the title compound as a brown oil (0.758 g, 70%).  
1H NMR (400 MHz, DMSO-d6) δ 8.61 (d, J = 2.0 Hz, 1H), 8.38 (dd, J = 7.0, 2.0 Hz, 1H), 
8.17 (d, J = 7.0 Hz, 1H), 0.27 (9H, s). 13C NMR (101 MHz, CDCl3) δ 143.5 (+), 140.6 (+), 
123.0 (+), 117.0 (-), 108.1 (-), 95.7 (-), 92.3 (-), 0.24 (+); IR (FTIR, cm-1) 3103, 2960, 
1605, 1596, 1527, 1341, 1251, 844. HRMS calcd for C10H13N2O3Si (M + H+) 237.0695, 
found 237.0690. 
 
Synthesis of 3-(iodoethynyl)-4-nitropyridine 1-oxide (142) 
 
4-Nitro-3-[(trimethylsilyl)ethynyl] pyridine 1-oxide 141 (0.300 g, 1.27 mmol, 1.0 eq.) and 
silver fluoride (0.161 g, 0.050 mmol, 0.05 eq.) were dissolved in DMF (5 mL) in a flask 
wrapped in aluminium foil. A solution of N-iodosuccinimide (0.286 g, 1.27 mmol, 1.0 eq.) 
in DMF (5 mL) was added and the reaction mixture was stirred at ambient temperature 




crude product was purified by flash column chromatography (silica gel, 20% 
EtOAc/petrol) to give the title compound as a yellow amorphous solid (0.240 g, 65%). 1H 
NMR (250 MHz, DMSO-d6) δ 8.63 (d, J = 2.0 Hz, 1H), 8.36 (dd, J = 7.0, 2.0 Hz, 1H), 
8.15 (d, J = 7.0 Hz, 1H). 13C NMR (101 MHz, DMSO) δ 151.9 (-), 144.3 (-), 132.3 (+), 
129.2 (+), 122.9 (+), 84.5 (-), 30.0 (-). IR (FTIR, cm-1) 2953, 2918, 2841, 1714, 1638, 
1542, 1492, 1018. HRMS calcd for C7H4N2O3127I (M + H+) 290.9267, found 290.9257. 
 
Synthesis of 2-iodo-3H-pyrrolo[2,3-c]pyridin-3-one 1-oxide (144) 
 
4-(Iodoethynyl)-3-nitropyridine 134 (0.050 g, 0.18 mmol, 1.0 eq.), p-benzoquinone (0.020 
g, 0.18 mmol, 1.0 eq.) and Pd(OAc)2 (0.004 g, 0.018 mmol, 0.1 eq.) were combined in 
THF (10 mL) and then stirred at 70 °C under a stream of N2 for 3.5 h. The solvent was 
removed in vacuo and the residue was purified by flash column chromatography (silica 
gel, 100% EtOAc) to afford the title compound as a dark brown amorphous solid (5 mg, 
10%). 1H NMR (400 MHz, CDCl3) δ 9.01 – 9.07 (m, 2H), 7.57 (d, J = 4.5 Hz, 1H). IR 
(FTIR, cm-1) 1709, 1598, 1485, 1455, 1345, 1316, 1296. HRMS calcd. mass for 













General Procedure A: Synthesis of trimethyl((2-nitrophenyl)ethynyl)silane (67)71 
 
1-Iodo-2-nitrobenzene (0.498 g, 2.00 mmol, 1 eq.), PdCl2(PPh3)2 (0.070 g, 0.100 mmol, 
0.05 eq.) and CuI (0.038 g, 0.2 mmol, 0.1 eq.) were dissolved in THF (10 mL). TMSA 
(0.342 mL, 2.40 mmol, 1.2 eq.) and DIPA (0.843 mL, 6.00 mmol, 3 eq.) were added and 
the reaction mixture, and the solution stirred at 0 °C under a stream of N2 for 1 h. Aqueous 
saturated NaHCO3 solution (10 mL) was added and the product extracted with EtOAc (3 
x 30 mL). The combined organic layers were washed with brine (20 mL) and dried with 
MgSO4. The crude product was purified by flash column chromatography (silica gel, 20% 
EtOAc/petrol) to give the title compound as a dark brown oil (0.355 g, 81%). 1H NMR 
(400 MHz, CDCl3) δ 8.00 (dd, J = 8.0, 1.0 Hz, 1H), 7.66 (dd, J = 8.0, 1.0 Hz, 1H), 7.56 
(ddd, J =, 8.0, 8.0, 1.0 Hz, 1H), 7.50-7.40 (m,1H), 0.30 (s, 9H). 13C NMR (101 MHz, 
CDCl3) δ 150.0, 135.4, 132.9, 129.1, 124.7, 118.7, 104.1, 99.6, -0.30. 
 
Synthesis of Trimethyl((4-methyl-2-nitrophenyl)ethynyl)silane (185) 
 
Reaction of 1-iodo-4-methyl-2-nitrobenzene (3.16 g, 12.0 mmol, 1 eq.), TMSA (2.05 mL, 
14.4 mmol, 1.2 eq.), PdCl2(PPh3)2 (0.421 g, 0.600 mmol, 0.05 eq.), CuI (0.229 g, 1.20 
mmol, 0.1 eq.) and DIPA (5.06 mL, 36.0 mmol, 3 eq.) in THF (100 mL) as described in 
general procedure A gave, after work-up and chromatography (silica gel, 10% 
EtOAc/petrol), the title compound as a yellow solid (2.61 g, 93%). Mp 54-56 °C (lit: 55-
57 °C)71; 1H NMR (250 MHz, CDCl3) δ 7.83 (d, J = 1.0 Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H), 




150.0 (+), 139.8 (+), 134.9 (–), 133.5 (–), 124.8 (–), 115.5 (+), 102.5 (+), 99.5 (+), 21.3 
(–), -0.32 (+). 
 
Synthesis of Trimethyl((5-methoxy-2-nitrophenyl)ethynyl)silane (182) 71 
 
Reaction of 2-iodo-4-methoxy-1-nitrobenzene (3.35 g, 12.0 mmol, 1 eq.), TMSA (2.05 
mL, 14.4 mmol, 1.2 eq.), PdCl2(PPh3)2 (0.421 g, 0.600 mmol, 0.05 eq.), CuI (0.229 g, 
1.20 mmol, 0.1 eq.) and DIPA (5.06 mL, 36.0 mmol, 3 eq.) in THF (100 mL) as described 
in general procedure A gave, after work-up and chromatography (silica gel, 10% 
EtOAc/petrol), the title compound as a light-brown solid (2.86 g, 96%). Mp 64-66 °C (lit: 
66-68 °C).71 1H NMR (400 MHz, CDCl3) δ 8.09 (d, J = 9.0 Hz, 1H), 7.09 (d, J = 3.0 Hz, 
1H), 6.93 (dd, J = 9.0, 3.0 Hz, 1H), 3.91 (s, 3H), 0.31 (s, 9H). 13C NMR (101 MHz, CDCl3) 
δ 162.7 (+), 143.2 (+), 127.0 (–), 120.7 (+), 119.1 (–), 114.9 (–), 103.6 (+), 100.0 (+), 56.0 
(–), -0.36 (+). 
 
 
Synthesis of Trimethyl((4-methoxy-2-nitrophenyl)ethynyl)silane (186)71 
 
Reaction of 1-iodo-4-methoxy-2-nitrobenzene (5.58 g, 20.0 mmol, 1 eq.), TMSA (3.42 
mL, 24.0 mmol, 1.2 eq.), PdCl2(PPh3)2 (0.702 g, 1.00 mmol, 0.05 eq.), CuI (0.381 g, 2.00 
mmol, 0.1 eq.) and DIPA (8.43 mL, 60.0 mmol, 3 eq.) in THF (100 mL) as described in 
general procedure A gave, after work-up and chromatography (silica gel, 20% 
EtOAc/petrol), the title compound as a light-brown solid (2.86 g, 97%). Mp 68-70 °C (lit: 
69-71 °C).71 1H NMR (250 MHz, CDCl3) δ 7.57 (d, J = 9.0 Hz, 1H), 7.53 (d, J = 3.0 Hz, 




δ 159.6 (+), 151.1 (+), 136.0 (–), 119.5 (–), 110.5 (+), 109.2 (–), 101.4 (+), 99.5 (+), 56.0 
(–), -0.28 (+). 
 
Synthesis of Trimethyl((2,4-dinitrophenyl)ethynyl)silane (187)71 
 
Reaction of 1-iodo-2,4-dinitrobenzene (3.53 g, 12.0 mmol, 1 eq.), TMSA (2.05 mL, 14.4 
mmol, 1.2 eq.), PdCl2(PPh3)2 (0.421 g, 0.600 mmol, 0.05 eq.), CuI (0.229 g, 1.20 mmol, 
0.1 eq.) and DIPA (5.06 mL, 36.0 mmol, 3 eq.) in THF (100 mL) as described in general 
procedure A gave, after work-up and chromatography (silica gel, 20% EtOAc/petrol), the 
title compound as a yellow solid (2.37 g, 75%). Mp 64-66 °C (lit: 65-68 °C).71 1H NMR 
(400 MHz, CDCl3) δ 8.91 (d, J = 2.0 Hz, 1H), 8.43 (dd, J = 9.0, 2.0 Hz, 1H), 7.87 (d, J = 
9.0 Hz, 1H), 0.31 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 150.0 (+), 146.5 (+), 136.2 (–), 
126.8 (–), 124.4 (+), 120.2 (–), 111.4 (+), 97.7 (+), -0.63 (+). 
 
 
Synthesis of 3-Nitro-4-((trimethylsilyl)ethynyl)aniline (188)177 
 
Reaction of 4-iodo-3-nitroaniline (0.500 g, 1.89 mmol, 1 eq.), TMSA (0.323 mL, 2.27 
mmol, 1.2 eq.), PdCl2(PPh3)2 (0.066 g, 0.090 mmol, 0.05 eq.), CuI (0.036 g, 0.190 mmol, 
0.1 eq.) and DIPA (0.800 mL, 5.67 mmol, 3 eq.) in THF (20 mL) as described in general 
procedure A gave, after work-up and chromatography (silica gel, 20% EtOAc/petrol), the 
title compound as a yellow solid (0.402 g, 91%). Mp 92-94 °C (lit: 95-99 °C).R18; 1H NMR 
(400 MHz, CDCl3) δ 7.42 (d, J = 8.0 Hz, 1H), 7.25 (d, J = 2.0 Hz, 1H), 6.80 (dd, J = 8.0, 
2.0 Hz, 1H), 4.19 (s, 2H), 0.27 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 151.2 (+), 147.2 




Synthesis of Trimethyl((4-chloro-2-nitrophenyl)ethynyl)silane (189)177 
 
Reaction of 5-chloro-2-iodonitrobenzene (1.13 g, 4.00 mmol, 1 eq.), TMSA (0.683 mL, 
4.80 mmol, 1.2 eq.), PdCl2(PPh3)2 (0.140 g, 0.200 mmol, 0.05 eq.), CuI (0.076 g, 0.400 
mmol, 0.1 eq.) and DIPA (1.67 mL, 12.0 mmol, 3 eq.) in THF (20 mL) as described in 
general procedure A gave, after work-up and chromatography (silica gel, 10% 
EtOAc/petrol), the title compound as a brown solid (1.01 g, 99%). Mp 45-50 °C (lit: 39-
41 °C).177 1H NMR (250 MHz, CDCl3) δ 8.04 (d, J = 2.0 Hz, 1H), 7.61 (d, J = 8.0 Hz, 1H), 
7.54 (dd, J = 8.0, 2.0 Hz, 1H), 0.29 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 150.4 (+), 
136.0 (–), 134.7 (+), 132.9 (–), 124.8 (–), 116.9 (+), 105.2 (+), 98.3 (+), -0.51 (+). 
 
Synthesis of Trimethyl((4-fluoro-2-nitrophenyl)ethynyl)silane (190) 
 
Reaction of 4-fluoro-1-iodo-2-nitrobenzene (0.541 mL, 4.00 mmol, 1 eq.), TMSA (0.683 
mL, 4.80 mmol, 1.2 eq.), PdCl2(PPh3)2 (0.140 g, 0.200 mmol, 0.05 eq.), CuI (0.076 g, 
0.400 mmol, 0.1 eq.) and DIPA (1.67 mL, 12.0 mmol, 3 eq.) in THF (20 mL) as described 
in general procedure A gave, after work-up and chromatography (silica gel, 10% 
EtOAc/petrol), the title product as an amorphous yellow solid (0.93 g, 98%). 1H NMR 
(400 MHz, CDCl3) δ 7.77 (dd, J = 8.0, 3.0 Hz, 1H), 7.67 (dd, J = 8.0, 6.0 Hz, 1H), 7.35 – 
7.27 (m, 1H), 0.29 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 161.3 (d, JCF = 253 Hz, +), 
150.8 (+), 136.7 (d, JCF = 8 Hz, –), 120.4 (d, JCF = 21 Hz, –), 114.7 (d, JCF = 4 Hz, +), 
112.3 (d, JCF = 27 Hz, –), 103.7 (+), 98.3 (+), -0.42 (+). IR (FTIR, cm-1) 2960, 2849, 2161, 
1602, 1581, 1518, 1338, 1293, 1276, 1090, 843. HRMS calcd for C11H12NO2FSi (M+H+) 





Synthesis of Trimethyl((5-chloro-6-nitrophenyl)-ethynyl)silane (191) 
 
Reaction of 2-chloro-6-iodonitrobenzene (2.27 g, 8.0 mmol, 1.0 eq.), TMSA (1.37 mL, 
9.6 mmol, 1.2 eq.), PdCl2(PPh3)2 (0.281 g, 0.40 mmol, 0.05 eq.), CuI (0.152 g, 0.80 mmol, 
0.1 eq.) and DIPA (3.34 mL, 24.0 mmol, 3 eq.) in THF (50 mL) as described in general 
procedure A gave, after work-up and chromatography (silica gel, 10% EtOAc/petrol), the 
title product as an amorphous off-white solid (2.00 g, 99%). 1H NMR (400 MHz, CDCl3) 
δ 7.50 – 7.45 (m, 2H), 7.39 (d, J = 8.0 Hz, 1H), 0.26 (s, 9H). 13C NMR (101 MHz, CDCl3) 
δ 131.5 (+), 130.5 (+), 130.4 (+), 125.2 (-), 118.1 (-), 116.9 (-), 104.0 (-), 96.2 (-), -0.56 
(+). IR (FTIR, cm-1) 2960, 2899, 1599, 1542, 1457, 1365, 1251, 911, 843. HRMS calcd 
for C11H13NO2ClSi (M+H+) 254.0404, found 254.0415. 
 
General Procedure B: Synthesis of trimethyl((2-methoxy-6-nitrophenyl)-
ethynyl)silane (192) 
 
2-Bromo-1-methoxy-3-nitrobenzene (0.500 g, 2.15 mmol, 1.0 eq) and PdCl2(PPh3)2 
(0.715 g, 0.220 mmol, 0.1 eq.) were dissolved in triethylamine (5 mL). 
Trimethylsilylacetylene (0.613 mL, 4.31 mmol, 2.0 eq.) was added and the reaction 
mixture was heated under reflux with stirring under a stream of N2 for 2 h. Aqueous 
saturated NaHCO3 solution (10 mL) was added and the product extracted with ethyl 
acetate (3 x 30 mL). The combined organic layers were washed with brine (20 mL) and 
dried with MgSO4. The crude product was purified by flash column chromatography 
(silica gel, 20% EtOAc/petrol) to give the title compound as a brown solid (0.363 g, 68%). 




(m, 1H), 7.12 (d, J = 8.0 Hz, 1H), 3.97 (s, 3H), 0.31 (s, 9H). IR (FTIR, cm-1) 2963, 2899, 
2841, 2157, 1532, 1472, 1350, 1275, 1250, 1055, 862, 845. 
 
Synthesis of Trimethyl((4-bromo-2-nitrophenyl)ethynyl)silane (193)178 
 
Reaction of 2,5-dibromonitrobenzene (2.00 g, 7.12 mmol, 1.0 eq.), TMSA (1.11 mL, 7.83 
mmol, 1.1 eq.) and PdCl2(PPh3)2 (0.250 g, 0.356 mmol, 0.05 eq.) in Et3N (10 mL) as 
described in general procedure B gave, after work-up and chromatography (silica gel, 
10% EtOAc/petrol), the title compound as a dark brown oil (1.92 g, 91%). 1H NMR (400 
MHz, CDCl3) δ 8.19 (d, J = 2.0 Hz, 1H), 7.70 (dd, J = 8.0, 2.0 Hz, 1H), 7.53 (d, J = 8.0 
Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 150.4 (+), 136.0 (–), 135.8 (–), 127.6 (–), 124.2 
(+), 117.3 (+), 105.4 (+), 98.4 (+), -0.45 (–). 
 
Synthesis of 3-Nitro-4-((trimethylsilyl)ethynyl)benzonitrile (194)179 
 
Reaction of 4-bromo-3-nitrobenzonitrile (1.00 g, 4.40 mmol, 1.0 eq.), TMSA (1.25 mL, 
8.81 mmol, 2.0 eq.) and PdCl2(PPh3)2 (0.309 g, 0.440 mmol, 0.1 eq.) in Et3N (10 mL) as 
described in general procedure B gave, after work-up and chromatography (silica gel, 
20% EtOAc/petrol), the title compound as a brown solid (0.670 g, 63%). Mp 81-82 °C (lit: 
81-82 °C).179 1H NMR (CDCl3) δ 8.32 (1H, d, J = 2.0 Hz), 7.85 (1H, dd, J = 8.0, 2.0 Hz), 
7.78 (1H, d, J = 8.0 Hz), 0.30 (9H, s). 13C NMR (101 MHz, CDCl3) δ 150.0 (+), 136.0 (–







Synthesis of Trimethyl((2-nitro-4-(trifluoromethyl)phenyl)ethynyl)silane (195)180 
 
Reaction of 1-bromo-2-nitro-4-(trifluoromethyl)benzene (0.567 mL, 3.70 mmol, 1.0 eq.), 
TMSA (0.727 mL, 7.40 mmol, 2.0 eq.) and PdCl2(PPh3)2 (0.260 g, 0.370 mmol, 0.1 eq.) 
in Et3N (5 mL) as described in general procedure B gave, after work-up and 
chromatography (silica gel, 20% EtOAc/petrol), the title compound as a brown solid (1.25 
g, 99%). Mp 70-72 °C (lit: 67-69 °C).180 1H NMR (250 MHz, CDCl3) δ 8.30 (s, 1H), 7.91 
– 7.69 (m, 2H), 0.31 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 150.0 (+), 135.9 (–), 130.9 
(q, JCF = 34 Hz, +), 129.1 (q, JCF = 3 Hz, –), 121.9 (q, JCF = 3 Hz, –), 121.2 (q, JCF = 271 
Hz, +), 107.8 (+), 98.0 (+), 87.0 (+), -0.53 (–). 
 
 
General Procedure C: Synthesis of 1-(Iodoethynyl)-2-nitrobenzene (68)71 
 
Trimethyl((2-nitrophenyl)ethynyl)silane 67 (0.219 g, 1.00 mmol, 1 eq.) and silver nitrate 
(0.008 g, 0.050 mmol, 0.05 eq.) were dissolved in DMF (5 mL) in a flask wrapped in 
aluminium foil, and the reaction mixture was cooled to 0 °C. A solution of N-
iodosuccinimide (0.247 g, 1.10 mmol, 1.1 eq.) in DMF (5 mL) was added and the reaction 
mixture stirred at ambient temperature under a stream of N2 for 5 h. Ice-cold H2O was 
added and the product extracted with diethyl ether (3 x 20 mL). The combined organic 
layers were washed with ice-cold H2O (50 mL) and dried with MgSO4. The crude product 
was purified by flash column chromatography (silica gel, 20% EtOAc/petrol) to give the 
title compound as a light-brown solid (0.218 g, 80%). Mp 66-68 °C (lit: 68-70 °C).71 1H 




7.56 – 7.47 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 150.4 (+), 135.9 (–), 132.9 (–), 129.1 
(–), 124.6 (–), 118.6 (+), 89.0 (+), 16.8 (+). 
 
Synthesis of 1-(Iodoethynyl)-4-methyl-2-nitrobenzene (197)71 
 
Reaction of trimethyl((4-methyl-2-nitrophenyl)ethynyl)silane 185 (0.466 g, 2.00 mmol, 1 
eq.), silver nitrate (0.017 g, 0.100 mmol, 0.05 eq.) and N-iodosuccinimide (0.495 g, 2.20 
mmol, 1.1 eq.) in DMF (10 mL) (5 h) as described in general procedure C gave, after 
work-up and chromatography (silica gel, 20% EtOAc/petrol), the title compound as a 
yellow solid (0.456 g, 79%). Mp 92-94 °C (lit: 94-96 °C).71 1H NMR (400 MHz, CDCl3) δ 
7.88 (s, 1H), 7.54 (d, J = 8.0 Hz, 1H), 7.40 (d, J = 8.0 Hz, 1H), 2.47 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 150.6 (–), 140.2 (–), 135.6 (+), 133.7 (+), 125.0 (+), 115.7 (–), 89.1 
(–), 21.3 (+), 15.1 (–). 
 
Synthesis of 2-(Iodoethynyl)-4-methoxy-1-nitrobenzene (183)71 
 
Reaction of ((5-methoxy-2-nitrophenyl)ethynyl) trimethylsilane 182 (1.00 g, 4.00 mmol, 
1 eq.) silver nitrate (0.034 g, 0.200 mmol, 0.05 eq.) and N-iodosuccinimide (0.994 g, 4.40 
mmol, 1.1 eq.) in DMF (20 mL) (5 h) as described in general procedure C gave, after 
work-up and chromatography (silica gel, 20% EtOAc/petrol), the title compound as an 
orange solid (0.808 g, 67%). Mp 88-90 °C (lit: 87-88 °C).71 1H NMR (400 MHz, CDCl3) δ 
8.12 (d, J = 9.0 Hz, 1H), 7.09 (d, J = 3.0 Hz, 1H), 6.95 (dd, J = 9.0, 3.0 Hz, 1H), 3.92 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ 162.9 (–), 143.3 (–), 127.1 (+), 120.8 (–), 119.9 (+), 





Synthesis of 4-Methoxy-2-nitro-1-(2-iodoethynyl)benzene (198)71 
 
Reaction of 2-(4-methoxy-2-nitrophenyl)-1-trimethylsilylethyne 186 (0.650 g, 2.61 mmol, 
1 eq.), silver nitrate (0.022 g, 0.130 mmol, 0.05 eq.) and N-iodosuccinimide (0.646 g, 
2.87 mmol, 1.1 eq.) in DMF (10 mL) (5 h) as described in general procedure C gave, 
after work-up and chromatography (silica gel, 20% EtOAc/petrol), the title compound as 
a light brown solid (0.808 g, 67%). Mp 86-88 °C (lit: 89-90 °C).71 1H NMR (400 MHz, 
CDCl3) δ 7.56 (d, J = 9.0 Hz, 1H), 7.55 (d, J = 3.0 Hz, 1H), 7.13 (dd, J = 9.0, 3.0 Hz, 1H), 
3.91 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 159.8 (–), 151.3 (–), 136.7 (+), 119.7 (+), 
110.7 (–), 109.3 (+), 88.9 (–), 56.1 (+), 13.7 (–).  
 
Synthesis of 2-(Iodoethynyl)-1-methoxy-3-nitrobenzene (199) 
 
Reaction of ((2-methoxy-6-nitrophenyl)ethynyl) trimethylsilane 192 (0.310 g, 1.24 mmol, 
1 eq.), silver nitrate (0.011 g, 0.060 mmol, 0.05 eq.) and N-iodosuccinimide (0.308 g, 
1.37 mmol, 1.1 eq.) in DMF (10 mL) (5 h) as described in general procedure C gave, 
after work-up and chromatography (silica gel, 20% EtOAc/petrol), the title compound as 
a yellow solid (0.259 g, 69%). Mp 90-92 °C; 1H NMR (400 MHz, CDCl3) δ 7.58 (dd, J = 
8.0, 1.0 Hz, 1H), 7.41 (app. t, J = 8.0 Hz, 1H), 7.15 (dd, J = 8.0, 1.0 Hz, 1H), 3.97 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 162.6 (–), 152.3 (–), 129.3 (+), 116.2 (+), 114.8 (+), 108.0 
(–), 84.3 (–), 57.1 (+), 20.1 (–). IR (FTIR, cm-1) 2923, 2853, 1619, 1599, 1532, 1470, 







Synthesis of 1-(Iodoethynyl)-2,4-dinitrobenzene (200)71 
 
Reaction of ((2,4-dinitrophenyl)ethynyl)trimethylsilane 187 (1.06 g, 4.00 mmol, 1 eq.), 
silver nitrate (0.034 g, 0.200 mmol, 0.05 eq.) and N-iodosuccinimide (0.990 g, 4.40 mmol, 
1.1 eq.) in DMF (20 mL) as described in general procedure C gave, after work-up and 
chromatography (silica gel, 10% EtOAc/petrol), the title compound as a yellow solid (1.19 
g, 94%). Mp 115-118 °C (lit: 115-117 °C).71 1H NMR (250 MHz, CDCl3) δ 8.94 (d, J = 2.0 
Hz, 1H), 8.45 (dd, J = 9.0, 2.0 Hz, 1H), 7.86 (d, J = 9.0 Hz, 1H). 13C NMR (101 MHz, 
CDCl3) δ 150.4 (-), 146.7 (-), 137.1 (+), 127.0 (+), 124.4 (-), 120.4 (+), 88.1 (-), 25.9 (-). 
 
 
Synthesis of 4-(Iodoethynyl)-3-nitroaniline (201) 
 
Reaction of 3-nitro-4-((trimethylsilyl)ethynyl)aniline 188 (0.350 g, 1.50 mmol, 1 eq.), silver 
nitrate (0.013 g, 0.080 mmol, 0.05 eq.) and N-iodosuccinimide (0.370 g, 1.65 mmol, 1.1 
eq.) in DMF (10 mL) as described in general procedure C gave, after work-up and 
chromatography (silica gel, 20% EtOAc/petrol), the title compound as a brown solid 
(0.183 g, 42%). Mp 96-98 °C; 1H NMR (250 MHz, CDCl3) δ 7.41 (d, J = 8.0 Hz, 1H), 7.29 
(d, J = 2.0 Hz, 1H), 6.82 (dd, J = 8.0, 2.0 Hz, 1H), 4.15 (s, 2H). 13C NMR (101 MHz, 
CDCl3) δ 147.3 (–), 136.8 (+), 118.6 (+), 109.7 (+), 89.4 (–), 68.0 (–), 25.6 (–), 11.3 (–). 
IR (FTIR, cm-1) 3323, 1615, 1557, 1516, 1346, 1311, 831. HRMS calcd for C8H5N2O2127I 







Synthesis of 4-Bromo-1-(iodoethynyl)-2-nitrobenzene (202) 
 
Reaction of ((4-bromo-2-nitrophenyl)ethynyl) trimethylsilane 193 (1.60 g, 5.46 mmol, 1 
eq.), silver nitrate (0.046 g, 0.273 mmol, 0.05 eq.) and N-iodosuccinimide (1.35 g, 6.00 
mmol, 1.1 eq.) in DMF (20 mL) (5 h) as described in general procedure C gave, after 
work-up and chromatography (silica gel, 10% EtOAc/petrol), the title compound as a 
brown solid (0.805 g, 42%); Mp 87-88 °C; 1H NMR (250 MHz, CDCl3) δ 8.22 (d, J = 2.0 
Hz, 1H), 7.72 (dd, J = 8.0, 2.0 Hz, 1H), 7.52 (d, J = 8.0 Hz, 1H). 13C NMR (101 MHz, 
CDCl3) δ 150.5 (–), 136.8 (+), 136.0 (+), 127.8 (+), 122.6 (–), 117.5 (–), 88.2 (–), 18.7 (–
); IR (FTIR, cm-1) 3090, 2169, 1599, 1549, 1524, 1472, 1339, 1094, 881, 830; HRMS 
calcd for C8H4NO279Br127I (MH+) 288.9474, found 288.9470. 
 
 
Synthesis of 4-Chloro-1-(iodoethynyl)-2-nitrobenzene (203)71 
 
Reaction of ((4-chloro-2-nitrophenyl)ethynyl) trimethylsilane 189 (1.01 g, 4.00 mmol, 1 
eq.), silver nitrate (0.034 g, 0.200 mmol, 0.05 eq.) and N-iodosuccinimide (0.990 g, 4.40 
mmol, 1.1 eq.) in DMF (20 mL) (5 h) as described in general procedure C gave, after 
work-up and chromatography (silica gel, 10% EtOAc/petrol), the title compound as an 
orange solid (0.850 g, 69%). Mp 90-92 °C (lit: 92-94 °C).71 1H NMR (250 MHz, CDCl3) δ 
8.07 (d, J = 2.0 Hz, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.58 (dd, J = 8.0, 2.0 Hz, 1H).13C NMR 







Synthesis of 4-Fluoro-1-(iodoethynyl)-2-nitrobenzene (204) 
 
Reaction of ((4-fluoro-2-nitrophenyl)ethynyl) trimethylsilane 190 (1.20 g, 5.20 mmol, 1 
eq.), silver nitrate (0.044 g, 0.260 mmol, 0.05 eq.) and N-iodosuccinimide (1.29 g, 5.72 
mmol, 1.1 eq.) in DMF (20 mL) (5 h) as described in general procedure C gave, after 
work-up and chromatography (silica gel, 10% EtOAc/petrol), the title compound as a 
yellow solid (0.820 g, 70%); Mp 80-82 °C; 1H NMR (400 MHz, CDCl3) δ 7.81 (dd, J = 8.0, 
3.0 Hz, 1H), 7.67 (dd, J = 9.0, 5.0 Hz, 1H), 7.35 (ddd, J = 9.0, 7.0, 3.0 Hz, 1H). 13C NMR 
(101 MHz, CDCl3) δ 161.5 (d, JCF = 250 Hz, –), 151.1 (–), 137.5 (d, JCF = 8 Hz, +), 120.6 
(d, JCF = 22 Hz, +), 114.9 (d, JCF = 4 Hz, –), 112.5 (d, JCF = 27 Hz, +), 88.0 (–), 16.9 (–). 
IR (FTIR, cm-1) 3096, 2164, 1580, 1530, 1490, 1345, 1270, 1200, 1129, 882, 837, 789. 
HRMS calcd mass for C8H3NO2F127I (M+H+) 290.9192, found 290.9199. 
 
 
Synthesis of 5-Chloro-1-(iodoethynyl)-2-nitrobenzene (205) 
 
Reaction of ((5-chloro-2-nitrophenyl)ethynyl) trimethylsilane 191 (2.00 g, 7.90 mmol, 1 
eq.), silver nitrate (0.067 g, 0.400 mmol, 0.05 eq.) and N-iodosuccinimide (1.95 g, 8.70 
mmol, 1.1 eq.) in DMF (50 mL) (5 h) as described in general procedure C gave, after 
work-up and chromatography (silica gel, 10% EtOAc/petrol), the title compound as an 
off-white solid (1.55 g, 64%). Mp 71-72 °C; 1H NMR (400 MHz, CDCl3) δ 7.52 – 7.49 (m, 
1H), 7.48 (d, J = 8.0 Hz, 1H), 7.42 (d, J = 8.0 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 




cm-1) 3236, 2924, 2856, 1616, 1539, 1469, 1437, 1264, 1136, 767, 742; HRMS calcd for 
C8H3NO235Cl127I (MH+) 306.8897, found 306.8907. 
 
Synthesis of 4-(Iodoethynyl)-3-nitrobenzonitrile (206) 
 
Reaction of 3-nitro-4-((trimethylsilyl)ethynyl)benzonitrile 194 (0.550 g, 2.25 mmol, 1 eq.), 
silver nitrate (0.019 g, 0.110 mmol, 0.05 eq.) and N-iodosuccinimide (0.558 g, 2.48 mmol, 
1.1 eq.) in DMF (10 mL) (5 h) as described in general procedure C gave, after work-up 
and chromatography (silica gel, 10% EtOAc/petrol), the title compound as a yellow solid 
(0.555 g, 83%); Mp 101-102 °C; 1H NMR (400 MHz, CDCl3) δ 8.38 (d, J = 2.0 Hz, 1H), 
7.86 (dd, J = 8.0, 2.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H).13C NMR (101 MHz, CDCl3) δ 
136.9 (+), 135.5 (+), 128.4 (+), 122.9 (–), 116.2 (–), 112.8 (–), 88.1 (–), 77.1 (–), 24.6 (–
). IR (FTIR, cm-1) 3091, 2925, 2854, 2275, 2237, 1614, 1430, 1351, 1200, 764; HRMS 
calcd for C9H3N2O2127I (MH+) 297.9239, found 297.9249. 
 
Synthesis of 1-(Iodoethynyl)-2-nitro-4-(trifluoromethyl)benzene (207) 
 
Reaction of trimethyl((2-nitro-4-(trifluoromethyl)phenyl) ethynyl)silane 195 (1.10 g, 3.83 
mmol, 1 eq.), silver nitrate (0.033 g, 0.190 mmol, 0.05 eq.) and N-iodosuccinimide (0.948 
g, 4.21 mmol, 1.1 eq.) in DMF (20 mL) (5 h) as described in general procedure C gave, 
after work-up and chromatography (silica gel, 10% EtOAc/petrol), the title compound as 
a brown solid (0.916 g, 70%). Mp 97-99 °C; 1H NMR (250 MHz, CDCl3) δ 8.34 (d, J = 0.5 
Hz, 1H), 7.88 – 7.84 (m, 1H), 7.81 (d, J = 8.0 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 
150.3 (–), 136.8 (+), 133.2 (q, JCF = 35.5 Hz, –), 129.3 (q, JCF = 3.0 Hz, +), 123.1 (–), 




1) 3096, 2928, 2853, 2168, 1634, 1538, 1440, 1319, 1174, 1132, 756; HRMS calcd for 
C9H3NO2F3127I (MH+) 340.9161, found 340.9177. 
 
Synthesis of N-[4-(iodoethynyl)-3-nitrophenyl]acetamide (215) 
 
Reaction of 3-nitro-4-((trimethylsilyl)ethynyl)acetanilide (2.20 g, 8.73 mmol, 1 eq.), silver 
nitrate (0.074 g, 0.440 mmol, 0.05 eq.) and N-iodosuccinimide (2.16 g, 9.60 mmol, 1.1 
eq.) in DMF (50 mL) (5 h) as described in general procedure C gave, after work-up and 
chromatography (silica gel, 20% EtOAc/petrol), the title compound as a yellow solid (2.88 
g, 78%). Mp decomp. 180 °C; 1H NMR (250 MHz, DMSO) δ 10.54 (s, 1H), 8.43 (d, J = 
2.0 Hz, 1H), 7.79 (dd, J = 8.5, 2.0 Hz, 1H), 7.67 (d, J = 8.5 Hz, 1H), 2.09 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 169.7 (–), 146.3 (–), 140.6 (–), 136.5 (+), 123.4 (+), 114.4 (+), 
111.8 (–), 88.1 (–), 25.8 (–), 24.6 (+); IR (FTIR, cm-1) 3411, 1678, 1592, 1534, 1371, 
1341, 1316, 1257; HRMS calcd for C10H6N2O3127I (MH+) 328.9423, found 328.9438. 
 
General Procedure D: Synthesis of 2-Iodo-3H-indol-3-one 1-oxide (209) 
 
1-(Iodoethynyl)-2-nitrobenzene 68 (0.273 g, 1.00 mmol, 1.0 eq.) and copper bromide 
dimethyl sulphide complex (0.051g, 0.250 mmol, 0.25 eq.) were dissolved in THF (20 
mL) and heated at reflux with stirring under a stream of N2 for 16 h. The solvent was 
removed under reduced pressure and the crude product was purified by flash column 
chromatography (silica gel, 20% EtOAc/petrol) to give the title compound as an orange 
film (0.243 g, 89%). 1H NMR (250 MHz, d6-DMSO) δ 7.79 – 7.69 (m, 1H), 7.69 – 7.55 




(–), 122.5 (+), 114.1 (+), 101.6 (–); IR (FTIR, cm-1) 3024, 1710, 1599, 1491, 1447,1283, 
1191, 1127, 760, 689, 652; HRMS calcd for C8H4NO2127I (MH+) 272.9287, found 
272.9289. 
 
Synthesis of 2-Iodo-6-methyl-3-oxo-3H-indole 1-oxide (210) 
 
Reaction of 1-(iodoethynyl)-4-methyl-2-nitrobenzene 197 (0.287 g, 1.00 mmol, 1.0 eq.) 
with CuBr.DMS (0.051g, 0.250 mmol, 0.25 eq) in THF (10 mL) (2 h) as described in 
general procedure D gave, after work-up and chromatography (silica gel, 20% 
EtOAc/petrol), the title compound as an orange solid (0.260 g, 91%). Mp 208-210 °C. 1H 
NMR (250 MHz, CDCl3) δ 7.54 (d, J = 8.0 Hz, 1H), 7.50 (s, 1H), 7.34 (d, J = 8.0 Hz, 1H), 
2.54 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 182.9, 149.3, 146.7, 131.3, 122.3, 121.5, 
114.9, 97.3, 22.3; IR (FTIR, cm-1) 3067, 2921, 2848, 718, 1596, 1501, 1466, 1300, 691; 
HRMS calcd for C9H7NO2127I (MH+) 287.9522, found 287.9528. 
 
Synthesis of 2-Iodo-5-methoxy-3-oxo-3H-indole 1-oxide (184)71 
 
Reaction of 2-(iodoethynyl)-4-methoxy-1-nitrobenzene 183 (1.21 g, 4.00 mmol, 1.0 eq.) 
with CuBr.DMS (0.206 g, 1.00 mmol, 0.25 eq.) (0.5 h) in THF (50 mL) as described in 
general procedure  D gave, after work-up and chromatography (silica gel, 20% 
EtOAc/petrol), the title compound as a bright red solid (1.20 g, 99%). Mp 175-178 °C (lit: 
172-175 °C).71 1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 9.0 Hz, 1H), 7.18 (d, J = 2.0 Hz, 
1H), 7.03 (dd, J = 9.0, 2.0 Hz, 1H), 3.92 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 183.1 (–




Synthesis of 2-Iodo-6-methoxy-3-oxo-3H-indole 1-oxide (213) 
 
Reaction of 4-methoxy-2-nitro-1-(2-iodoethynyl)benzene 198 (0.080 g, 0.260 mmol, 1.0 
eq.) with CuBr.DMS (0.014 g, 0.070 mmol, 0.25 eq.) in THF (10 mL)  (1.5 h) as described 
in general procedure D gave, after work-up and chromatography (silica gel, 20% 
EtOAc/petrol), the title compound as a red solid (0.076 g, 95%). Mp 177-180 °C. 1H NMR 
(400 MHz, CDCl3) δ 7.58 (d, J = 8.0 Hz, 1H), 7.23 (d, J = 2.0 Hz, 1H), 6.93 (dd, J = 8.0, 
2.0 Hz, 1H), 3.97 (s, 3H).13C NMR (101 MHz, CDCl3) δ 182.0 (–), 165.4 (–), 151.4 (–), 
124.2 (+), 116.1 (+), 114.9 (–), 101.6 (+), 98.2 (–), 56.5 (+); IR (FTIR, cm-1) 2922, 2852, 
1716, 1645, 1624, 1509, 1469, 1294, 1247; HRMS calcd for C9H7NO3127I (MH+) 
303.9471, found 303.9479. 
 
Synthesis of 2-Iodo-4-methoxy-3-oxo-3H-indole 1-oxide (214) 
 
Reaction of 2-(iodoethynyl)-1-methoxy-3-nitrobenzene 199 (0.100 g, 0.330 mmol, 1.0 
eq.) with CuBr.DMS (0.017 g, 0.080 mmol, 0.25 eq.) in THF (10 mL) (2 h) as described 
in general procedure D gave, after work-up and chromatography (silica gel, 20% 
EtOAc/petrol), the title compound as an orange solid (0.064 g, 64%). Mp 190-192 °C. 1H 
NMR (400 MHz, CDCl3) δ 7.66 – 7.58 (m, 1H), 7.31 (dd, J = 8.0, 3.0 Hz, 1H), 7.08 (d, J 
= 8.0 Hz, 1H), 4.07 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 180.9 (–), 155.5 (–), 150.1 (–
), 136.6 (+), 116.2 (+), 109.9 (–), 106.9 (+), 97.6 (–), 56.9 (+); IR (FTIR, cm-1) 3082, 2934, 
2844, 1712, 1591, 1499, 1474, 1435, 1292, 1171, 1043, 795, 690; HRMS calcd for 





Synthesis of N-(2-iodo-1-oxido-3-oxo-3H-indol-6-yl)acetamide (216) 
 
Rreaction of N-[4-(iodoethynyl)-3-nitrophenyl]acetamide 215 (1.12 g, 3.40 mmol, 1.0 eq.) 
with CuBr.DMS (0.175 g, 0.85 mmol, 0.25 eq.) in THF (50 mL)  (1 h) as described in 
general procedure D gave, after work-up and chromatography (silica gel, 20% 
EtOAc/petrol), the title compound as a brown solid (0.851 g, 75%). Mp 240 °C (dec.). 1H 
NMR (400 MHz, DMSO) δ 7.66 – 7.58 (m, 1H), 7.31 (dd, J = 8.0, 3.0 Hz, 1H), 7.08 (d, J 
= 8.0 Hz, 1H), 4.07 (s, 3H). 13C NMR (101 MHz, d6-DMSO) δ 183.4 (+), 169.9 (+), 150.4 
(+), 145.6 (+), 123.8 (+), 119.2 (+), 118.0 (–), 104.7 (+), 102.4 (–), 24.7 (+);  IR (FTIR, 
cm-1) 3355, 3071, 1716, 1680, 1594, 1540, 1504, 1469, 1343, 1300; HRMS calcd for 
C10H8N2O3127I (MH+) 330.9580, found 330.9570. 
 
General Procedure E: Synthesis of 2-Iodo-6-bromo-3-oxo-3H-indole 1-oxide (219) 
 
4-Bromo-1-(iodoethynyl)-2-nitrobenzene 202 (0.250 g, 0.710 mmol, 1.0 eq.) and 
tetrakis(acetonitrile) copper (I) tetrafluroborate (0.224 g, 0.710 mmol, 1.0 eq.) were 
dissolved in THF (10 mL) and heated at reflux with stirring under a stream of N2 for 0.5 
h. The solvent was removed under reduced pressure and the crude product was purified 
by flash column chromatography (silica gel, 10% EtOAc/petrol) to give the title compound 
as a red film (0.161 g, 64%). 1H NMR (400 MHz, CDCl3) δ 7.82 (d, J = 1.5 Hz, 1H), 7.71 
(dd, J = 8.0, 1.5 Hz, 1H), 7.52 (d, J = 8.0 Hz, 1H).; 13C NMR (101 MHz, CDCl3) δ; 182.1 
(–), 149.2 (–), 134.3 (+), 129.2 (–), 123.3 (+), 122.7 (–), 117.9 (+), 97.8 (–). IR (FTIR, cm-






Synthesis of 2-Iodo-6-chloro-3-oxo-3H-indole 1-oxide (221) 
 
Reaction of 4-chloro-1-(iodoethynyl)-2-nitrobenzene 203 (0.100 g, 0.330 mmol, 1.0 eq.) 
with Cu(MeCN)4BF4 (0.102 g, 0.330 mmol, 1.0 eq.) as described in general procedure E 
gave, after work-up and chromatography (silica gel, 10% EtOAc/petrol), the title 
compound as an orange film (0.059 g, 59%). 1H NMR (400 MHz, CDCl3) δ 7.68 (d, J = 
1.5 Hz, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.53 (dd, J = 8.0, 1.5 Hz, 1H); 13C NMR (101 MHz, 
CDCl3) δ 181.9 (–), 149.5 (–), 141.2 (–), 131.2 (+), 123.2 (+), 122.2 (–), 115.2 (+), 97.9 
(–). IR (FTIR, cm-1) 3410, 1741, 1718, 1613, 1499, 1330, 1297, 1147, 893, 811; HRMS 
calcd for C8H335ClNO2127I (MH+) 306.8892, found 306.8888. 
 
Synthesis of 2-Iodo-6-fluoro-3-oxo-3H-indole 1-oxide (222) 
 
Reaction of 4-fluoro-1-(iodoethynyl)-2-nitrobenzene 204 (0.100 g, 0.340 mmol, 1.0 eq.) 
with Cu(MeCN)4BF4 (0.108 g, 0.340 mmol, 1.0 eq.) in THF (10 mL) (0.5 h) as described 
in general procedure E gave, after work-up and chromatography (silica gel, 10% 
EtOAc/petrol), the title compound as a red-orange film (0.053 g, 53%). 1H NMR (400 
MHz, CDCl3) δ 7.67 (dd, J = 8.0, 5.0 Hz, 1H), 7.42 (dd, J = 7.0, 2.0 Hz, 1H), 7.22 (td, J 
= 8.0, 2.0 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 181.6 (–), 166.3 (d, JCF = 258 Hz, –), 
150.8 (d, JCF = 12 Hz, –), 124.3 (d, JCF = 10 Hz, +), 120.0 (–), 117.5 (d, JCF = 23 Hz, +), 
103.9 (d, JCF = 28 Hz, +), 98.0 (–). IR (FTIR, cm-1) 3082, 1714, 1608, 1495, 1464, 1302, 






Synthesis of 7-Chloro-2-iodo-3H-indol-3-one 1-oxide (223) 
 
Reaction of 1-chloro-3-(iodoethynyl)-2-nitrobenzene 205 (0.308 g, 1.00 mmol, 1.0 eq.) 
with Cu(MeCN)4BF4 (0.315 g, 1.00 mmol, 1.0 eq.) in THF (10 mL) (0.5 h) as described 
in general procedure E gave, after work-up and chromatography (silica gel, 10% 
EtOAc/petrol), the title compound as a dark red film (0.169 g, 54%). 1H NMR (400 MHz, 
CDCl3) δ 7.61 (dd, J = 7.5, 1.5 Hz, 1H), 7.58 (dd, 7.5, 1.5 Hz, 1H), 7.49 (t, J = 7.5 Hz, 
1H); 13C NMR (101 MHz, CDCl3) δ 182.5 (–), 137.7 (+), 132.2 (+), 126.7 (–), 122.3 (–), 
121.0 (+), 119.8 (–), 98.2 (–). IR (FTIR, cm-1) 3255, 2923, 2853, 1742, 1615, 1469, 1176, 
1138, 1031, 750; HRMS calcd for C8H3NO2Cl127I (MH+) 306.8897, found 306.8896. 
 
Synthesis of 2-Iodo-6-cyano-3-oxo-3H-indole 1-oxide (224) 
 
Reaction of 4-(iodoethynyl)-3-nitrobenzonitrile 206 (0.200 g, 0.670 mmol, 1.0 eq.) with 
Cu(MeCN)4BF4 (0.211 g, 0.670 mmol, 1.0 eq.) in THF (10 mL) (0.5 h) as described in 
general procedure E gave, after work-up and chromatography (silica gel, 10% 
EtOAc/petrol), the title compound as an orange film (0.135 g, 68%). 1H NMR (400 MHz, 
DMSO) δ 8.19 (s, 1H), 8.13 (d, J = 7.5 Hz, 1H), 7.83 (d, J = 7.5 Hz, 1H); 13C NMR (101 
MHz, DMSO) δ 183.6 (–), 148.8 (–), 137.0 (+), 128.1 (–), 122.8 (+), 117.3 (–), 116.6 (+), 
115.2 (–), 103.7 (–); IR (FTIR, cm-1) 3082, 2923, 2852, 2239, 1704, 1626, 1496, 1461, 







Synthesis of 2-Iodo-6-trifluoromethyl-3-oxo-3H-indole 1-oxide (218) 
 
Reaction of 1-(iodoethynyl)-2-nitro-4-(trifluoromethyl)benzene 207 (0.100 g, 0.290 mmol, 
1.0 eq.) with Cu(MeCN)4BF4 (0.092 g, 0.290 mmol, 1.0 eq.) in THF (10 mL) (0.5 h) as 
described in general procedure E gave, after work-up and chromatography (silica gel, 
10% EtOAc/petrol), the title compound as a yellow-orange film (0.036 g, 36%). 1H NMR 
(400 MHz, CDCl3) δ 7.95 (d, J = 1.0 Hz, 1H), 7.88 (dd, J = 8.0, 1.0 Hz, 1H), 7.81 (d, J = 
8.0 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 182.0 (–), 148.9 (–), 136.5 (q, JCF = 34.0 Hz), 
128.7 (q, JCF = 4.0 Hz, +), 126.7 (–), 122.6 (+), 122.5 (q, JCF = 286.0 Hz, –), 111.5 (q, JCF 
= 3.0 Hz, +), 97.9 (–); IR (FTIR, cm-1) 3096, 2923, 2852, 1721, 1513, 1472, 1317, 1176, 
1132, 1089, 1042, 898, 686; HRMS calcd for C9H3NO2F3127I (MH+) 340.9161, found 
340.9159. 
 
Synthesis of 5-methoxy-1H-indole-2,3-dione (212)71 
 
2-Iodo-5-methoxy-3-oxo-3H-indole 1-oxide 184 (0.100 g, 0.33 mmol, 1.0 eq.) and 
PdCl2(PPh3)2 (0.012 g, 0.02 mmol, 0.05 eq.) were dissolved in acetone (10 mL). The 
reaction mixture was heated at reflux with stirring under a stream of N2 for 16 h. After 
cooling down to rt, the solvent was removed in vacuo. The crude product was purified by 
flash column chromatography (silica gel, 20% EtOAc/petrol) to afford the title compound 
as a dark red solid (0.049 g, 85%). M.p. 200 °C (decomp.) (lit: 200-201 °C).71 1H NMR 
(400 MHz, DMSO) δ 10.84 (br, s, 1H), 7.18 – 7.06 (m, 2H), 6.84 (d, J = 8.5 Hz, 1H), 3.73 
(s, 3H). 13C NMR (101 MHz, DMSO) δ 184.0 (-), 159.5 (-), 155.4 (-), 144.5 (-), 124.8 (+), 




General Procedure F: Synthesis of 5-methoxy-1H-indole-2,3-dione (212) 71 
 
2-Iodo-5-methoxy-3-oxo-3H-indole 1-oxide 184 (0.151 g, 0.50 mmol, 1.0 eq.) and InCl3 
(0.221 g, 1.0 mmol, 2.0 eq.) were dissolved in MeCN/H2O (9:1, 10 mL). The reaction 
mixture was heated at reflux with stirring under a stream of N2 for 18 h. Aqueous 
saturated NH4Cl solution (20 mL) was added and the product extracted with ethyl acetate 
(3 x 20 mL). The combined organic layers were washed with brine (20 mL) and dried 
with MgSO4. The crude product was purified by flash column chromatography (silica gel, 
20% EtOAc/petrol) to give the title compound as a dark red solid (0.065 g, 73%). See 
above for data. 
 
Synthesis of 6-methoxy-1H-indole-2,3-dione (227) 71 
 
Reaction of 2-iodo-6-methoxy-3-oxo-3H-indole 1-oxide 213 (0.151 g, 0.50 mmol, 1.0 eq.) 
and InCl3 (0.221 g, 1.0 mmol, 2.0 eq.) in MeCN/H2O (9:1, 10 mL) as described in general  
procedure F gave, after work-up and chromatography (silica gel, EtOAc), the title 
compound as a yellow-orange solid (0.060 g, 68%). M.p. 200 °C, decomp. (lit: 229-230 
°C).71 1H NMR (400 MHz, DMSO) δ 10.98 (s, 1H), 7.48 (d, J = 8.5 Hz, 1H), 6.58 (dd, J = 
8.5, 2.0 Hz, 1H), 6.39 (d, J = 2.0 Hz, 1H), 3.87 (s, 3H). 13C NMR (101 MHz, DMSO) δ 
182.0 (-), 168.2 (-), 161.1 (-), 154.0 (-), 127.8 (+), 111.6 (-), 109.3 (+), 98.2 (+), 56.6 (+). 
 





Reaction of N-(2-iodo-1-oxido-3-oxo-3H-indol-6-yl)acetamide 216 (0.165 g, 0.50 mmol, 
1.0 eq.) and InCl3 (0.221 g, 1.0 mmol, 2.0 eq.) in MeCN/H2O (9:1, 10 mL) as described 
in general  procedure F gave, after work-up and chromatography (silica gel, EtOAc), the 
title compound as a brown solid (0.078 g, 76%). M.p. 200 °C, decomp. (lit: 200 °C, 
decomp.).181 1H NMR (400 MHz, DMSO) δ 10.98 (s, 1H), 10.52 (s, 1H), 7.50 (d, J = 2.0 
Hz, 1H), 7.47 (d, J = 8.5 Hz, 1H), 7.06 (dd, J = 8.5, 2.0 Hz, 1H), 2.11 (s, 3H). 13C NMR 
(101 MHz, DMSO) δ 182.4 (-), 170.1 (-), 160.8 (-), 153.1 (-), 148.8 (-), 126.8 (+), 112.9 
(-), 112.8 (+), 102.0 (+), 24.8 (+). 
 
General Procedure G: Synthesis of 5-Methoxy-2-(trimethylsilylethynyl)-3H-indol-3-
one 1-oxide (230) 
 
2-Iodo-5-methoxy-3-oxo-3H-indole 1-oxide 184 (0.151 g, 0.500 mmol, 1.0 eq.), 
PdCl2(PPh3)2 (0.018 g, 0.025 mmol, 0.05 eq.) and CuI (0.005 g, 0.025 mmol, 0.05 eq.), 
were dissolved in THF (10 mL). Trimethylsilylacetylene (0.214 mL,1.50 mmol, 3.0 eq.) 
and diisopropylamine (0.211 mL, 1.50 mmol, 3.0 eq.) were added and the reaction 
mixture was stirred at rt under a stream of N2 for 0.5 h. Aqueous saturated NaHCO3 
solution (20 mL) was added and the product extracted with ethyl acetate (3 x 30 mL). 
The combined organic layers were washed with brine (20 mL) and dried with MgSO4. 
The crude product was purified by flash column chromatography (silica gel, 20% 
EtOAc/petrol) to give the title compound as a dark red film (0.085 g, 68%). 1H NMR (400 
MHz, CDCl3) δ 7.54 (d, J = 8.5 Hz, 1H), 7.13 (d, J = 2.5 Hz, 1H), 7.08 (dd, J = 8.5, 2.5 
Hz, 1H), 3.91 (s, 3H), 0.33 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 183.5 (–), 163.3 (–), 
140.0 (–), 124.4 (–), 122.8 (–), 118.4 (+), 117.8 (–), 115.6 (+), 108.3 (+), 89.2 (–), 56.2 
(+), -0.45 (+). IR (FTIR, cm-1) 3339, 2956, 2900, 2836, 2252, 2158, 1698, 1621, 1598, 





Synthesis of 5-Methoxy-2-(phenylethynyl)-3H-indol-3-one 1-oxide (231) 
 
Reaction of 2-Iodo-5-methoxy-3-oxo-3H-indole 1-oxide 184 (0.151 g, 0.500 mmol, 1.0 
eq.), PdCl2(PPh3)2 (0.018 g, 0.025 mmol, 0.05 eq.), CuI (0.005 g, 0.025 mmol, 0.05 eq.) 
phenylacetylene (0.165 mL,1.50 mmol, 3.0 eq.) and diisopropylamine (0.211 mL, 1.50 
mmol, 3.0 eq.) in THF (10 mL) (0.5 h) as described in general procedure G gave, after 
work-up and chromatography (silica gel, 20% EtOAc/petrol), the title compound as a dark 
purple film (0.070 g, 51%). 1H NMR (400 MHz, CDCl3) δ 7.65 (dd, J = 8.5, 2.5 Hz, 2H), 
7.56 (d, J = 8.5 Hz, 1H), 7.48 – 7.35 (m, 3H), 7.15 (d, J = 2.5 Hz, 1H), 7.08 (dd, J = 8.5, 
2.5 Hz, 1H), 3.91 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 183.6 (–), 163.1 (–), 140.3 (–), 
132.1 (+), 130.0 (+), 128.5 (+), 124.6 (–), 123.2 (–), 121.4 (–), 118.4 (+), 115.6 (+), 109.3 
(–), 108.5 (+), 75.7 (–), 56.3 (+). IR (FTIR, cm-1) 3066, 2959, 2836, 2182, 1708, 1611, 
1482, 1434, 1404, 1277, 1226, 1020, 907, 750, 727; HRMS calcd for C17H12NO3 (MH+) 
278.0817, found 278.0830. 
 
Synthesis of 2-(Hex-1-yn-1-yl)-5-methoxy-3H-indol-3-one 1-oxide (232) 
 
Reaction of 2-iodo-5-methoxy-3-oxo-3H-indole 1-oxide 184 (0.151 g, 0.500 mmol, 1.0 
eq.), PdCl2(PPh3)2 (0.018 g, 0.025 mmol, 0.05 eq.), CuI (0.005 g, 0.025 mmol, 0.05 eq.), 
1-hexyne (0.172 mL,1.50 mmol, 3.0 eq.) and diisopropylamine (0.211 mL, 1.50 mmol, 
3.0 eq.) in THF (10 mL) (6 h) as described in general procedure G gave, after work-up 
and chromatography (silica gel, 20% EtOAc/petrol), the title compound as a dark purple 
film (0.063 g, 49%). 1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 8.5 Hz, 1H), 7.10 (d, J = 




1.61 (m, 2H), 1.54 – 1.43 (m, 2H), 0.94 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) 
δ 184.0 (–), 162.9 (–), 140.1 (–), 124.4 (–), 123.4 (–), 118.2 (+), 115.4 (+), 112.6 (–), 
108.4 (+), 67.2 (–), 56.2 (+), 30.1 (–), 22.0 (–), 20.3 (–), 13.6 (+). IR (FTIR, cm-1) 2958, 
2935, 2872, 2217, 1714, 1513, 1488, 1406, 1282, 1087, 1019, 783, 767; HRMS calcd 





2-Iodo-5-methoxy-3-oxo-3H-indole 1-oxide 184 (0.151 g, 0.500 mmol, 1.0 eq.), and CuI 
(0.005 g, 0.025 mmol, 0.05 eq.), were dissolved in THF (10 mL). Trimethylsilylacetylene 
(0.214 mL, 1.50 mmol, 3.0 eq.) and diisopropylamine (0.211 mL, 1.50 mmol, 3.0 eq.) 
were added and the reaction mixture was stirred at rt under a stream of N2 for 28 h. 
Aqueous saturated NaHCO3 solution (20 mL) was added and the product extracted with 
ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine (20 mL) 
and dried with MgSO4. The crude product was purified by flash column chromatography 
(silica gel, 10% EtOAc/petrol) to give the title compound as a dark red film (0.034 g, 
18%). 1H NMR (400 MHz, CDCl3) δ 7.14 – 7.10 (m, 2H), 6.82 (dd, J = 8.0, 1.0 Hz, 1H), 
6.18 (s, 1H), 4.09 – 4.01 (m, 1H), 3.80 (s, 3H), 3.54 – 3.46 (m, 1H), 1.72 (s, 1H), 1.61 (d, 
J = 7.0 Hz, 3H), 1.50 (d, J = 7.0 Hz, 3H), 1.21 (d, J = 7.0 Hz, 3H), 1.16 (d, J = 7.0 Hz, 
3H), 0.33 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 186.9 (-), 170.6 (-), 154.3 (-), 148.2 (-), 
141.9 (-), 127.6 (-), 126.0 (+), 122.1 (-), 113.2 (+), 105.9 (+), 55.8 (+), 50.7 (+), 45.9 (+), 
21.9 (+), 21.4 (+), 20.3 (+), 20.2 (+), -1.2 (+). IR (FTIR, cm-1) 3424, 3055, 2987, 2306, 









Sodium hydride (0.038 g, 1.58 mmol, 4.8 eq.) and allyl alcohol (0.068 mL, 0.99 mmol, 
3.0 eq.) were combined in THF (2 mL) and the reaction mixture was stirred at rt for 10 
min. 2-Iodo-5-methoxy-3-oxo-3H-indole 1-oxide 184 (0.100 g, 0.33 mmol, 1.0 eq.) in THF 
(3 mL) was added and the reaction mixture was stirred at rt under a stream of N2 for 5 
min. Aqueous saturated NH4Cl solution (10 mL) was added and the product extracted 
with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine (20 
mL) and dried with MgSO4 before filtering and removing the solvent in vacuo. The crude 
product was purified by flash column chromatography (silica gel, 50% EtOAc/petrol) to 
give the title compound as a yellow oil (0.027 g, 28%). 1H NMR (400 MHz, CDCl3) δ 7.39 
(d, J = 8.5 Hz, 1H), 7.27 (dd, J = 8.5, 2.5 Hz 1H), 7.22 (d, J = 2.5 Hz, 1H), 5.94 (ddt, J = 
17.0, 10.0, 5.5 Hz, 2H), 5.56 (s, 1H), 5.34 (dq, J = 17.0, 1.5 Hz, 2H), 5.26 (ddd, J = 10.0, 
2.5, 1.5 Hz, 2H), 4.31 (ddd, J = 5.5, 2.5, 1.5 Hz, 4H), 3.86 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 173.9 (-), 155.9 (-), 148.8 (-), 133.8 (-), 127.0 (-), 115.1 (+), 112.0 (+), 111.4 
(+), 105.4 (+), 97.8 (-), 59.0 (-), 55.9 (+). IR (FTIR, cm-1) 2999, 2963, 1691, 1639, 1597, 
1477, 1460, 1339, 1241, 1107, 838. HRMS calcd for C15H17NO5 (MH+) 291.1107, found 
291.1097. 
 





2-Iodo-5-methoxy-3-oxo-3H-indole 1-oxide 184 (0.151 g, 0.50 mmol, 1.0 eq.), indole 
(0.064 g, 0.55 mmol, 1.1 eq.) and In(OTf)3 (0.056 g, 0.10 mmol, 0.20 eq.) were combined 
in MeCN (5 mL) and then stirred at rt under a stream of N2 for 4 h. The solvent was 
removed in vacuo and the residue was purified by flash column chromatography (silica 
gel, EtOAc) to afford the title product as dark purple amorphous solid (0.185 g, 52%). 1H 
NMR (400 MHz, CDCl3) δ 8.73 (br s, 1H), 8.60 – 8.55 (m, 1H), 8.49 (s, 1H), 7.47 – 7.44 
(m, 1H), 7.41 – 7.30 (m, 3H), 7.10 (d, J = 3.0 Hz, 1H), 6.99 (dd, J = 8.0, 3.0 Hz, 1H), 3.86 
(s, 3H). 13C NMR (101 MHz, CDCl3) δ 167.6 (-), 158.9 (-), 136.5 (-), 136.2 (-), 131.1 (+), 
126.0 (-), 124.0 (+), 123.9 (-), 123.2 (+), 122.4 (+), 121.8 (+), 121.2 (-), 120.7 (+), 111.5 
(+), 110.9 (+), 110.8 (-), 56.0 (+). IR (FTIR, cm-1) 3308, 2952, 2918, 2842, 1714, 1638, 
1542, 1447, 1420, 1343, 1297, 1018. HRMS calcd for C17H13N2O3 (MH+) 293.0926, found 
293.0915. 
  
Synthesis of 5-Methoxy-2-phenyl-3H-indol-3-one 1-oxide (229)124 
 
2-Iodo-5-methoxy-3-oxo-3H-indole 1-oxide 184 (0.151 g, 0.50 mmol, 1.0 eq.), Pd2(dba)3 
(0.011 g, 0.013 mmol, 0.025 eq.) and SPhos (0.010 g, 0.025 mmol, 0.05 eq.) were 
combined in THF (10 mL) and then stirred for 15 mins. PhZnCl (0.5 M in THF, 3 mL, 3.0 
eq.) was added and the reaction mixture was stirred at rt under a stream of N2 for 4 h. 
Aqueous saturated NH4Cl solution (20 mL) was added and the product extracted with 
ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine (20 mL) 
and dried with MgSO4 before filtering and removing the solvent in vacuo. The crude 
product was purified by flash column chromatography (silica gel, 10% EtOAc/petrol) to 
give the title compound as a dark red purple solid (0.057 g, 45%). Mp 134-136 °C (lit: 
135.3-135.7 °C).108 1H NMR (400 MHz, CDCl3) δ 8.67 – 8.56 (m, 2H), 7.62 (d, J = 8.5 




(s, 3H). 13C NMR (101 MHz, CDCl3) δ 186.7 (–), 162.5 (–), 140.7 (–), 131.8 (–), 130.4 
(+), 128.5 (+), 127.5 (+), 126.1 (–), 124.6 (–), 118.3 (+), 115.5 (+), 107.9 (+), 56.2 (+). 
 
General Procedure H: Synthesis of 5-Methoxy-2-phenyl-3H-indol-3-one 1-oxide 
(229) 108 
 
Zinc chloride (2.75 mL, 1M, 5.5 eq.) was added to a solution of phenylmagnesium 
bromide (0.83 mL, 3M, 5.0 eq.) in THF (10 mL) and then stirred at ambient temperature 
under a stream of N2 for 15 min. The mixture was added to a solution of 2-iodo-5-
methoxy-3-oxo-3H-indole 1-oxide 184 (0.151 g, 0.5 mmol, 1.0 eq.) in THF (10 mL) via 
cannula and then stirred at ambient temperature under a stream of N2 for 5 h. Aqueous 
saturated NH4Cl solution (20 mL) was added to the reaction mixture and the product 
extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine 
(20 mL) and dried with MgSO4. The solvent was removed under reduced pressure and 
the crude product was purified by flash column chromatography (silica gel, 20% 
EtOAc/petrol) to give the title compound as a dark red-purple solid (0.078 g, 62%). See 
above for data. 
 
Synthesis of 2-(4-Chlorophenyl)-5-methoxy-3H-indol-3-one 1-oxide (243)108 
 
Reaction of zinc chloride (2.75 mL, 1M, 5.5 eq.), 4-chlorophenylmagnesium bromide (2.5 
mL, 1M, 5.0 eq.) and 2-iodo-5-methoxy-3-oxo-3H-indole 1-oxide 184 (0.151 g, 0.5 mmol, 
1.0 eq.) in THF (20 mL) (4 h) as described in general procedure H gave, after work-up 




purple solid (0.093 g, 65%). Mp 192-193 °C (lit: 190.5-191.1 °C).108 1H NMR (400 MHz, 
CDCl3) δ 8.64 (d, J = 8.5, 2H), 7.61 (d, J = 8.5 Hz, 1H), 7.50 (d, J = 8.5, 2H), 7.18 (d, J 
= 2.5 Hz, 1H), 7.11 (dd, J = 8.5, 2.5 Hz, 1H), 3.93 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
186.5 (–), 162.6 (–), 154.4 (–), 140.7(–), 136.2 (–), 128.8 (+), 128.7 (+), 124.6 (–), 118.5 
(+), 115.6 (+), 108.0 (+), 56.3 (+). 
 
Synthesis of 5-Methoxy-2-(4-methoxyphenyl)-3H-indol-3-one 1-oxide (244)108 
 
Reaction of zinc chloride (2.75 mL, 1M, 5.5 eq.), 4-methoxyphenylmagnesium bromide 
(5.0 mL, 0.5M, 5.0 eq.) and 2-iodo-5-methoxy-3-oxo-3H-indole 1-oxide 184 (0.151 g, 0.5 
mmol, 1.0 eq.) in THF (20 mL) (6 h) as described in general procedure H gave, after 
work-up and chromatography (silica gel, 5% EtOAc/petrol), the title compound as a dark 
purple solid (0.094 g, 66%). Mp 196-198 °C (lit: 196-196.8 °C).108 1H NMR (400 MHz, 
CDCl3) δ 8.67 (d, J = 8.5 Hz, 2H), 7.56 (d, J = 8.5 Hz, 1H), 7.14 (d, J = 2.5 Hz, 1H), 7.07 
(dd, J = 8.5, 2.5 Hz, 1H), 7.04 – 6.98 (m, 2H), 3.91 (s, 3H), 3.89 (s, 3H).13C NMR (101 
MHz, CDCl3) δ 187.1 (–), 162.1 (–), 161.1 (–), 153.3 (–), 140.9 (–), 129.4 (+), 124.6 (–), 
119.0 (–), 118.3 (+), 115.1 (+), 114.0 (+), 107.9 (+), 56.19 (+), 55.34 (+). 
 
Synthesis of 5-Methoxy-2-[4-(trifluoromethyl)phenyl]-3H-indol-3-one 1-oxide 
(242)108 
 
Reaction of zinc chloride (2.75 mL, 1M, 5.5 eq.), 4-(trifluoromethyl)benzylmagnesium 
bromide (2.5 mL, 1M, 5.0 eq.) and 2-iodo-5-methoxy-3-oxo-3H-indole 1-oxide 184 (0.151 




after work-up and chromatography (silica gel, 5% EtOAc/petrol), the title compound as a 
dark red solid (0.093 g, 59%). Mp 195-196 °C (lit: 193-198 °C).108 1H NMR (400 MHz, 
CDCl3) δ 8.75 (d, J = 8.5 Hz, 2H), 7.72 (d, J = 8.5 Hz, 2H), 7.61 (d, J = 8.5 Hz, 1H), 7.17 
(d, J = 2.5 Hz, 1H), 7.11 (dd, J = 8.5, 2.5 Hz, 1H), 3.96 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 186.3 (–), 162.9 (–), 140.6 (–), 130.6 (–), 129.3 (–), 127.4 (+), 125.4 (–), 125.2 
(–), 124.6 (–), 122.5 (–), 118.6 (+), 115.8 (+), 108.0 (+), 56.3 (+). 
 
Synthesis of 6-Fluoro-2-phenyl-3H-indol-3-one 1-oxide (245) 
 
Reaction of zinc chloride (3.0 mL, 1M, 5.5 eq.), phenylmagnesium bromide (1.8 mL, 
1.5M, 5.0 eq.) and 2-iodo-6-fluoro-3-oxo-3H-indole 1-oxide 222 (0.160 g, 0.55 mmol, 1.0 
eq.) in THF (20 mL) (4 h) as described in general procedure H gave, after work-up and 
chromatography (silica gel, 5% EtOAc/petrol), the title compound as an orange film 
(0.053 g, 40%); 1H NMR (400 MHz, CDCl3) δ 8.69 (d, J = 7.5 Hz, 2H), 7.67 – 7.70 (m, 
1H), 7.51 – 7.56 (m, 3H), 7.47 (d, J = 6.5 Hz, 1H), 7.22 – 7.78 (m, 1H). 13C NMR (101 
MHz, CDCl3) δ 185.4 (–), 166.8 (d, JCF = 260 Hz, –), 150.2 (d, JCF = 11 Hz, –), 133.0 (–), 
131.2 (+), 128.7 (+), 128.0 (+), 125.6 (–), 123.8 (d, JCF = 10 Hz, +), 118.8 (–), 117.7 (d, 
JCF = 23 Hz, +), 104.0 (d, JCF = 28 Hz, +). IR (FTIR, cm-1) 1718, 1612, 1523, 1493, 1381, 
1227, 778; HRMS calcd for C14H8NO2F (MH+) 242.0612, found 242.0612. 
 
Synthesis of 6-Bromo-2-phenyl-3H-indol-3-one 1-oxide (246) 
 
Reaction of zinc chloride (2.0 mL, 1M, 5.5 eq.), phenylmagnesium bromide (1.2 mL, 




1.0 eq.) in THF (20 mL) (4 h) as described in general procedure H gave, after work-up 
and chromatography (silica gel, 5% EtOAc/petrol), the title compound as an orange film 
(0.051 g, 48%); 1H NMR (400 MHz, CDCl3) δ 8.68 – 8.64 (m, 2H), 7.89 (d, J = 1.5 Hz, 
1H), 7.74 (dd, J = 7.5, 1.5 Hz, 1H), 7.57 – 7.51 (m, 4H). 13C NMR (101 MHz, CDCl3)  δ 
185.8 (–), 161.8 (–), 148.5 (–), 134.2 (+), 131.1 (+), 129.2 (–), 128.6 (+), 127.9 (+), 125.6 
(–), 122.7 (+), 121.6 (–), 118.1 (+). IR (FTIR, cm-1) 1716, 1595, 1478, 1445, 1378, 1085, 
894, 778; HRMS calcd for C14H8NO279Br (MH+) 301.9811, found 301.9809. 
 
Synthesis of 7-Chloro-2-phenyl-3H-indol-3-one 1-oxide (247) 
 
Reaction of zinc chloride (3.1 mL, 1M, 5.5 eq.), phenylmagnesium bromide (1.8 mL, 1M, 
5.0 eq.) and 2-iodo-7-chloro-3-oxo-3H-indole 1-oxide 223 (0.170 g, 0.55 mmol, 1.0 eq.) 
in THF (20 mL) (4 h) as described in general procedure H gave, after work-up and 
chromatography (silica gel, 5% EtOAc/petrol), the title compound as a dark red oil (0.068 
g, 46%); 1H NMR (400 MHz, CDCl3) δ 7.70 – 7.23 (m, 6H), 6.99 – 6.90 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ 140.4, 138.1, 136.4, 132.0, 131.0, 128.7, 128.1, 127.8, 127.4, 123.8, 
120.4, 120.1. IR (FTIR, cm-1) 1710, 1613, 1487, 1447, 1127, 739, 699; HRMS calcd for 












General procedure I: Synthesis of methyl 2-(5-methoxy-1-oxido-3-oxo-3H-indol-2-
yl)-3-oxo-3-phenylpropanoate (256) 
 
Sodium hydride (0.076 g, 3.20 mmol, 3.2 eq.) was suspended in THF (5 mL) and then 
methyl benzoyl acetate (0.189 mL, 1.20 mmol, 1.2 eq.) was added. The mixture was 
heated at reflux for 10 mins after which a solution of 2-iodo-5-methoxy-3-oxo-3H-indole 
1-oxide 184 (0.303 g, 1.00 mmol, 1.0 eq.) in THF (15 mL) was added. The reaction 
mixture was stirred at reflux under a stream of N2 for 0.5 h. Aqueous saturated NH4Cl 
solution (20 mL) was added and the product extracted with ethyl acetate (3 x 30 mL). 
The combined organic layers were washed with brine (20 mL) and dried with MgSO4. 
The crude product was purified by flash column chromatography (silica gel, 20% 
EtOAc/petrol) to give the title compound (as an inseparable mixture of tautomers) as a 
dark red solid (0.303 g, 86%). Mp 125-126 °C. Data reported only for the major tautomer 
(enol form): 1H NMR (400 MHz, CDCl3) δ 13.70 (s, 1H), 7.50 – 7.45 (m, 3H), 7.38 (d, J = 
8.0 Hz, 1H), 7.34 – 7.27 (m, 2H), 7.04 (d, J = 8.0 Hz, 2H), 3.87 (s, 3H), 3.81 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 185.5 (–), 177.5 (–), 171.4 (–), 162.5 (–), 140.0 (–), 134.4 (–), 
132.9 (–), 131.4 (+), 128.6 (+), 127.0 (+), 124.9 (–), 117.7 (+), 115.5 (+), 108.1 (+), 87.7 
(–), 56.2 (+), 52.6 (+). IR (FTIR, cm-1) 2952, 2840, 1709, 1640, 1605, 1522, 1481, 1433, 
1353, 1279, 1140, 777; HRMS calcd for C19H16NO6 (MH+) 354.0978, found 354.0985. 
 






Reaction of sodium hydride (0.076 g, 3.20 mmol, 3.2 eq.), 3-(4-chlorophenyl)-3-oxo-
propionic acid methyl ester (0.255 g, 1.20 mmol, 1.2 eq.) and 2-iodo-5-methoxy-3-oxo-
3H-indole 1-oxide 184 (0.303 g, 1.00 mmol, 1.0 eq.) in THF (20 mL) (0.5 h) as described 
in general procedure I gave, after work-up and chromatography (silica gel, 20% 
EtOAc/petrol), the title compound (as an inseparable mixture of tautomers) as a dark red 
amorphous solid (0.339 g, 88%). Data reported only for the major tautomer (enol form): 
1H NMR (400 MHz, CDCl3) δ 13.69 (s, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.44 – 7.39 (m, 2H), 
7.31 – 7.26 (m, 2H), 7.06 (m, 2H), 3.89 (s, 3H), 3.81 (s, 3H). 13C NMR (101 MHz, CDCl3) 
δ 185.4 (–), 176.1 (–), 171.3 (–), 162.6 (–), 139.9 (–), 137.6 (–), 132.8 (–), 132.5 (–), 
128.9 (+), 128.4 (+), 124.8 (–), 117.9 (+), 115.6 (+), 108.2 (+), 88.0 (–), 56.2 (+), 52.7 (+). 
IR (FTIR, cm-1) 2917, 2849, 1707, 1605, 1521, 1484, 1280, 1229, 1089, 838; HRMS 
calcd for C19H15NO635Cl (MH+) 388.0588, found 388.0607. 
 
Synthesis of methyl 3-(4-methoxyphenyl)-2-(5-methoxy-1-oxido-3-oxo-3H-indol-2-
yl)-3-oxopropanoate (258) 
 
Reaction of sodium hydride (0.076 g, 3.20 mmol, 3.2 eq.), 3-(4-methoxyphenyl)-3-oxo-
propionic acid methyl ester (0.250 g, 1.20 mmol, 1.2 eq.) and 2-iodo-5-methoxy-3-oxo-
3H-indole 1-oxide 184 (0.303 g, 1.00 mmol, 1.0 eq.) in THF (20 mL) (0.5 h) as described 
in general procedure I gave, after work-up and chromatography (silica gel, 20% 
EtOAc/petrol), the title compound (as an inseparable mixture of tautomers) as a dark red 
amorphous solid (0.339 g, 87%). Data reported only for the major tautomer (enol form): 
1H NMR (400 MHz, CDCl3) δ 13.73 (s, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.47 – 7.42 (m, 2H), 
7.07 – 7.03 (m, 2H), 6.83 – 6.78 (m, 2H), 3.89 (s, 3H), 3.80 (s, 3H), 3.78 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 185.6 (-), 177.2 (-), 171.5 (-), 164.2 (-), 162.5 (-), 162.1 (-), 




(-), 56.2 (+), 55.3 (+), 52.44 (+). IR (FTIR, cm-1) 2952, 2843, 1744, 1710, 1683, 1560, 
1507, 1485, 1436, 1257, 1170, 1022, 838; HRMS calcd for C20H18NO7 (MH+) 384.1083, 
found 384.1075. 
 
Synthesis of methyl 2-(6-methyl-1-oxido-3-oxo-3H-indol-2-yl)-3-oxo-3-
phenylpropanoate (259) 
 
Reaction of sodium hydride (0.076 g, 3.20 mmol, 3.2 eq), methyl benzoylacetate (0.190 
mL, 1.20 mmol, 1.2 eq.) and 2-iodo-6-methyl-3-oxo-3H-indole 1-oxide 210 (0.287 g, 1.00 
mmol, 1.0 eq.) in THF (20 mL) (0.5 h) as described in general procedure I gave, after 
work-up and chromatography (silica gel, 20% EtOAc/petrol), the title compound (as an 
inseparable mixture of tautomers) as an orange solid (0.253 g, 75%). Mp 108-110 °C. 
Data reported only for the major tautomer (enol form): 1H NMR (400 MHz, CDCl3) δ 13.71 
(s, 1H), 7.48 – 7.46 (m, 2H), 7.42 (s, 1H), 7.39 – 7.37 (m, 2H), 7.32 – 7.26 (m, 3H), 3.80 
(s, 3H), 2.49 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 185.4 (–), 177.6 (–), 171.3 (–), 147.6 
(–), 146.4 (–), 134.4 (–), 133.7 (–), 131.5 (+), 131.4 (+), 128.6 (+), 127.0 (+), 121.7 (+), 
120.6 (–), 115.1 (+), 87.7 (–), 52.5 (+), 22.3 (+). IR (FTIR, cm-1) 3056, 2959, 2856, 1709, 
1595, 1528, 1447, 1352, 1266, 1142, 698; HRMS calcd for C19H16NO5 (MH+) 338.1028, 
found 338.1022. 
 






Methyl 2-(5-methoxy-1-oxido-3-oxo-3H-indol-2-yl)-3-oxo-3-phenylpropanoate 256 
(0.140 g, 0.400 mmol, 1.0 eq.) and lithium iodide (0.162 g, 1.20 mmol, 3 eq.) were 
dissolved in N,N-dimethylformamide (10 mL) and then heated at 180 °C with stirring 
under a stream of N2 for 18 h. The reaction mixture was poured onto ice-cold H2O (100 
mL) and the product was extracted with diethyl ether (3 x 30 mL). The combined organic 
layers were washed with brine (50 mL) and then dried with MgSO4 before removing the 
solvent under pressure. The crude product was purified by flash column chromatography 
(Florisil, 20% EtOAc/petrol) to give the title compound as a dark purple solid (0.062 g, 
56%). Mp 166-168 °C.  1H NMR (400 MHz, CDCl3) δ 9.99 (s, 1H), 8.09 – 8.05 (m, 2H), 
7.66 – 7.57 (m, 1H), 7.56 – 7.48 (m, 2H), 7.22 (d, J = 2.5 Hz, 1H), 7.13 (dd, J = 8.5, 2.5 
Hz, 1H), 6.93 (s, 1H), 6.91 (d, J = 8.5 Hz, 1H), 3.83 (s, 3H); 13C NMR (101 MHz, CDCl3) 
δ 192.4 (–), 188.7 (–), 155.5 (–), 147.7 (–), 145.3 (–), 138.4 (–), 132.9 (+), 128.7 (+), 
127.9 (+), 125.4 (+), 120.4 (–), 112.9 (+), 108.1 (+), 94.9 (+), 55.9 (+).; IR (FTIR, cm-1) 
3341, 2162, 2029, 1708, 1645, 1623, 1604, 1314, 1230, 1130, 825, 750, 698; HRMS 





Reaction of methyl 3-(4-chlorophenyl)-2-(5-methoxy-1-oxido-3-oxo-3H-indol-2-yl)-3-
oxopropanoate 257 (0.180 g, 0.47 mmol, 1.0 eq.) and lithium iodide (0.187 g, 1.40 mmol, 
3 eq.) in DMF (10 mL) as described in general procedure J gave, after work-up and 
chromatography (silica gel, 20% EtOAc/petrol), the title compound as a dark purple solid 
(0.069 g, 47%). Mp 205-206 °C. 1H NMR (400 MHz, CDCl3) δ 9.99 (s, 1H), 7.99 (d, J = 
9.0 Hz, 2H), 7.49 (d, J = 9.0 Hz, 2H), 7.20 (d, J = 2.5 Hz, 1H), 7.13 (dd, J = 9.0, 2.5 Hz, 
1H), 6.93 (d, J = 9.0 Hz, 1H), 6.85 (s, 1H), 3.83 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 




(+), 125.5 (+), 120.4 (–), 113.0 (+), 108.2 (+), 94.3 (+), 55.9 (+); IR (FTIR, cm-1) 2923, 
2852, 1702, 1647, 1592, 1497, 1466, 1318, 1130; HRMS calcd for C17H13NO335Cl (MH+) 





Reaction of methyl 2-(5-methoxy-1-oxido-3-oxo-3H-indol-2-yl)-3-(4-methoxyphenyl)-3-
oxopropanoate 258 (0.180 g, 0.47 mmol, 1.0 eq.) and lithium iodide (0.189 g, 1.41 mmol, 
3 eq.) in DMF (10 mL) as described in general procedure J gave, after work-up and 
chromatography (silica gel, 20% EtOAc/petrol), the title compound as a dark red oil 
(0.035 g, 24%). 1H NMR (400 MHz, CDCl3) δ 9.96 (s, 1H), 8.05 (d, J = 9.0 Hz, 2H), 7.20 
(d, J = 2.5 Hz, 1H), 7.11 (dd, J = 9.0, 2.5 Hz, 1H), 6.99 (d, J = 9.0 Hz, 1H), 6.90 (d, J = 
9.0 Hz, 2H), 6.88 (s, 1H), 3.91 (s, 3H), 3.82 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 190.9 
(-), 188.8 (-), 163.6 (-), 155.3 (-), 147.9 (-), 145.1 (-), 132.3 (+), 131.5 (-), 130.2 (+), 125.5 
(+), 120.4 (-), 113.9 (+), 113.7 (+), 112.9 (+), 108.0 (+), 95.1 (+), 55.9 (+), 55.5 (+) ; IR 
(FTIR) 2917, 2849, 1667, 1597, 1488, 1437, 1252, 1166, 1137, 1023; HRMS calcd for 
C18H16NO4 (M+H+) 310.1072, found 310.1079. 
 
Synthesis of 6-methyl-2-(2-oxo-2-phenylethylidene)-1,2-dihydro-3H-indol-3-one 
(262) 
 
Reaction of methyl 2-(6-methyl-1-oxido-3-oxo-3H-indol-2-yl)-3-oxo-3-phenylpropanoate 




(10 mL) as described in general procedure J gave, after work-up and chromatography 
(silica gel, 20% EtOAc/petrol), the title compound as a dark red solid (0.032 g, 40%). Mp 
164-166 °C. 1H NMR (400 MHz, CDCl3 δ 10.06 (s, 1H), 8.14 – 8.02 (m, 2H), 7.66 – 7.58 
(m, 2H), 7.55 – 7.45 (m, 2H), 6.94 (s, 1H), 6.84 (d, J = 8.0 Hz, 1H), 6.78 (s, 1H), 2.42 (s, 
3H); 13C NMR (101 MHz, CDCl3) δ 192.6 (–), 187.8 (–), 153.6 (–), 149.5 (–), 145.4 (–), 
138.4 (–), 133.0 (+), 128.7 (+), 128.0 (+), 125.5 (+), 123.4 (+), 117.9 (–), 112.5 (+), 94.9 
(+), 22.6 (+); IR (FTIR, cm-1) 3330, 2921, 2852, 1709, 1650, 1619, 1560, 1453, 1308, 
1289, 1234, 752, 690; HRMS calcd for C17H14NO2 (MH+) 264.1025, found 264.1030. 
 
General Procedure K: Synthesis of 5-Methoxy-2-(2-oxo-2-phenylethylidene)-1,2-
dihydro-3H-indol-3-one (251) 
 
Methyl 2-(5-methoxy-1-oxido-3-oxo-3H-indol-2-yl)-3-oxo-3-phenylpropanoate 256 
(0.140 g, 0.400 mmol, 1.0 eq.) and sodium iodide (0.180 g, 1.20 mmol, 3 eq.) were 
dissolved in N,N-dimethylformamide (10 mL) and then heated at 180 °C with stirring 
under a stream of N2 for 18 h. The reaction mixture was poured onto ice-cold H2O (100 
mL) and the product was extracted with diethyl ether (3 x 30 mL). The combined organic 
layers were washed with brine (50 mL) and then dried with MgSO4 before removing the 
solvent under pressure. The crude product was purified by flash column chromatography 
(Florisil, 20% EtOAc/petrol) to give the title compound as a dark purple solid (0.069 g, 











Reaction of methyl 3-(4-chlorophenyl)-2-(5-methoxy-1-oxido-3-oxo-3H-indol-2-yl)-3-
oxopropanoate 257 (0.135 g, 0.350 mmol, 1.0 eq.) and sodium iodide (0.157 g, 1.05 
mmol, 3.0 eq.) in DMF (5 mL) as described in general procedure K gave, after work-up 
and chromatography (Florisil, 20% EtOAc/petrol), the title compound as a dark purple 





Reaction of methyl 2-(5-methoxy-1-oxido-3-oxo-3H-indol-2-yl)-3-(4-methoxyphenyl)-3-
oxopropanoate 258 (0.130 g, 0.34 mmol, 1.0 eq.) and sodium iodide (0.153 g, 1.02 mmol, 
3 eq.) in DMF (5 mL) as described in general procedure K gave, after work-up and 
chromatography (silica gel, 20% EtOAc/petrol), the title compound as a dark red oil 
(0.044 g, 42%). See page 197 for data. 
 






Reaction of methyl 2-(6-methyl-1-oxido-3-oxo-3H-indol-2-yl)-3-oxo-3-phenylpropanoate 
259 (0.169 g, 0.500 mmol, 1.0 eq.) and sodium iodide (0.225 g, 1.50 mmol, 3.0 eq.) in 
DMF (5 mL) as described in general procedure K gave, after work-up and 
chromatography (Florisil, 20% EtOAc/petrol), the title compound as a red solid (0.078 g, 
59%). See page 198 for data. 
 
Synthesis of 3-(Oxiran-2-ylmethyl)quinazolin-4(3H)-one (267)182 
 
Quinazolin-4(3H)-one (1.461 g, 10 mmol) and potassium carbonate (4.15 g, 30.0 mmol) 
were suspended in acetone (50 mL) and then 2-(chloromethyl)oxirane (2.352 mL, 30.0 
mmol) was added. The reaction mixture was heated at reflux with stirring under a stream 
of nitrogen for 18 h. The reaction mixture was cooled down and filtered and the solid 
washed with DCM (3 x 15 mL). The combined extracts were evaporated in vacuo and 
the residue dissolved in DCM (50 mL), washed with water (2 x 25 mL) and then dried 
with sodium sulfate before filtering and removing the solvent in vacuo. The crude product 
was recrystallized with DCM/hexane to afford the title compound as a white solid (1.25 
g, 62%). M.p. 80-82 °C (lit: 82-84 °C).182 1H NMR (400 MHz, CDCl3) δ 8.34 (dd, J = 8.0, 
1.5 Hz, 1H), 8.06 (s, 1H), 7.83 – 7.73 (m, 2H), 7.54 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 4.59 
(dd, J = 14.5, 3.0 Hz, 1H), 3.88 (dd, J = 14.5, 6.0 Hz, 1H), 3.39 (ddt, J = 6.0, 3.0, 2.5 Hz, 
1H), 2.94 – 2.88 (m, 1H), 2.63 (dd, J = 4.5, 2.5 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 
161.1 (-), 148.2 (-), 146.5 (+), 134.5 (+), 127.7 (+), 127.4 (+), 126.7 (+), 121.9 (-), 49.7 
(+), 47.7 (-), 45.5 (-). IR (FTIR, cm-1) 3054, 2986, 1665, 1615, 1471, 1372, 954, 860, 772. 






General Procedure L: Synthesis of 3-(3-((Cyclopropylmethyl)amino)-2-
hydroxypropyl)quinazolin-4(3H)-one (272) 
 
3-(Oxiran-2-ylmethyl)quinazolin-4(3H)-one 267 (0.051 g, 0.25 mmol, 1.0 eq.) was 
suspended in water (1 mL) and then cyclopropylmethanamine (0.043 mL, 0.50 mmol, 
2.0 eq.) was added. The reaction mixture was stirred at 20 °C for 18 h. Water (20 mL) 
was added to the reaction mixture and the product extracted with EtOAc (3 x 20 mL). 
The organic phase was dried with MgSO4 before filtering and removing the solvent in 
vacuo. The residue was dissolved in DMSO:MeOH (1:1, 1 mL) and purified by Mass 
Directed Auto Preparative HPLC to afford the title compound as a colourless oil (0.036 
g, 53%). 1H NMR (400 MHz, CDCl3) δ 8.23 (d, J = 8.0 Hz, 1H), 8.17 (s, 1H), 7.77 – 7.70 
(m, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.50 – 7.43 (m, 1H), 4.30 (dd, J = 13.5, 2.5 Hz, 1H), 
4.13 – 3.99 (m, 1H), 3.81 (dd, J = 13.5, 7.0 Hz, 1H), 2.87 (dd, J = 12.0, 3.5 Hz, 1H), 2.61 
(dd, J = 12.0, 8.5 Hz, 1H), 2.54 – 2.40 (m, 2H), 0.88 – 0.86 (m, 1H), 0.43 (app q, J = 5.0 
Hz, 2H), 0.08 (app q, J = 5.0 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 161.7, 148.2, 147.6, 
134.3, 127.5, 127.1, 126.6, 121.9, 67.9, 54.6, 51.9, 50.1, 11.0, 3.4, 3.3. IR (FTIR, cm-1) 
3362, 2921, 2853, 1652, 1611, 1475, 1376, 1327, 1106, 773, 697. HRMS calcd for 
C15H19N3O2 (MH+) 274.1550, found 274.1546. 
 
Synthesis of 3-(3-((2-Fluoroethyl)amino)-2-hydroxypropyl)quinazolin-4(3H)-one 
(273) 
 
Reaction of oxiran-2-ylmethyl)quinazolin-4(3H)-one 267 (0.051 g, 0.25 mmol, 1.0 eq.), 
2-fluoroethanamine hydrochloride (100 mg, 1.0 mmol, 2.0 eq.) and triethylamine (0.139 




work-up and purification by Mass Directed Auto Preparative HPLC, the title compound 
as a white solid (0.042 g, 32%). 1H NMR (400 MHz, CDCl3) δ 8.22 – 8.18 (m, 1H), 8.15 
(s, 1H), 7.71 (ddd, J = 8.0, 5.0, 1.0 Hz, 2H), 7.65 – 7.60 (m, 1H), 7.45 (ddd, J = 8.0, 5.0, 
1.0 Hz, 1H), 4.52 (dt, J = 47.0, 4.5 Hz, 2H), 4.37 – 4.27 (m, 1H), 4.10 – 4.05 (m, 1H), 
3.84 (dd, J = 14.0, 7.0 Hz, 1H), 2.98 – 2.88 (m, 3H), 2.65 (dd, J = 12.0, 8.5 Hz, 1H). 13C 
NMR (101 MHz, CDCl3) δ 161.6, 147.9, 147.6, 134.3, 127.3, 127.2, 126.5, 121.7, 83.2 
(d, J = 166.7 Hz), 68.0, 52.1, 50.3, 49.4 (d, J = 19.2 Hz). IR (FTIR, cm-1) 3346, 2900, 
1729, 1612, 1662, 1475, 1375, 1324, 774, 698. HRMS calcd for C13H16N3O2F (MH+) 
266.1299, found 266.1298. 
 
Synthesis of 3-(2-Hydroxy-3-((2-hydroxy-2-methylpropyl)amino)propyl) 
quinazolin-4(3H)-one (274) 
 
Reaction of 3-(oxiran-2-ylmethyl)quinazolin-4(3H)-one 267 (0.051 g, 0.25 mmol, 1.0 eq.) 
and 1-amino-2-methylpropan-2-ol (0.048 mL, 0.50 mmol, 2.0 eq.) in water (0.5 mL) as 
described in general procedure L gave, after work-up and purification by Mass Directed 
Auto Preparative HPLC, the title compound as a colourless oil (0.033 g, 45%). 1H NMR 
(400 MHz, CDCl3) δ 8.27 (d, J = 7.5 Hz, 1H), 8.17 (s, 1H), 7.78 – 7.74 (m, 1H), 7.70 (d, 
J = 7.5 Hz, 1H), 7.51 – 7.47 (m, 1H), 4.32 (dd, J = 13.5, 3.0 Hz, 1H), 4.10 – 4.06 (m, 1H), 
3.88 (dd, J = 13.5, 7.0 Hz, 1H), 2.90 (dd, J = 12.0, 3.5 Hz, 1H), 2.66 (d, J = 12.0 Hz, 1H), 
2.63 (dd, J = 12.0, 8.5 Hz, 1H), 2.57 (d, J = 12.0 Hz, 1H), 1.22 (s, 6H). 13C NMR (101 
MHz, CDCl3) δ 161.7, 148.0, 147.5, 134.3, 127.4, 127.2, 126.6, 121.8, 70.1, 68.4, 60.3, 
53.1, 50.4, 27.5, 27.4. IR (FTIR, cm-1) 3343, 2922, 2853, 1660, 1612, 1475, 1377, 1324, 






Synthesis of 3-(2-Hydroxy-3-(((1-methylpyrrolidin-3-yl)methyl)amino)propyl) 
quinazolin-4(3H)-one (275) 
 
Reaction of 3-(oxiran-2-ylmethyl)quinazolin-4(3H)-one 267 (0.051 g, 0.25 mmol) and (1-
methylpyrrolidin-3-yl)methanamine (0.062 mL, 0.500 mmol) in water (0.5 mL) as 
described in general procedure L gave, after work-up and purification by Mass Directed 
Auto Preparative HPLC, the title compound as a colourless oil (0.020 g, 25%). 1H NMR 
(400 MHz, CDCl3) δ 8.32 – 8.28 (m, 1H), 8.19 (s, 1H), 7.77 (ddd, J = 8.5, 7.0, 1.5 Hz, 
1H), 7.73 (dd, J = 8.5, 1.5 Hz, 1H), 7.51 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 4.32 (dd, J = 
13.5, 2.5 Hz, 1H), 4.03 – 3.96 (m, 1H), 3.88 (ddd, J = 13.5, 7.0, 2.5 Hz, 1H), 2.87 (dd, J 
= 12.0, 8.5 Hz, 1H), 2.72 – 2.41 (m, 7H), 2.33 (s, 3H), 2.27 – 2.20 (m, 1H), 2.05 – 1.94 
(m, 1H), 1.52 – 1.42 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 161.7, 148.2, 147.6, 134.3, 
127.5, 127.1, 126.7, 121.9, 68.0, 67.8, 60.9, 56.0, 54.7, 52.3, 50.0, 42.2, 38.4, 29.5. IR 
(FTIR, cm-1) 3340, 2920, 1660, 1615, 1475, 1370, 1170, 1110, 770, 699. HRMS calcd 
for C17H25N4O2 (MH+) 317.1978, found 317.1978. 
 
Synthesis of 3-(3-((4-Ethoxyphenyl)amino)-2-hydroxypropyl)quinazolin-4(3H)-one 
(276) 
 
Reaction of 3-(oxiran-2-ylmethyl)quinazolin-4(3H)-one 267 (0.051 g, 0.25 mmol) and 4-
ethoxyaniline (0.064 mL, 0.50 mmol) in water (0.5 mL) as described in general procedure 
L gave, after work-up and purification by Mass Directed Auto Preparative HPLC, the title 
compound as a white solid (0.017 g, 20%). 1H NMR (400 MHz, CDCl3) δ 8.16 (dd, J = 
8.0, 1.0 Hz, 1H), 8.06 (s, 1H), 7.74 – 7.65 (m, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.47 – 7.39 




1H), 4.30 – 4.22 (m, 1H), 3.97 (q, J = 7.0 Hz, 2H), 3.88 (dd, J = 13.5, 7.0 Hz, 1H), 3.33 
(dd, J = 13.0, 4.0 Hz, 1H), 3.15 (dd, J = 13.0, 7.0 Hz, 1H), 1.39 (t, J = 7.0 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 161.7, 152.1, 147.7, 147.4, 141.9, 134.4, 127.3, 127.2, 126.5, 
121.6, 115.9, 115.0, 68.3, 64.1, 50.7, 48.6, 15.0. IR (FTIR, cm-1) 3282, 2982, 2925, 2865, 
1670, 1610, 1514, 1475, 1367, 1236, 1102, 1058, 772, 697. HRMS calcd for C19H21N3O3 





Reaction of 3-(oxiran-2-ylmethyl)quinazolin-4(3H)-one 267 (0.051 g, 0.25 mmol) and (4-
methoxyphenyl)methanamine (0.065 mL, 0.50 mmol) in water (0.5 mL) as described in 
general procedure L gave, after work-up and purification by Mass Directed Auto 
Preparative HPLC, the title compound as a white film (0.056 g, 66%). 1H NMR (400 MHz, 
CDCl3) δ 8.34 – 8.29 (m, 1H), 8.18 (s, 1H), 7.81 – 7.71 (m, 2H), 7.52 (ddd, J = 8.0, 7.0, 
1.5 Hz, 1H), 7.25 – 7.20 (m, 2H), 6.90 – 6.85 (m, 2H), 4.32 (dd, J = 13.5, 2.5 Hz, 1H), 
4.05 – 4.00 (m, 1H), 3.89 (dd, J = 13.5, 7.0 Hz, 1H), 3.82 (s, 3H), 3.80 – 3.71 (m, 2H), 
2.89 (dd, J = 12.0, 4.0 Hz, 1H), 2.61 (dd, J = 12.0, 5.0 1H). 13C NMR (101 MHz, CDCl3) 
δ 161.8, 158.8, 148.2, 147.5, 134.3, 131.9, 129.3, 127.5, 127.2, 126.7, 122.0, 113.9, 
68.2, 55.3, 53.1, 51.5, 50.0. IR (FTIR, cm-1) 3260, 2887, 1676, 1608, 1515, 1371, 1253, 









General Procedure M: Synthesis of 3-[3-(diethylamino)-2-hydroxypropyl] 
quinazolin-4(3H)-one (278) 
 
3-(Oxiran-2-ylmethyl)quinazolin-4(3H)-one 267 (0.404 g, 2.0 mmol, 1.0 eq.) was 
dissolved in water (5 mL) and then diethylamine (0.62 mL, 6.0 mmol, 3.0 eq.) was added. 
The reaction mixture was stirred at rt for 18 h. Water (20 mL) added to the reaction 
mixture and the product extracted with EtOAc (3 x 20 mL). The combined organic layers 
were dried with MgSO4 before filtering and removing the solvent in vacuo. The crude 
product was purified by flash column chromatography (silica gel, 10% MeOH/DCM) to 
afford the title compound as a colourless oil (0.394 g, 72%). 1H NMR (400 MHz, CDCl3) 
δ 8.24 (dd, J = 8.0, 1.5 Hz, 1H), 8.19 (s, 1H), 7.73 – 7.68 (m, 1H), 7.68 – 7.64 (m, 1H), 
7.44 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 4.33 (dd, J = 13.5, 2.5 Hz, 1H), 4.00 – 3.94 (m, 1H), 
3.69 (dd, J = 13.5, 7.5 Hz, 1H), 2.66 – 2.46 (m, 5H), 2.32 (dd, J = 12.0, 10.0 Hz, 1H), 
0.98 (t, J = 7.0 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 161.4 (-), 148.2 (-), 147.7 (+), 
134.1 (+), 127.4 (+), 127.0 (+), 126.6 (+), 121.9 (-), 65.8 (+), 56.4 (-), 50.1 (-), 47.1 (-), 
11.8 (+). IR (FTIR, cm-1) 3383, 2969, 2820, 1673, 1612, 1562, 1475, 1377, 1324, 1293, 
1058, 774, 698. HRMS calcd for C15H21N3O2 (MH+) 276.1707, found 276.1706. 
 
Synthesis of 3-[2-hydroxy-3-(piperidin-1-yl)propyl]quinazolin-4(3H)-one (279) 
 
Reaction of 3-(oxiran-2-ylmethyl)quinazolin-4(3H)-one 267 (0.404 g, 2.0 mmol, 1.0 eq.) 
and piperidine (0.60 mL, 6.0 mmol, 3.0 eq.) in water (5 mL) as described in general 
procedure M gave, after work-up and purification by flash column chromatography (silica 
gel, 10% MeOH/DCM), the title compound as a white film (0.370 g, 65%). 1H NMR (400 




1H), 7.43 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 4.30 (dd, J = 13.5, 2.5 Hz, 1H), 4.11 – 3.99 (m, 
1H), 3.69 (dd, J = 13.5, 7.0 Hz, 1H), 2.54 – 2.46 (m, 2H), 2.40 (dd, J = 12.0, 4.0 Hz, 1H), 
2.27 – 2.21 (m, 3H), 1.55 – 1.40 (m, 4H), 1.37 – 1.33 (m, 2H). 13C NMR (101 MHz, CDCl3) 
δ 161.5 (-), 148.1 (-), 147.8 (+), 134.1 (+), 127.4 (+), 127.0 (+), 126.6 (+), 121.9 (-), 65.1 
(+), 61.7 (-), 54.7 (-), 50.1 (-), 26.0 (-), 24.1 (-). IR (FTIR, cm-1) 3366, 2930, 2857, 2800, 
1667, 1610, 1562, 1474, 1373, 1323, 1293, 1107, 772, 697. HRMS calcd for C16H21N3O2 
(MH+) 288.1707, found 288.1704. 
 
Synthesis of 3-[2-hydroxy-3-(morpholin-4-yl)propyl]quinazolin-4(3H)-one (280) 
 
Reaction of 3-(oxiran-2-ylmethyl)quinazolin-4(3H)-one 267 (0.506 g, 2.5 mmol, 1.0 eq.) 
and morpholine (0.65 mL, 7.5 mmol, 3.0 eq.) in water (5 mL) as described in general 
procedure M gave, after work-up and purification by flash column chromatography (silica 
gel, 10% MeOH/DCM), the title compound as a colourless oil (0.468 g, 65%). 1H NMR 
(400 MHz, CDCl3) δ 8.32 (dd, J = 8.0, 1.5 Hz, 1H), 8.23 (s, 1H), 7.79 (ddd, J = 8.0, 7.0, 
1.5 Hz, 1H), 7.76 – 7.73 (m, 1H), 7.53 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 4.36 (dd, J = 13.5, 
2.5 Hz, 1H), 4.15 – 4.09 (m, 1H), 3.88 (dd, J = 13.5, 7.0 Hz, 1H), 3.78 – 3.65 (m, 5H), 
2.71 – 2.61 (m, 2H), 2.56 (dd, J = 12.0, 4.0 Hz, 1H), 2.49 – 2.40 (m, 2H), 2.34 (dd, J = 
12.0, 10.0 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 161.7 (-), 148.2 (-), 147.7 (+), 134.4 
(+), 127.5 (+), 127.2 (+), 127.0 (+), 121.9 (-), 67.0 (-), 65.1 (+), 61.3 (-), 53.6(-), 49.8 (-). 
IR (FTIR, cm-1) 3390, 2924, 2857, 2813, 1667, 1611, 1562, 1475, 1375, 1114, 867, 774, 
732, 697. HRMS calcd for C15H19N3O3 (MH+) 290.1499, found 290.1497. 
 





Reaction of 3-(oxiran-2-ylmethyl)quinazolin-4(3H)-one 267 (0.404 g, 2.0 mmol, 1.0 eq.) 
and dimethylamine (0.40 mL, 6.0 mmol, 3.0 eq.) in water (5 mL) as described in general 
procedure M gave, after work-up and purification by flash column chromatography (silica 
gel, 10% MeOH/DCM), the title compound as a pale yellow oil (0.417 g, 84%). 1H NMR 
(400 MHz, CDCl3) δ 8.28 (dd, J = 8.0, 1.5 Hz, 1H), 8.21 (s, 1H), 7.75 (ddd, J = 8.0, 7.0, 
1.5 Hz, 1H), 7.70 (dd, J = 8.0, 1.5 Hz, 1H), 7.49 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 4.34 (dd, 
J = 13.5, 2.5 Hz, 1H), 4.07 – 4.01 (m, 1H), 3.77 (dd, J = 13.5, 7.0 Hz, 1H), 2.38 (dd, J = 
12.0, 4.0 Hz, 1H), 2.32 (dd, J = 12.0, 10.0 Hz, 1H), 2.27 (s, 6H). 13C NMR (101 MHz, 
CDCl3) δ 161.6 (-), 148.2 (-), 147.8 (+), 134.3 (+), 127.5 (+), 127.1 (+), 126.7 (+), 121.9 
(-), 66.0 (+), 62.2 (-), 50.0 (-), 45.5 (+). IR (FTIR, cm-1) 3340, 2942, 2827, 2776, 1667, 
1610, 1564, 1474, 1373, 1323, 1231, 1106, 1035, 870, 773. HRMS calcd for C13H17N3O2 
(MH+) 248.1394, found 248.1392. 
 
Synthesis of 3-(3-[di(propan-2-yl)amino]-2-hydroxypropyl)quinazolin-4(3H)-one 
(282) 
 
Reaction of 3-(oxiran-2-ylmethyl)quinazolin-4(3H)-one 267 (0.404 g, 2.0 mmol, 1.0 eq.) 
and diisopropylamine (0.85 mL, 6.0 mmol, 3.0 eq.) in water (5 mL) as described in 
general procedure M gave, after work-up and purification by flash column 
chromatography (silica gel, 10% MeOH/DCM), the title compound as a pale yellow oil 
(0.392 g, 65%). 1H NMR (400 MHz, CDCl3) δ 8.30 (dd, J = 8.0, 1.5 Hz, 1H), 8.25 (s, 1H), 
7.78 – 7.74 (m, 1H), 7.72 (dd, J = 8.0, 1.5 Hz, 1H), 7.50 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 
4.41 (dd, J = 13.5, 2.5 Hz, 1H), 3.66 (dd, J = 13.5, 7.5 Hz, 1H), 3.39 – 3.35 (m, 1H), 3.06 
– 3.00 (m, 2H), 2.72 (dd, J = 13.0, 4.0 Hz, 1H), 2.28 (dd, J = 13.0, 10.0 Hz, 1H), 1.02 (d, 
J = 6.5 Hz, 6H), 1.00 (d, J = 6.5 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 161.4 (-), 148.1 
(-), 147.7 (+), 134.2 (+), 127.5 (+), 127.0 (+), 126.6 (+), 121.8 (-), 65.4 (+), 50.3 (-), 48.3 




1322, 1180, 1163, 1107, 772, 733, 696. HRMS calcd for C17H25N3O2 (MH+) 304.2020, 
found 304.2023. 
 
Synthesis of 3-[2-hydroxy-3-(pyrrolidin-1-yl)propyl]quinazolin-4(3H)-one (283) 
 
Reaction of 3-(oxiran-2-ylmethyl)quinazolin-4(3H)-one 267 (0.404 g, 2.0 mmol, 1.0 eq.) 
and pyrrolidine (0.49 mL, 6.0 mmol, 3.0 eq.) in water (5 mL) as described in general 
procedure M gave, after work-up and purification by flash column chromatography (silica 
gel, 10% MeOH/DCM), the title compound as a pale yellow oil (0.431 g, 79%). 1H NMR 
(400 MHz, CDCl3) δ 8.27 (dd, J = 8.0, 1.0 Hz, 1H), 7.74 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 
7.69 (dd, J = 8.0, 1.0 Hz, 1H), 7.48 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 4.35 (dd, J = 13.5, 2.5 
Hz, 1H), 4.08 – 4.02 (m, 1H), 3.78 (dd, J = 13.5, 7.5 Hz, 1H), 2.69 – 2.56 (m, 3H), 2.53 
– 2.45 (m, 3H), 1.76 – 1.71 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 161.6 (-), 148.1 (-), 
147.9 (+), 134.3 (+), 127.4 (+), 127.1 (+), 126.6 (+), 121.9 (-), 67.0 (+), 59.0 (-), 54.1 (-), 
50.1 (-), 23.6 (-). IR (FTIR, cm-1) 3318, 2957, 2793, 1671, 1611, 1564, 1475, 1374, 1324, 
1296, 1169, 1107, 774, 698. HRMS calcd for C15H19N3O2 (MH+) 274.1550, found 
274.1554. 
 





3-(Oxiran-2-ylmethyl)quinazolin-4(3H)-one 267 (50.6 mg, 0.25 mmol) was suspended in 




The reaction mixture was stirred at 20 °C for 1 hr. The reaction mixture was diluted with 
water (10 mL) and the product extracted with EtOAc (3 x 10 mL). The combined organic 
layers were dried with MgSO4 before filtering and removing the solvent in vacuo. The 
residue was dissolved in 50:50 (MeOH:DMSO, 2 mL) and then purified by Mass Directed 
Auto Preparative HPLC to afford the two title compounds as colourless oils.  
Isomer 1 (0.029 g, 38 %). 1H NMR (400 MHz, CDCl3) δ 8.18 (dd, J = 8.0, 1.5 Hz, 1H), 
8.15 (s, 1H), 7.69 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 7.59 (dd, J = 8.0, 1.5 Hz, 1H), 7.41 
(ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 4.45 (dd, J = 13.5, 2.5 Hz, 1H), 4.15 – 4.09 (m, 1H), 3.67 
(dd, J = 13.5, 8.0 Hz, 1H), 3.58 (dd, J = 11.0, 5.0 Hz, 1H), 3.44 (dd, J = 11.0, 5.0 Hz, 
1H), 3.21 (dt, J = 9.0, 5.0, 1H), 2.90 (dd, J = 12.5, 6.0 Hz, 1H), 2.75 (td, J = 9.0, 5.0 Hz, 
1H), 2.61 (dd, J = 12.5, 6.0 Hz, 1H), 2.51 – 2.45 (m, 1H), 1.95 – 1.83 (m, 1H), 1.80 – 
1.70 (m, 2H), 1.68 – 1.62 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 161.6, 147.9, 147.8, 
134.3, 127.2, 127.1, 126.5, 121.7, 68.4, 65.9, 64.0, 59.4, 56.4, 51.2, 27.4, 24.0. IR (FTIR, 
cm-1) 3362, 2948, 2925, 2870, 2820, 1661, 1612, 1560, 1475, 1371, 1324, 1071, 773, 
732, 698. HRMS calcd for C16H21N3O3 (MH+) 304.1656, found 304.1651. [α]25D = -128 (c 
= 0.95, MeOH) 
Isomer 2 (0.030 g, 40 %). 1H NMR (400 MHz, CDCl3) δ 8.24 (dd, J = 8.0, 1.5 Hz, 1H), 
8.18 (s, 1H), 7.72 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 7.65 (dd, J = 8.0, 1.5 Hz, 1H), 7.48 – 
7.43 (m, 1H), 4.33 (dd, J = 13.5, 2.5 Hz, 1H), 4.09 – 4.05 (m, 1H), 3.71 (dd, J = 13.5, 7.5 
Hz, 1H), 3.57 (dd, J = 11.0, 5.0 Hz, 1H), 3.43 (dd, J = 11.0, 5.0 Hz, 1H), 3.17 (dt, J = 9.0, 
5.0 Hz, 1H), 2.77 (dd, J = 12.5, 3.0 Hz, 1H), 2.71 (td, J = 9.0, 5.0 Hz, 1H), 2.59 (dd, J = 
12.5, 3.0 Hz, 1H), 2.40 – 2.28 (m, 1H), 1.92 – 1.82 (m, 1H), 1.80 – 1.60 (m, 3H). 13C 
NMR (101 MHz, CDCl3) δ 161.4, 148.0, 147.8, 134.3, 127.3, 127.1, 126.6, 121.8, 67.6, 
65.5, 63.7, 59.0, 54.7, 50.2, 27.2, 23.7. IR (FTIR, cm-1) 3351, 2952, 2870, 1661, 1562, 
1475, 1376, 1327, 1217, 1106, 1027, 867, 746, 700, 666. HRMS calcd for C16H21N3O3 










Reaction of 3-(oxiran-2-ylmethyl)quinazolin-4(3H)-one 267 (50.6 mg, 0.25 mmol) and 
(R)-pyrrolidin-2-ylmethanol (0.049 mL, 0.500 mmol) in water (0.5 mL) as described in 
general procedure N gave, after work-up and purification by Mass Directed Auto 






Reaction of 3-(oxiran-2-ylmethyl)quinazolin-4(3H)-one 267 (0.071 g, 0.35 mmol) and (S)-
2-amino-3-methylbutan-1-ol (0.108 g, 1.05 mmol) in water (1 mL) as described in general 
procedure N gave, after work-up and purification by Mass Directed Auto Preparative 
HPLC, the two title compounds as an inseparable mixture of colourless oils (0.069 g, 
64%). (Data reported for 1:1 mixture.) 1H NMR (400 MHz, CDCl3) δ 8.18 – 8.12 (m, 4H), 
7.70 – 7.64 (m, 2H), 7.60 – 7.57 (m, 2H), 7.44 – 7.38 (m, 2H), 4.28 (dd, J = 13.5, 2.5 Hz, 
2H), 4.13 – 4.07 (m, 2H), 3.84 – 3.76 (m, 4H), 3.65 (ddd, J = 11.0, 3.5, 2.0 Hz, 2H), 3.43 
(dt, J = 11.0, 7.5 Hz, 2H), 2.96 (dd, J = 12.0, 4.0 Hz, 1H), 2.87 (dd, J = 12.0, 4.0 Hz, 1H), 
2.71 (dd, J = 12.0, 8.0 Hz, 1H), 2.63 (dd, J = 12.0, 8.0 Hz, 1H), 2.47 – 2.40 (m, 2H), 1.82 
– 1.76 (m, 2H), 0.93 (d, J = 7.0 Hz, 6H), 0.87 (d, J = 7.0 Hz, 6H). 13C NMR (101 MHz, 




61.1, 60.9, 50.4, 50.3, 28.9, 28.8, 19.4, 19.3, 18.3, 18.2. IR (FTIR, cm-1) 3328, 2963, 
1666, 1611, 1475, 1372, 1323, 1217, 1106, 1049, 749, 696, 666. HRMS calcd for 






Reaction of 3-(oxiran-2-ylmethyl)quinazolin-4(3H)-one 267 (0.071 g, 0.35 mmol) and (S)-
2-amino-3-methylbutan-1-ol (0.108 g, 1.05 mmol) in water (1 mL) as described in general 
procedure N gave, after work-up and purification by Mass Directed Auto Preparative 
HPLC, the two title compounds as an inseparable mixture of colourless oils (0.036 g, 
34%). See page 210 for data. 
 
Synthesis of 3-(But-3-en-1-yl)-2,3-dihydroquinazolin-4(1H)-one (296)152 
 
Quinazolin-4(3H)-one (0.585 g, 4 mmol) and potassium carbonate (0.829 g, 6 mmol) 
were suspended in acetone (50 mL) and then 4-bromobut-1-ene (1.21 mL, 12.0 mmol) 
was added. The reaction mixture was heated at reflux with stirring under a stream of 
nitrogen for 18 h. The reaction mixture was cooled down and filtered and the solid was 
washed with DCM (3 x 20 mL). The combined extracts were evaporated in vacuo and 
the residue dissolved in DCM (50 mL), washed with water (2 x 25 mL) and then dried 
with sodium sulfate before filtering and removing the solvent in vacuo. The crude product 
was recrystallized with DCM/hexane to afford the title compound as a white solid (0.638 




1H), 8.01 (s, 1H), 7.86 – 7.68 (m, 2H), 7.59 – 7.46 (m, 1H), 5.84 (m, 1H), 5.17 – 5.04 (m, 
2H), 4.09 (t, J = 7.0 Hz, 2H), 2.66 – 2.54 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 161.0, 
148.2, 146.6, 134.2, 133.5, 127.5, 127.2, 126.7, 122.2, 118.7, 46.4, 33.4. 
 
Synthesis of 2-(2-Bromoethyl)oxirane (297)142 
 
4-Bromobut-1-ene (1.02 mL, 10 mmol) was dissolved in dichloromethane (50 mL) and 
then m-CPBA (6.90 g, 40 mmol) was added portionwise. The reaction mixture was stirred 
at rt for 18 h. 10% Aqueous sodium thiosulfate solution (100 mL) was added to remove 
excess m-CPBA and then the product extracted with EtOAc (3 x 50 mL). The combined 
organic layers were washed with saturated aqueous sodium bicarbonate solution (5 x 50 
mL) and then brine (100 mL). The organic phase was dried with sodium sulfate before 
filtering and removing the solvent in vacuo. The title compound was obtained as a 
colourless oil (1.5 g, 99%). 1H NMR (400 MHz, CDCl3) δ 3.53 (dd, J = 7.5, 6.0 Hz, 2H), 
3.14 – 3.06 (m, 1H), 2.85 (dd, J = 5.0, 4.0 Hz, 1H), 2.60 (dd, J = 5.0, 2.5 Hz, 1H), 2.22 – 
2.14 (m, 1H), 2.11 – 2.02 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 50.7 (+), 47.1 (-), 35.7 
(-), 29.0 (-). 
 
Synthesis of 3-(2-(Oxiran-2-yl)ethyl)quinazolin-4(3H)-one (294)142 
 
Quinazolin-4(3H)-one (0.731 g, 5 mmol) and potassium carbonate (1.04 g, 7.5 mmol) 
were suspended in acetone (25 mL) and then 2-(2-bromoethyl)oxirane 297 (1.51 g, 10.0 
mmol) was added. The reaction mixture was heated at reflux with stirring under a stream 
of nitrogen for 18 h. The reaction mixture was cooled down and filtered and the solid 




the residue dissolved in DCM (50 mL), washed with water (2 x 25 mL) and then dried 
with sodium sulfate before filtering and removing the solvent in vacuo. The crude product 
was recrystallized with DCM/hexane to afford the title compound as a white solid (1.01 
g, 93%). M.p. 86-88 °C (lit: 88-89 °C).142 1H NMR (400 MHz, CDCl3) δ 8.39 – 8.28 (m, 
1H), 8.09 (s, 1H), 7.85 – 7.68 (m, 2H), 7.61 – 7.48 (m, 1H), 4.32 – 4.12 (m, 2H), 3.03 (m, 
1H), 2.82 (dd, J = 5.0, 2.5 Hz, 1H), 2.53 (dd, J = 5.0, 2.5 Hz, 1H), 2.38 – 2.21 (m, 1H), 
1.93 – 1.72 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 161.2, 148.2, 146.4, 134.3, 127.6, 
127.4, 126.7, 122.2, 49.5, 46.9, 44.4, 32.0. 
 
General Procedure O: Synthesis of 3-(4-(Dimethylamino)-3-
hydroxybutyl)quinazolin-4(3H)-one (298) 
 
3-(2-(Oxiran-2-yl)ethyl)quinazolin-4(3H)-one 294 (0.054 g, 0.25 mmol) was suspended 
in water (1 mL) and then dimethylamine (0.051 mL, 0.75 mmol) was added. The reaction 
mixture was stirred at room temp. for 18 h and then the solvent was removed in vacuo. 
The residue was dissolved in 50:50 (MeOH:DMSO, 1 mL) and then purified by Mass 
Directed Auto Preparative HPLC to afford the title compound as a colourless oil (0.045 
g, 65%). 1H NMR (400 MHz, CDCl3) δ 8.28 (dd, J = 8.0, 1.5 Hz, 1H), 8.16 (s, 1H), 7.74 
(ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 7.70 (dd, J = 8.0, 1.5 Hz, 1H), 7.48 (ddd, J = 8.0, 7.0, 1.5 
Hz, 1H), 4.24 (ddd, J = 13.0, 7.5, 5.0 Hz, 1H), 4.15 (ddd, J = 13.0, 7.5, 5.0 Hz, 1H), 3.70 
(tt, J = 10.0, 3.0 Hz, 1H), 2.52 (dd, J = 12.0, 10.0 Hz, 1H), 2.38 (s, 6H), 2.35 (dd, J = 
12.0, 4.0 Hz, 1H), 2.06 – 1.97 (m, 1H), 1.75 – 1.65 (m, 1H). 13C NMR (101 MHz, CDCl3) 
δ 161.3, 148.2, 147.1, 134.2, 127.5, 127.1, 126.5, 122.1, 64.9, 63.6, 45.1, 44.1, 33.7. IR 
(FTIR, cm-1). 3358, 1668, 1611, 1475, 1376, 1323, 1292, 1167, 1106, 776, 753, 700. 





Synthesis of 3-(4-(Diethylamino)-3-hydroxybutyl)quinazolin-4(3H)-one (299) 
 
Reaction of 3-(2-(oxiran-2-yl)ethyl)quinazolin-4(3H)-one 294 (0.054 g, 0.25 mmol) and 
diethylamine (0.078 mL, 0.75 mmol) in water (1 mL) as described in general procedure 
O gave, after work-up and purification by Mass Directed Auto Preparative HPLC, the title 
compound as a colourless oil (0.051 g, 67%). 1H NMR (400 MHz, CDCl3) δ 8.28 (dd, J = 
8.0, 1.5 Hz, 1H), 8.16 (s, 1H), 7.73 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 7.69 (dd, J = 8.0, 1.5 
Hz, 1H), 7.48 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 4.28 – 4.22 (m, 1H), 4.19 – 4.10 (m, 1H), 
3.70 (tt, J = 10.0, 3.0 Hz, 1H), 2.72 (dq, J = 14.0, 7.0 Hz, 2H), 2.62 (dq, J = 14.0, 7.0 Hz, 
2H), 2.51 (dd, J = 13.0, 4.0 Hz, 1H), 2.44 (dd, J = 13.0, 10.0 Hz, 1H), 2.07 – 1.96 (m, 
1H), 1.71 – 1.63 (m, 1H), 1.06 (t, J = 7.2 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 161.3, 
148.2, 147.2, 134.1, 127.5, 127.1, 126.5, 122.1, 63.5, 59.1, 47.3, 44.2, 33.7, 11.1. IR 
(FTIR, cm-1). HRMS calcd for C16H23N3O2 (MH+) 290.1790, found 290.1791. 
 
Synthesis of 3-(4-(Diisopropylamino)-3-hydroxybutyl)quinazolin-4(3H)-one (300) 
 
Reaction of 3-(2-(oxiran-2-yl)ethyl)quinazolin-4(3H)-one 294 (0.054 g, 0.25 mmol) and 
diisopropylamine (0.106 mL, 0.75 mmol) in water (1 mL) as described in general 
procedure O gave, after work-up and purification by Mass Directed Auto Preparative 
HPLC, the title compound as a colourless oil (0.037 g, 44%). 1H NMR (400 MHz, CDCl3) 
δ 8.28 (dd, J = 8.0, 1.5 Hz, 1H), 8.16 (s, 1H), 7.75 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 7.69 
(dd, J = 8.0, 1.5 Hz, 1H), 7.49 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 4.29 – 4.13 (m, 2H), 4.09 
– 4.03 (m, 1H), 3.50 (hept, J = 6.5 Hz, 2H), 2.88 (dd, J = 13.0, 10.0 Hz, 1H), 2.76 (dd, J 
= 13.0, 2.0 Hz, 1H), 2.18 – 2.07 (m, 1H), 1.83 – 1.71 (m, 1H), 1.33 (d, J = 6.5 Hz, 6H), 




127.1, 126.4, 122.0, 63.9, 54.8, 54.3, 44.3, 33.7, 18.4. IR (FTIR, cm-1) 3351, 2967, 1669, 
1609, 1473, 1367, 1348, 1323, 1160, 775, 755, 699. HRMS calcd for C18H27N3O2 (MH+) 
318.2176, found 318.2176. 
 
Synthesis of 3-(3-Hydroxy-4-(pyrrolidin-1-yl)butyl)quinazolin-4(3H)-one (301) 
 
Reaction of 3-(2-(oxiran-2-yl)ethyl)quinazolin-4(3H)-one 294 (0.054 g, 0.25 mmol) and 
pyrrolidine (0.061 mL, 0.75 mmol) in water (1 mL) as described in general procedure O 
gave, after work-up and purification by Mass Directed Auto Preparative HPLC, the title 
compound as a colourless oil (0.047 g, 62%). 1H NMR (400 MHz, CDCl3) δ 8.28 (dd, J = 
8.0, 1.5 Hz, 1H), 8.14 (s, 1H), 7.72 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 7.68 (dd, J = 8.0, 1.5 
Hz, 1H), 7.46 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 4.22 (ddd, J = 13.0, 7.0, 5.0 Hz, 1H), 4.13 
(ddd, J = 13.0, 7.0, 5.0 Hz, 1H), 3.80 (tt, J = 10.0, 3.0 Hz, 1H), 2.93 – 2.83 (m, 2H), 2.82 
– 2.73 (m, 3H), 2.54 (dd, J = 13.0, 4.0 Hz, 1H), 2.07 – 1.97 (m, 1H), 1.91 – 1.78 (m, 4H), 
1.77 – 1.66 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 161.3, 148.2, 147.1, 134.1, 127.5, 
127.1, 126.4, 122.0, 64.5, 61.9, 54.3, 44.0, 33.8, 23.3. IR (FTIR, cm-1) 3328, 2960, 2804, 
1660, 1610, 1475, 1325, 1372, 1325, 1160, 883, 774, 698. HRMS calcd for C16H21N3O2 
(MH+) 288.1707, found 288.1704. 
 
Synthesis of 3-(3-Hydroxy-4-(piperidin-1-yl)butyl)quinazolin-4(3H)-one (302) 
 
Reaction of 3-(2-(oxiran-2-yl)ethyl)quinazolin-4(3H)-one 294 (0.054 g, 0.25 mmol) and 
piperidine (0.074 mL, 0.75 mmol) in water (1 mL) as described in general procedure O 
gave, after work-up and purification by Mass Directed Auto Preparative HPLC, the title 




8.0, 1.5 Hz, 1H), 8.14 (s, 1H), 7.71 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 7.68 (dd, J = 8.0, 1.5 
Hz, 1H), 7.46 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 4.27 – 4.19 (m, 1H), 4.16 – 4.07 (m, 1H), 
3.94 (tt, J = 10.0, 3.0 Hz, 1H), 2.93 – 2.79 (m, 4H), 2.78 – 2.70 (m, 1H), 2.59 (dd, J = 
13.0, 4.0 Hz, 1H), 2.08 – 1.94 (m, 1H), 1.85 – 1.65 (m, 6H), 1.60 – 1.43 (m, 2H). 13C 
NMR (101 MHz, CDCl3) δ 161.3, 148.2, 147.1, 134.2, 127.5, 127.1, 126.4, 122.0, 63.7, 
62.5, 54.6, 43.9, 33.7, 23.7, 22.7. IR (FTIR, cm-1) 3335, 2934, 2853, 2796, 1669, 1610, 
1474, 1373, 1324, 1159, 1119, 775, 699. HRMS calcd for C17H23N3O2 (MH+) 302.1863, 
found 302.1860. 
 
Synthesis of 3-(3-hydroxy-4-morpholinobutyl)quinazolin-4(3H)-one (303) 
 
Reaction of 3-(2-(oxiran-2-yl)ethyl)quinazolin-4(3H)-one 294 (0.054 g, 0.25 mmol) and 
morpholine (0.064 mL, 0.75 mmol) in water (1 mL) as described in general procedure O 
gave, after work-up and purification by Mass Directed Auto Preparative HPLC, the title 
compound as a colourless oil (0.054 g, 68%). 1H NMR (400 MHz, CDCl3) δ 8.27 (dd, J = 
8.0, 1.5 Hz, 1H), 8.15 (s, 1H), 7.73 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 7.69 (dd, J = 8.0, 1.5 
Hz, 1H), 7.48 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 4.28 – 4.19 (m, 1H), 4.18 – 4.09 (m, 1H), 
3.77 (tt, J = 10.0, 3.0 Hz, 1H), 3.74 – 3.66 (m, 4H), 2.77 – 2.65 (m, 2H), 2.59 – 2.49 (m, 
2H), 2.49 – 2.39 (m, 2H), 2.07 – 1.94 (m, 1H), 1.76 – 1.65 (m, 1H). 13C NMR (101 MHz, 
CDCl3) δ 161.3, 148.1, 147.1, 134.2, 127.4, 127.2, 126.5, 122.0, 66.2, 64.2, 62.9, 53.5, 
44.0, 33.7. IR (FTIR, cm-1) 3404, 2925, 2857, 2811, 1667, 1610, 1474, 1373, 1324, 1294, 









Reaction of 3-(2-(oxiran-2-yl)ethyl)quinazolin-4(3H)-one 294 (0.070 g, 0.32 mmol) and 
(R)-pyrrolidin-2-ylmethanol (0.063 mL, 0.65 mmol) in water (0.5 mL) as described in 
general procedure O gave, after work-up and purification by Mass Directed Auto 
Preparative HPLC, the two title compounds as colourless oils.  
Isomer 1 (0.042 g, 41 %). 1H NMR (400 MHz, CDCl3) δ 8.29 (dd, J = 8.0, 1.5 Hz, 1H), 
8.15 (s, 1H), 7.76 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 7.71 (dd, J = 8.0, 1.5 Hz, 1H), 7.50 
(ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 4.30 – 4.22 (m, 1H), 4.20 – 4.11 (m, 1H), 3.81 (tt, J = 
10.0, 3.0 Hz, 1H), 3.59 (dd, J = 11.0, 4.0 Hz, 1H), 3.47 (dd, J = 11.0, 4.0 Hz, 1H), 3.20 
(dt, J = 10.0, 5.0 Hz, 1H), 2.88 (td, J = 10.0, 5.0 Hz, 1H),  2.81 – 2.76 (m, 1H), 2.63 – 
2.51 (m, 2H), 2.07 – 1.99 (m, 1H), 1.94 – 1.71 (m, 4H), 1.69 – 1.61 (m, 1H). 13C NMR 
(101 MHz, CDCl3) δ 161.6, 148.1, 146.9, 134.3, 127.4, 127.3, 126.6, 121.9, 66.5, 65.5, 
63.7, 61.9, 56.7, 43.9, 34.4, 27.3, 24.0. IR (FTIR, cm-1) 3381, 2922, 1667, 1612, 1475, 
1377, 1323, 1296, 1160, 1068, 777, 699. HRMS calcd for C17H23N3O3 (MH+) 318.1812, 
found 318.1807. [α]25D = +38 (c = 1.20, MeOH) 
Isomer 2 (0.040 g, 39 %). 1H NMR (400 MHz, CDCl3) δ 8.29 (dd, J = 8.0, 1.5 Hz, 1H), 
8.18 (s, 1H), 7.75 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 7.71 (dd, J = 8.0, 1.5 Hz, 1H), 7.50 
(ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 4.23 – 4.17 (m, 2H), 3.81 (tt, J =10.0, 3.0 Hz, 1H), 3.68 
(dd, J = 11.5, 4.0 Hz, 1H), 3.56 (dd, J = 11.0, 4.0 Hz, 1H), 3.30 (dt, J = 10.0, 5.0 Hz, 1H), 
2.93 – 2.85 (m, 2H), 2.52 (dd, J = 13.0, 4.0 Hz, 1H), 2.39 (dd, J = 13.0, 10.0 Hz, 1H), 
2.06 – 1.98 (m, 1H), 1.95 – 1.88 (m, 1H), 1.84 – 1.70 (m, 4H). 13C NMR (101 MHz, CDCl3) 
δ 161.4, 148.2, 147.1, 134.2, 127.4, 127.2, 126.5, 122.0, 66.7, 65.3, 63.0, 61.9, 54.8, 
44.0, 33.7, 27.0, 23.6. IR (FTIR, cm-1) 3351, 2925, 1670, 1612, 1475, 1375, 1261, 1159, 
1102, 768, 750, 699. HRMS calcd for C17H23N3O3 (MH+) 318.1812, found 318.1810. [α]25D 









Reaction of 3-(2-(oxiran-2-yl)ethyl)quinazolin-4(3H)-one 294 (0.070 g, 0.32 mmol) and 
(S)-pyrrolidin-2-ylmethanol (0.063 mL, 0.65 mmol) in water (0.5 mL) as described in 
general procedure O gave, after work-up and purification by Mass Directed Auto 
Preparative HPLC, the two title compounds as colourless oils.  
Isomer 1 (0.037 g, 36%). Isomer 2 (0.036 g, 35%). See page 217 for data. 
 
Synthesis of 2-[(benzyloxy)methyl]oxirane (316)183 
 
Glycidol (1.11 g, 15 mmol, 1.0 eq.) was added to a suspension of sodium hydride (0.720 
g, 30 mmol, 2.0 eq.) in THF (5 mL) dropwise at 0 °C for 15 mins. Benzyl bromide (2.0 
mL, 16.5 mmol, 1.1 eq.) was added and the reaction mixture was stirred at rt under a 
stream of N2 for 4 h. Water (20 mL) was added to the reaction mixture and the product 
extracted with dichloromethane (3 x 20 mL). The combined organic layers were washed 
with brine (20 mL) and then dried with MgSO4 before filtering and removing the solvent 
in vacuo. The crude product was purified by flash column chromatography (silica gel, 
20% EtOAc/petrol) to afford the title compound as a yellow oil (0.892 g, 36%). 1H NMR 
(400 MHz, CDCl3) δ 7.40 – 7.33 (m, 3H), 7.36 – 7.29 (m, 2H), 4.65 (d, J = 12.0 Hz, 1H), 
4.59 (d, J = 12.0 Hz, 1H), 3.79 (dd, J = 11.0, 3.0 Hz, 1H), 3.47 (dd, J = 11.0, 5.0 Hz, 1H), 
3.24 – 3.20 (m, 1H), 2.83 (t, J = 5.0 Hz, 1H), 2.65 (dd, J = 5.0, 3.0 Hz, 1H). 13C NMR 
(101 MHz, CDCl3) δ 137.9 (-), 128.4 (+), 128.3 (+), 127.8 (+), 73.3 (-), 70.8 (-), 50.9 (+), 




Synthesis of 2-[(benzyloxy)methyl]oxetane (317)184 
 
Potassium tert-butoxide (0.260 g, 2.2 mmol, 2.0 eq.) and trimethylsulfoxonium iodide 
(0.510 g, 2.2 mmol, 2.0 eq.) were suspended in tert-butanol (5 mL) and the reaction 
mixture was stirred at 70 °C for 1 h. 2-[(Benzyloxy)methyl]oxirane 316 (0.190 g, 1.1 
mmol, 1.0 eq.) in tert-butanol (5 mL) was added dropwise and the reaction mixture was 
stirred at 70 °C for 24 h. After cooling down to rt, the solvent was removed in vacuo. The 
residue was diluted with water (20 mL) and then the product was extracted with hexane 
(3 x 20 mL). The combined organic layers were dried with MgSO4 before filtering and 
removing the solvent in vacuo. The title product was obtained as a colourless oil (0.095 
g, 53%). 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.29 (m, 5H), 5.04 – 4.97 (m, 1H), 4.73 – 
4.66 (m, 2H), 4.64 – 4.57 (m, 2H), 3.68 – 3.65 (m, 2H), 2.75 – 2.53 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ 139.0 (-), 128.2 (+), 127.4 (+), 127.3 (+), 80.7 (+), 73.7 (-), 72.8 (-), 
67.8 (-), 23.6 (-). 
 
Synthesis of 2-[(1-ethoxyethoxy)methyl]oxirane (320)185 
 
Glycidol (9 mL, 135 mmol, 1.0 eq.) was dissolved in ethyl vinyl ether (52 mL, 540 mmol, 
4.0 eq.) and then p-toluenesulfonic acid (0.257 g, 1.35 mmol, 0.01 eq.) was added at 0 
°C. The reaction mixture was stirred at ambient temperature for 3 h. Aqueous saturated 
NaHCO3 solution (50 mL) was added and then the product was extracted with diethyl 
ether (2 x 50 mL). The combined organic layers were dried with MgSO4 before filtering 
and removing the solvent in vacuo. The title product was obtained as a pale yellow oil 




3.58 (dd, J = 11.5, 5.5 Hz, 1H), 3.54 – 3.47 (m, 1H), 3.44 (dd, J = 11.5, 5.5 Hz, 1H), 3.20 
– 3.14 (m, 1H), 2.83 (ddd, J = 5.0, 4.0, 1.0 Hz, 1H), 2.65 (ddd, J = 14.5, 5.0, 2.5 Hz, 1H), 
1.34 (d, J = 6.0, Hz, 3H), 1.22 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 99.7 (+), 
65.7 (-), 60.9 (-), 50.9 (+), 44.6 (-), 19.7 (+), 15.2 (+). 
 
Synthesis of 2-[(1-ethoxyethoxy)methyl]oxetane (321)185 
 
Potassium tert-butoxide (26.9 g, 240 mmol, 2.0 eq.) and trimethylsulfoxonium iodide 
(52.8 g, 240 mmol, 2.0 eq.) were suspended in tert-butanol (120 mL) and the reaction 
mixture was stirred at 70 °C for 1 h. 2-[(1-Ethoxyethoxy)methyl]oxirane 320 (17.5 g, 120 
mmol, 1.0 eq.) in tert-butanol (120 mL) was added dropwise and the reaction mixture 
was stirred at 70 °C for 24 h. After cooling down to rt, the solvent was removed in vacuo. 
The residue was diluted with water (20 mL) and then the product was extracted with 
hexane (3 x 100 mL). The combined organic layers were dried with MgSO4 before 
filtering and removing the solvent in vacuo. The title product was obtained as a colourless 
oil (15.8 g, 82%) 1H NMR (400 MHz, CDCl3) δ 4.95 – 4.87 (m, 1H), 4.80 – 4.76 (m, 1H), 
4.67 – 4.60 (m, 1H), 4.57 – 4.51 (m, 1H), 3.73 – 3.56 (m, 4H), 2.69 – 2.44 (m, 2H), 1.32 
(d, J = 6.0 Hz, 3H), 1.19 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 99.9 (+), 81.0 
(+), 68.9 (-), 68.0 (-), 60.9 (-), 31.2 (+), 23.8 (-), 15.3 (+). 
 
Synthesis of oxetan-2-ylmethanol (319)185 
 
2-[(1-Ethoxyethoxy)methyl]oxetane 321 (5.0 g, 31.2 mmol, 1.0 eq.) was dissolved in 10% 
acetic acid in water (25 mL) and the reaction mixture was stirred at ambient temperature 




The residual solution was cooled to rt and then solid K2CO3 was added until it was 
saturated. The product was extracted with dichloromethane (3 x 30 mL) and then dried 
with MgSO4 before filtering. The solvent was removed via short-path distillation to afford 
the title product as a yellow oil (1.55 g, 56%). 1H NMR (400 MHz, CDCl3) δ 4.99 – 4.90 
(m, 1H), 4.70 (ddd, J = 8.5, 7.5, 6.0 Hz, 1H), 4.54 (dt, J = 8.5, 6.0 Hz, 1H), 3.76 (dd, J = 
12.5, 4.0 Hz, 1H), 3.64 (dd, J = 12.5, 4.0 Hz, 1H), 2.70 – 2.58 (m, 2H). 13C NMR (101 
MHz, CDCl3) δ 82.7 (+), 69.0 (-), 65.4 (-), 22.6 (-). 
 
Synthesis of oxetan-2-ylmethyl 4-methylbenzenesulfonate (322)185 
 
Tosyl chloride (2.6 g, 13.7 mmol, 1.1 eq.) was dissolved in pyridine (3 mL) and the 
solution cooled to 0 °C. Oxetan-2-ylmethanol 319 (1.1 g, 12.5 mmol, 1.0 eq.) in pyridine 
(2.5 mL) was added dropwise and the reaction mixture was stirred at ambient 
temperature for 18 h. Water (20 mL) was added and the product was extracted with 
diethyl ether (3 x 30 mL). The combined organic layers were washed with 10% H2SO4 
solution (3 x 30 mL) and then brine (30 mL) and dried with MgSO4 before filtering and 
removing the solvent in vacuo. The title product was obtained as a pale yellow oil (1.24 
g, 40%) 1H NMR (400 MHz, CDCl3) δ 7.85 (d, J = 8.0 Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 
4.98 – 4.91 (m, 1H), 4.66 – 4.59 (m, 1H), 4.56 – 4.50 (m, 1H), 4.17 (d, J = 4.0 Hz, 2H), 
2.78 – 2.68 (m, 1H), 2.64 – 2.54 (m, 1H), 2.47 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
145.0 (-), 133.0 (-), 130.0 (+), 128.0 (+), 78.7 (+), 72.1 (-), 69.0 (-), 23.5 (-), 21.8 (+). 
 
Synthesis of oxetan-2-ylmethyl methanesulfonate (324)186 
 
Oxetan-2-ylmethanol 319 (0.500 g, 5.68 mmol, 1.0 eq.) was dissolved in 




chloride (0.53 mL, 6.82 mmol, 1.2 eq.) were added at 0 °C. The reaction mixture was 
stirred at 0 °C for 1 h and then allowed to warm to ambient temperature for 18 h. Water 
(20 mL) was added and the product was extracted with dichloromethane (3 x 20 mL). 
The combined organic layers were washed with brine (20 mL) and dried with MgSO4 
before filtering and removing the solvent in vacuo. The title product was obtained as a 
yellow oil (0.801 g, 86%) 1H NMR (400 MHz, CDCl3) δ 5.08 – 5.02 (m, 1H), 4.73 – 4.68 
(m, 1H), 4.64 – 4.57 (m, 1H), 4.38 (d, J = 4.0 Hz, 2H), 3.13 (s, 3H), 2.83 – 2.74 (m, 1H), 
2.70 – 2.60 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 78.9 (+), 72.0 (-), 68.9 (-), 37.7 (+), 
23.2 (-). 
 
Synthesis of 3-(oxetan-2-ylmethyl)quinazolin-4(3H)-one (308) 
 
Quinazolinone (0.146 g, 1.00 mmol, 1.0 eq) and potassium carbonate (0.207 g, 1.50 
mmol, 1.5 eq.) were suspended in acetone (10 mL) and then heated at reflux for 0.5 h. 
2-(Tosyloxymethyl)oxetane 322 (0.347 g, 1.40 mmol, 1.4 eq) was added and the reaction 
mixture was stirred at reflux under a stream of N2 for 18 h. The reaction mixture was 
cooled down and then filtered. The solid was washed with dichloromethane (2 x 20 mL) 
and then added to the initial filtrate. The combined solution was evaporated to dryness 
and the residue dissolved in dichloromethane (20 mL).  The solution was washed with 
water (3 x 20 mL) and then dried with MgSO4 before filtering and removing the solvent 
in vacuo. The crude product was purified by flash column chromatography (silica gel, 
EtOAc) to afford the title compound as a pale yellow oil (0.119 g, 55%). 1H NMR (400 
MHz, DMSO) δ 8.36 (s, 1H), 8.18 (dd, J = 8.0, 1.5 Hz, 1H), 7.85 (ddd, J = 8.0, 7.0, 1.5 
Hz, 1H), 7.70 (d, J = 8.0, 1.5 Hz, 1H), 7.56 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 5.03 – 4.95 
(m, 1H), 4.50 (dd, J = 14.0, 7.0 Hz, 1H), 4.42 – 4.29 (m, 2H), 4.23 (dd, J = 14.0, 7.0 Hz, 




148.9 (+), 148.4 (-), 134.9 (+), 127.7 (+), 127.5 (+), 126.6 (+), 121.9 (-), 79.1 (+), 68.2 (-
), 50.5 (-), 24.6 (-). IR (FTIR, cm-1) 2957, 2859, 1720, 1612, 1475, 1354, 1175, 946, 777. 
HRMS calcd for C12H12N2O2 (MH+) 217.0972, found 217.0968. 
 
General Procedure P: Synthesis of 3-[2-hydroxy-4-(morpholin-4-yl)butyl] 
quinazolin-4(3H)-one (325) 
 
3-(Oxetan-2-ylmethyl)quinazolin-4(3H)-one 308 (0.044 g, 0.20 mmol, 1.0 eq) and 
gadolinium triflate (0.123 g, 0.20 mmol, 1.0 eq) were dissolved in acetonitrile (2 mL) and 
then morpholine (0.05 mL, 0.60 mmol, 3 eq.) was added. The reaction mixture was 
heated at reflux under a stream of N2 for 24 h. The reaction mixture was added to water 
(10 mL) and the product extracted with dichloromethane (3 x 10 mL). The combined 
organic layers were dried with MgSO4 before filtering and removing the solvent in vacuo. 
The crude product was purified by flash column chromatography (silica gel, 10% 
methanol/dichloromethane) to afford the title compound as a pale yellow oil (0.034 g, 
56%). 1H NMR (400 MHz, CDCl3) δ 8.31 (dd, J = 8.0, 1.5 Hz, 1H), 7.76 (ddd, J = 8.0, 
7.0, 1.5 Hz, 1H), 7.72 (dd, J = 8.0, 1.5 Hz, 1H), 7.50 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 4.30 
(dd, J = 13.5, 3.0 Hz, 1H), 4.24 – 4.16 (m, 1H), 3.79 (dd, J = 13.5, 7.5 Hz, 1H), 3.74 – 
3.64 (m, 4H), 2.74 – 2.60 (m, 4H), 2.45 – 2.35 (m, 2H), 1.78 – 1.62 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ 161.5 (-), 148.2 (-), 147.7 (+), 134.2 (+), 127.7 (+), 127.5 (+), 126.7 
(+), 122.0 (-), 71.7 (+), 66.8 (-), 57.9 (-), 53.6 (-), 51.9 (-), 28.4 (-). IR (FTIR, cm-1) 2957, 
2859, 1666, 1613, 1475, 1380, 1115, 914, 776. HRMS calcd for C16H22N3O3 (MH+) 






Synthesis of 3-[2-hydroxy-4-(piperidin-1-yl)butyl]quinazolin-4(3H)-one (326) 
 
Reaction of 3-(oxetan-2-ylmethyl)quinazolin-4(3H)-one 308 (0.108 g, 0.50 mmol, 1.0 eq), 
gadolinium triflate (0.302 g, 0.50 mmol, 1.0 eq) and piperidine (0.15 mL, 1.5 mmol, 3 eq.) 
in acetonitrile (2 mL) as described in General Procedure P gave, after work-up and 
chromatography (silica gel, 10% MeOH, dichloromethane), the title compound as a pale 
yellow oil (0.086 g, 57%). 1H NMR (400 MHz, CDCl3) δ 8.20 (s, 1H), 8.19 (dd, J = 8.0, 
1.5 Hz, 2H), 7.69 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 7.61 (dd, J = 8.0, 1.5 Hz, 1H), 7.43 (ddd, 
J = 8.0, 7.0, 1.5 Hz, 1H), 4.23 (dd, J = 13.0, 3.0 Hz, 1H), 4.20 – 4.15 (m, 1H), 3.86 (dd, 
J = 13.0, 7.5 Hz, 1H), 3.21 – 3.16 (m, 1H), 3.08 – 2.91 (m, 3H), 2.80 – 2.70 (m, 2H), 1.89 
– 1.63 (m, 8H). 13C NMR (101 MHz, DMSO) δ 161.0 (-), 149.1 (+), 148.5 (-), 134.8 (+), 
127.6 (+), 127.4 (+), 126.5 (+), 122.1 (-), 119.5 (-), 66.1 (+), 54.0 (-), 52.7 (-), 52.2 (-), 
29.0 (-), 23.1 (-), 21.8 (-). IR (FTIR, cm-1) 3442, 2956, 1669, 1612, 1475, 1283, 1244, 
1224, 1153, 1029, 778, 638. HRMS calcd for C17H23N3O2 (MH+) 302.1863, found 
302.1864. 
 
Synthesis of 3-[4-(diethylamino)-2-hydroxybutyl]quinazolin-4(3H)-one (327) 
 
Reaction of 3-(oxetan-2-ylmethyl)quinazolin-4(3H)-one 308 (0.108 g, 0.50 mmol, 1.0 eq), 
gadolinium triflate (0.302 g, 0.50 mmol, 1.0 eq) and diethylamine (0.16 mL, 1.5 mmol, 3 
eq.) in acetonitrile (2 mL) as described in General Procedure P gave, after work-up and 
chromatography (silica gel, 10% MeOH, dichloromethane), the title compound as a 
brown oil (0.074 g, 51%). 1H NMR (400 MHz, CDCl3) δ 8.27 (dd, J = 8.0, 1.5 Hz, 1H), 
8.22 (s, 1H), 7.75 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 7.69 (dd, J = 8.0, 1.5 Hz, 1H), 7.49 




3.0 Hz, 1H), 3.90 (dd, J = 13.5, 7.0 Hz, 1H), 2.97 – 2.89 (m, 3H), 2.79 – 2.72 (m, 2H), 
1.84 – 1.77 (m, 2H), 1.19 (t, J = 7.0 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 161.7 (-), 
148.3 (-), 147.7 (+), 134.2 (+), 127.5 (+), 127.1 (+), 126.6 (+), 121.9 (-), 70.1 (+), 52.0 (-
), 51.6 (-), 47.1 (-), 29.0 (-), 10.2 (+). IR (FTIR, cm-1) 3411, 2922, 1661, 1613, 1476, 1243, 
1225, 1163, 1029, 775, 698, 637. HRMS calcd for C16H23N3O2 (MH+) 290.1863, found 
290.1863. 
 
General Procedure Q: Synthesis of 3-[3-(diethylamino)-2-oxopropyl]quinazolin-
4(3H)-one (328) 
  
Trifluoroacetic acid (0.15 mL, 1.98 mmol, 1.1 eq) was added to a solution of 3-[3-
(diethylamino)-2-hydroxypropyl]quinazolin-4(3H)-one 278 (0.495 g, 1.80 mmol, 1.0 eq) 
in dichloromethane (5 mL) and then stirred for 30 min. Oxalyl chloride (0.19 mL, 2.16 
mmol, 1.2 eq) was dissolved in dichloromethane (5 mL) and then dimethyl sulfoxide (0.32 
mL, 4.50 mmol, 2.5 eq) in dichloromethane (8 mL) was added at -78 °C. The solution 
was stirred for 2 mins after which, the amino alcohol/TFA solution was added. The 
reaction mixture was stirred at -78 °C under a stream of N2 for 1 h. Triethylamine (1.1 
mL, 7.56 mmol, 4.2 eq) was added and the reaction mixture was allowed to warm to rt 
and stirred for 4 h. Aqueous saturated NaHCO3 solution (20 mL) was added to the 
reaction mixture and the product extracted with dichloromethane (3 x 30 mL). The 
combined organic layers were washed with brine (20 mL) and then dried with MgSO4 
before filtering and removing the solvent in vacuo. The crude product was purified by 
flash column chromatography (silica gel, 10% methanol/dichloromethane) to afford the 
title compound as a yellow oil (0.383 g, 78%). 1H NMR (400 MHz, CDCl3) δ 8.30 (dd, J 
= 8.0, 1.5 Hz, 1H), 7.91 (s, 1H), 7.79 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 7.75 (dd, J = 8.0, 




7.0 Hz, 4H), 1.12 (t, J = 7.0 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 202.8 (-), 161.1 (-), 
148.3 (-), 146.6 (+), 134.5 (+), 127.6 (+), 127.4 (+), 126.7 (+), 121.9 (-), 62.5 (-), 53.3 (-
), 48.6 (-), 12.1 (+). IR (FTIR, cm-1) 2924, 2853, 1735, 1661, 1610, 1566, 1474, 1371, 
1324, 1295, 772, 753, 664. HRMS calcd for C15H19N3O2 (MH+) 274.1550, found 
274.1550. 
 
Synthesis of 3-[2-oxo-3-(piperidin-1-yl)propyl]quinazolin-4(3H)-one (329) 
 
Reaction of 3-[2-hydroxy-3-(piperidin-1-yl)propyl]quinazolin-4(3H)-one 279 (0.517 g, 
1.80 mmol, 1.0 eq), trifluoroacetic acid (0.15 mL, 1.98 mmol, 1.1 eq), oxalyl chloride (0.19 
mL, 2.16 mmol, 1.2 eq), dimethyl sulfoxide (0.32 mL, 4.50 mmol, 2.5 eq) and 
triethylamine (1.1 mL, 7.56 mmol, 4.2 eq) in dichloromethane (18 mL) for 4 h as 
described in General Procedure Q gave, after work-up and chromatography (silica gel, 
10% MeOH, dichloromethane), the title compound as a yellow-orange oil (0.479 g, 84%). 
1H NMR (400 MHz, CDCl3) δ 8.29 (dd, J = 8.0, 1.5, Hz, 1H), 7.91 (s, 1H), 7.82 – 7.73 (m, 
2H), 7.53 (ddd, J = 8.0, 6.5, 1.5 Hz, 1H), 4.97 (s, 2H), 3.29 (s, 2H), 2.56 – 2.45 (m, 4H), 
1.66 (m, 4H), 1.54 – 1.41 (m, 2H).13C NMR (101 MHz, CDCl3) δ 202.8 (-), 161.1 (-), 148.3 
(-), 146.6 (+), 134.5 (+), 127.6 (+), 127.4 (+), 126.7 (+), 121.9 (-), 67.5 (-), 55.3 (-), 53.3 
(-), 25.9 (-), 23.7 (-). IR (FTIR, cm-1) 2933, 1735, 1675, 1612, 1475, 1364, 1324, 776. 
HRMS calcd for C16H19N3O2 (MH+) 286.1550, found 286.1549. 
 
Synthesis of 3-[3-(morpholin-4-yl)-2-oxopropyl]quinazolin-4(3H)-one (330) 
 
Reaction of 3-[2-hydroxy-3-(morpholin-4-yl)propyl]quinazolin-4(3H)-one 280 (0.376 g, 




mL, 1.56 mmol, 1.2 eq), dimethyl sulfoxide (0.23 mL, 3.25 mmol, 2.5 eq) and 
triethylamine (0.76 mL, 5.46 mmol, 4.2 eq) in dichloromethane (18 mL) for 4 h as 
described in General Procedure Q gave, after work-up and chromatography (silica gel, 
10% MeOH, dichloromethane), the title compound as a yellow oil (0.310 g, 84%) 1H NMR 
(400 MHz, CDCl3) δ 8.28 (dd, J = 8.0, 1.5 Hz, 1H), 7.92 (s, 1H), 7.80 (ddd, J = 8.0, 7.0, 
1.5 Hz, 1H), 7.75 (dd, J = 8.0, 1.5 Hz, 1H), 7.53 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 4.94 (s, 
2H), 3.81 – 3.77 (m, 4H), 3.37 (s, 2H), 2.62 – 2.59 (m, 4H). 13C NMR (101 MHz, CDCl3) 
δ 201.5 (-), 161.0 (-), 148.2 (-), 146.4 (+), 134.6 (+), 127.7 (+), 127.5 (+), 126.7 (+), 121.8 
(-), 66.8 (-), 61.3 (-), 53.6 (-), 49.8 (-). IR (FTIR, cm-1) 2923, 2852, 1735, 1672, 1612, 
1564, 1474, 1363, 1324, 1296, 1115, 776, 698. HRMS calcd for C15H17N3O3 (MH+) 
288.1343, found 288.1338. 
 
Synthesis of 3-[3-(dimethylamino)-2-oxopropyl]quinazolin-4(3H)-one (331) 
 
Reaction of 3-[3-(dimethylamino)-2-hydroxypropyl]quinazolin-4(3H)-one 281 (0.300 g, 
1.20 mmol, 1.0 eq), trifluoroacetic acid (0.10 mL, 1.32 mmol, 1.1 eq), oxalyl chloride (0.12 
mL, 1.44 mmol, 1.2 eq), dimethyl sulfoxide (0.21 mL, 3.00 mmol, 2.5 eq) and 
triethylamine (0.70 mL, 5.04 mmol, 4.2 eq) in dichloromethane (18 mL) for 4 h as 
described in General Procedure Q gave, after work-up and chromatography (silica gel, 
10% MeOH, dichloromethane), the title compound as a pale yellow oil (0.129 g, 44%) 1H 
NMR (400 MHz, CDCl3) δ 8.26 (dd, J = 8.0, 1.5 Hz, 1H), 7.92 (s, 1H), 7.76 (ddd, J = 8.0, 
7.0, 1.5 Hz, 1H), 7.71 (dd, J = 8.0, 1.5 Hz, 1H), 7.49 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 4.93 
(s, 2H), 3.51 (s, 2H), 2.65 (s, 3H), 1.82 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 202.0 (-), 
161.0 (-), 148.2 (-), 146.4 (+), 134.6 (+), 127.7 (+), 127.5 (+), 126.7 (+), 121.8 (-), 61.3 (-
), 53.6 (-), 44.8 (+). IR (FTIR, cm-1) 2979, 1737, 1671, 1610, 1562, 1473, 1369, 1324, 






Synthesis of 3-[2-oxo-3-(pyrrolidin-1-yl)propyl]quinazolin-4(3H)-one (333) 
 
Reaction of 3-[2-hydroxy-3-(pyrrolidin-1-yl)propyl]quinazolin-4(3H)-one 283 (0.328 g, 
1.20 mmol, 1.0 eq), trifluoroacetic acid (0.10 mL, 1.32 mmol, 1.1 eq), oxalyl chloride (0.12 
mL, 1.44 mmol, 1.2 eq), dimethyl sulfoxide (0.21 mL, 3.00 mmol, 2.5 eq) and 
triethylamine (0.70 mL, 5.04 mmol, 4.2 eq) in dichloromethane (18 mL) for 4 h as 
described in General Procedure Q gave, after work-up and chromatography (silica gel, 
10% MeOH, dichloromethane), the title compound as a pale yellow oil (0.112 g, 34%) 1H 
NMR (400 MHz, CDCl3) δ 8.28 (dd, J = 8.0, 1.5 Hz, 1H), 7.94 (s, 1H), 7.80 (ddd, J = 8.0, 
7.0, 1.5 Hz, 1H), 7.75 (dd, J = 8.0, 1.5 Hz, 1H), 7.53 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 4.94 
(s, 2H), 3.45 (s, 2H), 3.17 – 3.11 (m, 4H), 1.37 – 1.33 (m, 4H). 13C NMR (101 MHz, 
CDCl3) δ 196.4 (-), 162.8 (-), 148.8 (-), 143.9 (+), 134.8 (+), 127.6 (+), 127.3 (+), 126.4 
(+), 122.6 (-), 63.1 (-), 53.1 (-), 45.7 (-), 24.8 (-). IR (FTIR, cm-1) 2994, 1744, 1670, 1612, 
1475, 1201, 1180, 1134, 906, 724, 699. HRMS calcd for C15H17N3O2 (MH+) 272.1394, 
found 272.1396. 
 
Synthesis of 3-(5-ethyl-3-oxoheptyl)quinazolin-4(3H)-one (334) 
 
Reaction of 3-(4-(diethylamino)-3-hydroxybutyl)quinazolin-4(3H)-one 299 (0.181 g, 0.63 
mmol, 1.0 eq), trifluoroacetic acid (0.05 mL, 0.69 mmol, 1.1 eq), oxalyl chloride (0.06 mL, 
0.76 mmol, 1.2 eq), dimethyl sulfoxide (0.11 mL, 1.58 mmol, 2.5 eq) and triethylamine 
(0.37 mL, 2.65 mmol, 4.2 eq) in dichloromethane (12 mL) for 4 h as described in General 
Procedure Q gave, after work-up and chromatography (silica gel, 10% MeOH, 




MHz, CDCl3) δ 8.29 (dd, J = 8.0, 1.5 Hz, 1H), 8.24 (s, 1H), 7.76 (ddd, J = 8.0, 7.0, 1.5 
Hz, 1H), 7.71 (dd, J = 8.0, 1.5 Hz, 1H), 7.50 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 4.25 (t, J = 
6.0 Hz, 2H), 3.18 (s, 2H), 3.14 (t, J = 6.0 Hz, 2H), 2.50 (q, J = 7.0 Hz, 4H), 0.97 (t, J = 
7.0 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 209.2 (-), 161.3 (-), 148.1 (-), 147.5 (+), 134.2 
(+), 127.4 (+), 127.2 (+),126.5 (+), 122.0 (-), 63.6 (-), 48.2 (-), 42.3 (-), 38.4 (-), 11.5 (+). 
IR (FTIR, cm-1) 2987, 2933, 1722, 1664, 1609, 1563, 1473, 1373, 1323, 1157, 773, 732, 
697. HRMS calcd for C16H21N3O2 (MH+) 288.1707, found 288.1709. 
 
Synthesis of 3-[3-oxo-4-(piperidin-1-yl)butyl]quinazolin-4(3H)-one (335) 
 
Reaction of 3-(3-hydroxy-4-(piperidin-1-yl)butyl)quinazolin-4(3H)-one 302 (0.207 g, 0.69 
mmol, 1.0 eq), trifluoroacetic acid (0.06 mL, 0.76 mmol, 1.1 eq), oxalyl chloride (0.07 mL, 
0.83 mmol, 1.2 eq), dimethyl sulfoxide (0.12 mL, 1.73 mmol, 2.5 eq) and triethylamine 
(0.40 mL, 2.90 mmol, 4.2 eq) in dichloromethane (12 mL) for 4 h as described in General 
Procedure Q gave, after work-up and chromatography (silica gel, 10% MeOH, 
dichloromethane), the title compound as a pale yellow oil (0.128 g, 62%) 1H NMR (400 
MHz, CDCl3) δ 8.29 (dd, J = 8.0, 1.5 Hz, 1H), 8.24 (s, 1H), 7.76 (ddd, J = 8.5, 7.0, 1.5 
Hz, 1H), 7.71 (dd, J = 8.0, 1.5 Hz, 1H), 7.50 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 4.25 (t, J = 
6.0 Hz, 2H), 3.13 – 3.09 (m, 4H), 2.37 – 2.30 (m, 4H), 1.58 – 1.52 (m, 4H), 1.42 – 1.36 
(m, 2H). 13C NMR (101 MHz, CDCl3) δ 207.6 (-), 161.3 (-), 148.2 (-), 147.5 (+), 134.2 (+), 
127.5 (+), 127.2 (+), 126.5 (+), 122.0 (-), 68.6 (-), 54.9 (-), 42.3 (-), 38.5 (-), 25.7 (-), 23.7 
(-). IR (FTIR, cm-1) 2964, 1705, 1662, 1612, 1590, 1472, 1383, 1201, 1182, 1133, 721, 








Synthesis of 3-[4-(morpholin-4-yl)-3-oxobutyl]quinazolin-4(3H)-one (336) 
 
Reaction of 3-(3-hydroxy-4-morpholinobutyl)quinazolin-4(3H)-one 303 (0.250 g, 0.82 
mmol, 1.0 eq), trifluoroacetic acid (0.07 mL, 0.90 mmol, 1.1 eq), oxalyl chloride (0.08 mL, 
0.98 mmol, 1.2 eq), dimethyl sulfoxide (0.15 mL, 2.05 mmol, 2.5 eq) and triethylamine 
(0.48 mL, 3.44 mmol, 4.2 eq) in dichloromethane (12 mL) for 4 h as described in General 
Procedure Q gave, after work-up and chromatography (silica gel, 10% MeOH, 
dichloromethane), the title compound as a pale yellow oil (0.160 g, 65%) 1H NMR (400 
MHz, CDCl3) δ 8.23 (dd, J = 8.0, 1.5 Hz, 1H), 8.19 (s, 1H), 7.72 (ddd, J = 8.0, 7.0, 1.5 
Hz, 1H), 7.66 (dd, J = 8.0, 1.5 Hz, 1H), 7.46 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 4.21 (t, J = 
6.0 Hz, 2H), 3.65 – 3.62 (m, 4H), 3.12 (s, 2H), 3.07 (t, J = 6.0 Hz, 2H), 2.42 – 2.37 (m, 
4H). 13C NMR (101 MHz, CDCl3) δ 206.4 (-), 161.2 (-), 148.1 (-), 147.4 (+), 134.3 (+), 
127.5 (+), 127.2 (+), 126.3 (+), 121.9 (-), 67.8 (-), 66.6 (-), 53.7 (-), 42.3 (-), 38.5 (-). IR 
(FTIR, cm-1) 2972, 2861, 2811, 1719, 1669, 1610, 1562, 1473, 1378, 1265, 1115, 776, 
731, 699. HRMS calcd for C16H19N3O3 (MH+) 302.1499, found 302.1497. 
 
Synthesis of 3-[4-(dimethylamino)-3-oxobutyl]quinazolin-4(3H)-one (337) 
 
Reaction of 3-(4-(dimethylamino)-3-hydroxybutyl)quinazolin-4(3H)-one 298 (0.138 g, 
0.52 mmol, 1.0 eq), trifluoroacetic acid (0.04 mL, 0.57 mmol, 1.1 eq), oxalyl chloride (0.05 
mL, 0.62 mmol, 1.2 eq), dimethyl sulfoxide (0.09 mL, 1.30 mmol, 2.5 eq) and 
triethylamine (0.30 mL, 2.18 mmol, 4.2 eq) in dichloromethane (12 mL) for 4 h as 
described in General Procedure Q gave, after work-up and chromatography (silica gel, 
10% MeOH, dichloromethane), the title compound as a pale yellow oil (0.044 g, 33%). 




Hz, 1H), 7.70 (dd, J = 8.0, 1.5 Hz, 1H), 7.50 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 4.25 (t, J = 
6.0 Hz, 2H), 3.16 (s, 2H), 3.08 (t, J = 6.0 Hz, 2H), 2.27 (s, 6H). 13C NMR (101 MHz, 
CDCl3) δ 206.6 (-), 161.3 (-), 148.1 (-), 147.4 (+), 134.3 (+), 127.5 (+), 127.2 (+), 126.5 
(+), 121.9 (-), 68.6 (-), 43.4 (-), 38.5 (-), 8.5 (+). IR (FTIR, cm-1) 2993, 2690, 1719, 1669, 
1612, 1565, 1383, 1200, 1178, 1128, 799, 776, 720, 699. HRMS calcd for C14H17N3O2 
(MH+) 260.1394, found 260.1391. 
 
Synthesis of 3-[3-oxo-4-(pyrrolidin-1-yl)butyl]quinazolin-4(3H)-one (339) 
 
Reaction of 3-(3-hydroxy-4-(pyrrolidin-1-yl)butyl)quinazolin-4(3H)-one 301 (0.156 g, 0.54 
mmol, 1.0 eq), trifluoroacetic acid (0.05 mL, 0.59 mmol, 1.1 eq), oxalyl chloride (0.06 mL, 
0.65 mmol, 1.2 eq), dimethyl sulfoxide (0.10 mL, 1.35 mmol, 2.5 eq) and triethylamine 
(0.31 mL, 2.27 mmol, 4.2 eq) in dichloromethane (12 mL) for 4 h as described in General 
Procedure Q gave, after work-up and chromatography (silica gel, 10% MeOH, 
dichloromethane), the title compound as a pale yellow oil (0.112 g, 34%). 1H NMR (400 
MHz, CDCl3) δ 8.30 (dd, J = 8.0, 1.5 Hz, 1H), 8.25 (s, 1H), 7.77 (ddd, J = 8.0, 7.0, 1.5 
Hz, 1H), 7.72 (dd, J = 8.0, 1.5 Hz, 1H), 7.51 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 4.27 (t, J = 
6.0 Hz, 2H), 3.37 (s, 2H), 3.10 (t, J = 6.0 Hz, 2H), 2.63 – 2.53 (m, 4H), 1.85 – 1.74 (m, 
4H). 13C NMR (101 MHz, CDCl3) δ 206.5 (-), 161.3 (-), 148.2 (-), 147.4 (+), 134.3 (+), 
127.6 (+), 127.2 (+), 126.4 (+), 122.0 (-), 65.3 (-), 54.3 (-), 42.3 (-), 38.5 (-), 23.7 (-). IR 
(FTIR, cm-1) 2954, 2865, 1719, 1667, 1610, 1474, 1372, 1265, 775, 731, 698. HRMS 









General Procedure R: Synthesis of 4-[2-(oxiran-2-yl)ethyl]morpholine (342)187 
 
Potassium carbonate (0.341 g, 2.47 mmol, 1.3 eq.) was added to a solution of 2-(4-
bromoethyl)oxirane 297 (0.287 g, 1.90 mmol, 1 eq.) in acetonitrile (10 mL). Morpholine 
(0.16 mL, 1.90 mmol, 1 eq.) was added and the reaction mixture was stirred at 80 °C 
under a stream of N2 for 2 h. Water (20 mL) was added and then the product was 
extracted with dichloromethane (3 x 20 mL). The combined organic layers were dried 
with MgSO4 before filtering and removing the solvent in vacuo, giving the title compound 
as a pale yellow oil (0.212 g, 71%), which was used without further purification. 1H NMR 
(400 MHz, CDCl3) δ 3.79 – 3.66 (m, 4H), 3.02 – 2.93 (m, 1H), 2.78 (dd, J = 4.5, 4.5 Hz, 
1H), 2.56 – 2.44 (m, 7H), 1.86 – 1.75 (m, 1H), 1.62- 1.70 (m, 1H). 13C NMR (101 MHz, 
CDCl3) δ, 66.9 (-), 55.4 (-), 53.7 (-), 50.8 (+), 47.1 (-), 29.8 (-). 
 
Synthesis of N,N-diethyl-2-(oxiran-2-yl)ethanamine (344) 
 
Reaction of 2-(4-bromoethyl)oxirane 297 (0.453 g, 3.00 mmol, 1 eq.), potassium 
carbonate (0.539 g, 3.90 mmol, 1.3 eq.) and diethylamine (0.26 mL, 3.00 mmol, 1 eq.) in 
acetonitrile (20 mL) as described in General Procedure R gave, after work-up, the title 
compound as a pale yellow oil (0.258 g, 60%). 1H NMR (400 MHz, CDCl3) δ 3.00 – 2.96 
(m, 1H), 2.80 – 2.77 (m, 1H), 2.65 – 2.59 (m, 3H), 2.55 (q, J = 7.0 Hz, 4H), 1.81 – 1.70 
(m, 1H), 1.70 – 1.59 (m, 1H), 1.05 (t, J = 7.0 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 51.2 
(+), 49.4 (-), 47.2 (-), 46.9 (-), 30.4 (-), 11.8 (+). IR (FTIR, cm-1) 2925, 1720, 1575, 1467, 






Synthesis of 1-[2-(oxiran-2-yl)ethyl]piperidine (343) 
 
Reaction of 2-(4-bromoethyl)oxirane 297 (0.453 g, 3.00 mmol, 1 eq.), potassium 
carbonate (0.539 g, 3.90 mmol, 1.3 eq.) and piperidine (0.30 mL, 3.00 mmol, 1 eq.) in 
acetonitrile (20 mL) as described in General Procedure R gave, after work-up, the title 
compound as a pale yellow oil (0.316 g, 68%) 1H NMR (400 MHz, CDCl3) δ 3.00 – 2.95 
(m, 1H), 2.80 – 2.76 (m, 1H), 2.53 – 2.47 (m, 3H), 2.45 – 2.35 (m, 4H), 1.84 – 1.67 (m, 
2H), 1.64 – 1.54 (m, 4H), 1.51 – 1.36 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 55.7 (-), 
54.6 (-), 51.1 (+), 47.1 (-), 30.2 (-), 25.8 (-), 24.4 (-). IR (FTIR, cm-1) 2930, 2853, 2807, 
1647, 1443, 1376, 1351, 1273, 1118, 1038, 863. HRMS calcd for C9H17NO (MH+) 
157.1415, found 157.1416. 
 
Synthesis of 3-[2-hydroxy-4-(morpholin-4-yl)butyl]quinazolin-4(3H)-one (325) 
 
Quinazolinone (0.073 g, 0.50 mmol, 1 eq.) was dissolved in EtOH (3 mL) and then 4’-(4-
(oxiran-2-yl)ethyl)morpholine 342 (0.095 g, 0.6 mmol, 1.2 eq.) in EtOH (2 mL) was 
added. Triethylamine (0.14 mL, 1 mmol, 2 eq.) was added and the reaction mixture was 
heated at 60 °C under a stream of N2 for 18 h. The reaction mixture was cooled down to 
room temperature and then the solvent was removed in vacuo. The crude product was 
purified by flash column chromatography (silica gel, 5% methanol/dichloromethane) to 






Synthesis of 3-[2-hydroxy-4-(morpholin-4-yl)butyl]quinazolin-4(3H)-one (325) 
 
Quinazolinone (0.078 g, 0.53 mmol, 1 eq.) was dissolved in EtOH (3 mL) and then a 
mixture of 4’-(4-(oxiran-2-yl)ethyl)morpholine 342 (0.063 g, 0.4 mmol, 0.75 eq.) and 4’-
(4-(oxiran-2-yl)ethyl)piperidine 343 (0.062 g, 0.4 mmol, 0.75 eq.)  in EtOH (2 mL) was 
added. Triethylamine (0.15 mL, 1.07 mmol, 2 eq.) was added and the reaction mixture 
was heated at 60 °C under a stream of N2 for 18 h. The reaction mixture was cooled 
down to room temperature and then the solvent was removed in vacuo. The crude 
product was purified by flash column chromatography (silica gel, 5% 
methanol/dichloromethane) to afford the title compound as a pale yellow oil (0.036 g, 
23%). See page 224 for data. 
 
General Procedure S: Synthesis of 4-(diethylamino)butan-2-one (352)162 
 
 
Silicon tetrachloride (0.12 mL, 1.0 mmol, 0.02 eq.) was added to a mixture of methyl vinyl 
ketone (4.2 mL, 50 mmol, 1.0 eq.) and diethylamine (5.4 mL, 52 mmol, 1.04 eq.) at 0 °C. 
The reaction mixture was stirred at 60 °C under a stream of N2 for 4 h. Water was added 
and the product was extracted with EtOAc (3 x 20 mL). The combined organic layers 
were dried over MgSO4 before filtering and removing the solvent in vacuo. The title 
compound was obtained as a dark red oil (5.2 g, 73%). 1H NMR (400 MHz, CDCl3) δ 
2.69 (t, J = 7.5 Hz, 2H), 2.53 (t, J = 7.5 Hz, 2H), 2.45 (q, J = 7.0 Hz, 4H), 2.11 (s, 3H), 
0.96 (t, J = 7.0 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 208.5 (-), 47.3 (-), 46.8 (-), 41.4 (-




Synthesis of 4-(morpholin-4-yl)butan-2-one (353)162 
 
Reaction of silicon tetrachloride (0.12 mL, 1.0 mmol, 0.02 eq.), methyl vinyl ketone (4.2 
mL, 50 mmol, 1.0 eq.) and morpholine (4.5 mL, 52 mmol, 1.04 eq.) as described in 
General Procedure S gave, after work-up, the title compound as a yellow-orange oil (5.0 
g, 64%). 1H NMR (400 MHz, CDCl3) δ 3.63 – 3.57 (m, 4H), 2.57 – 2.55 (m, 4H), 2.40 – 
2.33 (m, 4H), 2.10 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 207.7 (-), 66.9 (-), 53.5 (-), 53.1 
(-), 40.9 (-), 30.1 (+). 
 
Synthesis of N,N-diethyl-3-[(trimethylsilyl)oxy]- 3-buten-1-amine (354)163 
 
LDA (2.4 mmol) was prepared by adding n-BuLi (2.5 M in hexanes, 0.96 mL) to a solution 
of diisopropylamine (0.37 mL) in THF (5 mL) at -78 oC for 5 min then allowing to warm to 
0 C for 5 mins. Chlorotrimethylsilane (0.15 mL, 1.2 mmol, 1.2 eq.) was added at -78 C 
then 4-(diethylamino)butan-2-one (0.143 g, 1.0 mmol, 1.0 eq.) in THF (1 mL) was added. 
The reaction mixture was stirred at -78 °C under a stream of N2 for 0.5 h. Aqueous 
saturated NaHCO3 solution (10 mL) and brine (10 mL) were added and the product was 
extracted with pentane (3 x 20 mL). The combined organic layers were dried with Na2SO4 
before filtering and removing the solvent in vacuo. The title compound was obtained as 
a yellow oil (0.210 g, 98%). 1H NMR (400 MHz, CDCl3) δ 4.09 (s, 1H), 4.08 (s, 1H) 2.71 
– 2.61 (m, 2H), 2.55 (q, J = 7.0 Hz, 4H), 2.23 – 2.15 (m, 2H), 1.06 (t, J = 7.0 Hz, 6H), 







Synthesis of 2-(1-bromoethyl)-2-(bromomethyl)-1,3-dioxolane (360)164 
 
2-Ethyl-2-methyl-1,3-dioxolane 359 (11.6 g, 100 mmol, 1.0 eq.) was dissolved in 
dichloromethane (100 mL) and then bromine (10. 3 mL, 200 mmol, 2.0 eq.) was added 
dropwise over 20 mins. The reaction mixture was stirred at reflux under a stream of N2 
for 5 h. Ice-cold H2O (200 mL) was added and sodium bisulfite was added until the yellow 
colour of unreacted bromine had disappeared. The organic phase was separated and 
washed with ice-cold H2O (200 mL) and aqueous saturated NaHCO3 solution (200 mL). 
The organic phase was dried with MgSO4 before filtering and removing the solvent in 
vacuo. The title compound was obtained as a pale yellow oil (2.7 g, 99%). 1H NMR (400 
MHz, CDCl3) δ 4.48 (q, J = 7.0 Hz, 1H), 4.23 – 4.14 (m, 4H), 3.82 (d, J = 11.0 Hz, 1H), 
3.60 (d, J = 11.0 Hz, 1H), 1.73 (d, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 108.6 
(-), 69.1 (-), 67.1 (-), 50.0 (+), 34.4 (-), 20.2 (+). 
 
Synthesis of 2-(bromomethyl)-2-ethenyl-1,3-dioxolane (361)164 
 
Potassium tert-butoxide (1.02 g, 9.1 mmol, 1.4 eq.) was suspended in THF (8 mL) and 
then 2-(1-bromoethyl)-2-(bromomethyl)-1,3-dioxolane 360 (1.78 g, 6.5 mmol, 1.0 eq.) in 
THF (2 mL) was added dropwise over 10 mins. The reaction mixture was stirred at 50 
°C under a stream of N2 for 1 h. The reaction mixture was cooled to rt and the solvent 
was removed to reveal a brown residue. Water (30 mL) was added and the product was 
extracted with diethyl ether (3 x 20 mL). The organic phase was washed with brine (10 
mL) and then dried with MgSO4 before filtering and removing the solvent in vacuo. The 
title compound was obtained as a yellow oil (0.765 g, 61%). 1H NMR (400 MHz, CDCl3) 




Hz, 1H), 4.13 – 4.10 (m, 2H), 4.00 – 3.97 (m, 2H), 3.50 (s, 2H). 13C NMR (101 MHz, 
CDCl3) δ 134.9 (+), 117.8 (-), 106.1 (-), 66.6 (-), 36.3 (-). 
  
Synthesis of 1-bromobut-3-en-2-one (358)164 
 
2-(Bromomethyl)-2-ethenyl-1,3-dioxolane 361 (0.772 g, 4.0 mmol, 1.0 eq.) was dissolved 
in pentane (4 mL) and then formic acid (1.5 mL, 40 mmol, 10 eq.) was added. The 
reaction mixture was stirred at 40 °C under a stream of N2 for 6 h. Water (20 mL) was 
added and the product was extracted with pentane (3 x10 mL). MgO2 (5 mg) and 
hydroquinone (5 mg) were added to the organic phase before removing the solvent in 
vacuo. The title compound was obtained as a pale yellow oil (0.337 g, 57%). 1H NMR 
(400 MHz, CDCl3) δ 6.58 (dd, J = 17.5, 10.5 Hz, 1H), 6.40 (dd, J = 17.5, 1.0 Hz, 1H), 
5.97 (dd, J = 10.5, 1.0 Hz, 1H), 4.06 (s, 2H). 
 
Synthesis of 3-(2-oxopropyl)quinazolin-4(3H)-one (372)188 
 
 
Quinazolinone (1.46 g, 10 mmol, 1.0 eq.) and potassium carbonate (2.07 g, 15 mmol, 
1.5 eq.) were suspended in acetone (100 mL) and then chloroacetone (1.2 mL, 15 mmol, 
1.5 eq.) was added. The reaction mixture was heated at reflux with stirring under a 
stream of N2 for 18 h. The reaction mixture was cooled down to rt and then filtered under 
vacuum. The solid was washed with dichloromethane (3 x 20 mL) and then added to the 
initial filtrate. The solvent was removed in vacuo to reveal the crude product which was 
recrystallized with EtOH to obtain the title product as an off-white solid (1.40 g, 69%). 
M.p. 158 – 160 °C (lit: 158 °C).188 1H NMR (400 MHz, CDCl3) δ 8.31 (dd, J = 8.0, 1.5 Hz, 




(ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 4.82 (s, 2H), 2.38 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
200.0 (-), 160.9 (-), 148.1 (-), 146.2 (+), 134.6 (+), 127.6 (+), 127.5 (+), 126.8 (+), 121.9 
(-), 54.7 (-), 27.5 (+). 
 
General Procedure T: Synthesis of 3-[3-(diethylamino)-2-fluoropropyl]quinazolin-
4(3H)-one (375) 
 
3-[3-(Diethylamino)-2-hydroxypropyl]quinazolin-4(3H)-one 278 (0.80 g, 0.28 mmol, 1.0 
eq.) was dissolved in dichloromethane (0.5 mL) and then Deoxo-Fluor (0.36 mL, 50% in 
THF, 0.84 mmol, 3.0 eq.) was added dropwise at -78 °C. The reaction mixture was 
allowed to warm to rt and stirred under a stream of N2 for 18 h. Aqueous saturated 
NaHCO3 solution (10 mL) was added and the product extracted with dichloromethane (3 
x 10 mL). The organic phase was dried with MgSO4 before filtering and removing the 
solvent in vacuo. The crude product was purified by flash column chromatography (silica 
gel, 5% MeOH, dichloromethane) to afford the title compound as a pale yellow oil (0.044 
g, 55%). 1H NMR (400 MHz, CDCl3) δ 8.33 (dd, J = 8.0, 1.5 Hz, 1H), 8.09 (s, 1H), 7.80 
(ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 7.75 (dd, J = 8.0, 1.5 Hz, 1H), 7.54 (ddd, J = 8.0, 7.0, 1.5 
Hz, 1H), 5.07 – 4.85 (m, 1H), 4.66 (ddd, J = 32.0, 14.5, 2.5 Hz, 1H), 3.90 (ddd, J = 15.0, 
14.5, 8.5 Hz, 1H), 2.80 (dd, J = 20.0, 5.0 Hz, 2H), 2.70 – 2.56 (m, 4H), 1.07 (t, J = 7.0 
Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 161.3 (-), 148.2 (-), 147.0 (+), 134.4 (+), 127.6 
(+), 127.3 (+), 126.7 (+), 122.0 (-), 90.5 (d, JCF = 173.7 Hz, +),  54.4 (d, JCF = 21.2 Hz, -
), 49.4 (d, JCF = 20.2 Hz, -), 47.9 (-), 11.9 (+). 19F NMR (377 MHz, CDCl3) δ -188. 7. IR 
(FTIR, cm-1) 2966, 2934, 2820, 1670, 1609, 1564, 1473, 1368, 1322, 1293, 1035, 837, 






Synthesis of 3-[2-fluoro-3-(piperidin-1-yl)propyl]quinazolin-4(3H)-one (376) 
 
Reaction of 3-[2-hydroxy-3-(piperidin-1-yl)propyl]quinazolin-4(3H)-one 279 (0.100 g, 
0.36 mmol, 1.0 eq.) and Deoxo-Fluor (0.46 mL, 50% in THF, 1.1 mmol, 3.0 eq.) in 
dichloromethane (1 mL) for 18 h as described in General Procedure T gave, after work-
up and chromatography (silica gel, 5% MeOH, dichloromethane), the title compound as 
a yellow oil (0.063 g, 63%). 1H NMR (400 MHz, CDCl3) δ 8.33 (dd, J = 8.0, 1.5 Hz, 1H), 
8.11 (s, 1H), 7.79 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 7.74 (dd, J = 8.0, 1.5 Hz, 1H), 7.53 
(ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 5.16 – 4.89 (m, 1H), 4.60 (ddd, J = 30.0, 14.5, 3.0 Hz, 
1H), 3.97 (ddd, J = 16.0, 14.5, 8.0 Hz, 1H), 2.68 (dd, J = 22.0, 5.0 Hz, 2H), 2.57 – 2.41 
(m, 4H), 1.67 – 1.36 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 161.3 (-), 148.2 (-), 147.0 
(+), 134.4 (+), 127.6 (+), 127.3 (+), 126.7 (+), 122.0 (-), 89.7 (d, JCF = 174.7 Hz, +), 60.0 
(d, JCF = 21.2 Hz, -), 55.3 (-), 49.1 (d, JCF = 22.2 Hz, -), 26.0 (-), 24.0 (-).19F NMR (377 
MHz, CDCl3) δ -187.3. IR (FTIR, cm-1) 2966, 2934, 2820, 1670, 1610, 1564, 1474, 1370, 
1323, 1293, 1036, 844, 774, 733, 697. HRMS calcd for C16H20FN3O (MH+) 290.1663, 
found 290.1665. 
 
Synthesis of 3-[2-fluoro-3-(morpholin-4-yl)propyl]quinazolin-4(3H)-one (377) 
 
Reaction of 3-[2-hydroxy-3-(morpholin-4-yl)propyl]quinazolin-4(3H)-one 280 (0.087 g, 
0.30 mmol, 1.0 eq.) and Deoxo-Fluor (0.39 mL, 50% in THF, 0.9 mmol, 3.0 eq.) in 
dichloromethane (3 mL) for 18 h as described in General Procedure T gave, after work-
up and chromatography (silica gel, 5% MeOH, dichloromethane), the title compound as 
a light brown oil (0.063 g, 63%). 1H NMR (400 MHz, CDCl3) δ 8.30 (dd, J = 8.0, 1.5 Hz, 




(ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 5.13 – 4.92 (m, 1H), 4.58 (ddd, J = 30.0, 14.5, 3.0 Hz, 
1H), 4.00 (ddd, J = 16.0, 14.5, 8.0 Hz, 1H), 3.75 – 3.64 (m, 4H), 2.72 (dd, J = 22.0, 5.0, 
Hz, 2H), 2.63 – 2.51 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 161.3 (-), 148.1 (-), 146.9 
(+), 134.4 (+), 127.6 (+), 127.4 (+), 126.6 (+), 121.9 (-), 89.7 (d, JCF = 174.7 Hz, +), 66.9 
(-), 59.6 (d, JCF = 20.2 Hz, -), 54.3 (-), 49.0 (d, JCF = 21.2 Hz, -). 19F NMR (377 MHz, 
CDCl3) δ -187.8. IR (FTIR, cm-1) 2952, 2858, 2816, 1668, 1610, 1564, 1474, 1368, 1322, 
1293, 1115, 1007, 909, 774, 727, 697. HRMS calcd for C15H18FN3O2 (MH+) 292.1456, 
found 292.1455. 
 
Synthesis of 3-[3-(dimethylamino)-2-fluoropropyl]quinazolin-4(3H)-one (378) 
 
Reaction of 3-[3-(dimethylamino)-2-hydroxypropyl]quinazolin-4(3H)-one 281 (0.074 g, 
0.30 mmol, 1.0 eq.) and Deoxo-Fluor (0.39 mL, 50% in THF, 0.9 mmol, 3.0 eq.) in 
dichloromethane (3 mL) for 18 h as described in General Procedure T gave, after work-
up and chromatography (silica gel, 5% MeOH, dichloromethane), the title compound as 
a pale yellow oil (0.010 g, 13%). 1H NMR (400 MHz, CDCl3) δ 8.32 (dd, J = 8.0, 1.5 Hz, 
1H), 8.09 (s, 1H), 7.80 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 7.74 (dd, J = 8.0, 1.5 Hz, 1H), 7.54 
(ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 5.08 – 4.89 (m, 1H), 4.60 (ddd, J = 30.0, 14.5, 3.0 Hz, 
1H), 3.95 (ddd, J = 16.0, 14.5, 8.0 Hz, 1H), 2.71 – 2.62 (m, 2H), 2.35 (s, 6H). 13C NMR 
(101 MHz, CDCl3) δ 161.6 (-), 147.9 (+), 147.8 (-), 134.4 (+), 127.2 (+), 127.1 (+), 126.6 
(+), 121.7 (-), 89.6 (d, JCF = 174.7 Hz, +), 60.2 (d, JCF = 20.2 Hz, -), 49.9 (d, JCF = 21.2 
Hz, -), 45.5 (+).19F NMR (377 MHz, CDCl3) δ -188.4. IR (FTIR, cm-1) 2944, 2830, 2770, 
1672, 1611, 1564, 1474, 1363, 1323, 1294, 1104, 1035, 776, 730, 697. HRMS calcd for 








Synthesis of 3-[2-fluoro-3-(pyrrolidin-1-yl)propyl]quinazolin-4(3H)-one (380) 
 
 
Reaction of 3-[2-hydroxy-3-(pyrrolidin-1-yl)propyl]quinazolin-4(3H)-one 283 (0.082 g, 
0.30 mmol, 1.0 eq.) and Deoxo-Fluor (0.39 mL, 50% in THF, 0.9 mmol, 3.0 eq.) in 
dichloromethane (3 mL) for 18 h as described in General Procedure T gave, after work-
up and chromatography (silica gel, 5% MeOH, dichloromethane), the title compound as 
a pale yellow oil (0.020 g, 24%). 1H NMR (400 MHz, CDCl3) δ 8.32 (dd, J = 8.0, 1.5 Hz, 
1H), 8.10 (s, 1H), 7.79 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 7.74 (dd, J = 8.0, 1.5 Hz, 1H), 7.53 
(ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 5.09 – 4.91 (m, 1H), 4.60 (ddd, J = 30.0, 14.5, 3.0 Hz, 
1H), 4.00 (ddd, J = 16.0, 14.5, 8.0 Hz, 1H), 2.84 (dd, J = 22.0, 5.0 Hz, 2H), 2.71 – 2.55 
(m, 4H), 1.86 – 1.72 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 161.7 (-), 151.8 (-), 147.5 
(+), 134.6 (+), 127.7 (+), 127.4 (+), 126.7 (+), 118.3 (-), 90.8 (d, JCF = 174.7 Hz, +), 63.4 
(d, JCF = 21.2 Hz, -), 56.3 (d, JCF = 22.2 Hz, -), 54.9 (-), 23.6 (-). 19F NMR (377 MHz, 
CDCl3) δ -188.4. IR (FTIR, cm-1) 2941, 1670, 1612, 1540, 1475, 1375, 1323, 1264, 1107, 
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Table 1.  Crystal data and structure refinement for zhu1_0m. 
Identification code  zhu1_0m 
Empirical formula  C17 H13 N O2 
Formula weight  263.28 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P 21/c 
Unit cell dimensions a = 5.5472(3) Å a= 90°. 
 b = 30.6096(15) Å b= 93.921(3)°. 
 c = 7.4225(3) Å g = 90°. 
Volume 1257.37(10) Å3 
Z 4 
Density (calculated) 1.391 Mg/m3 
Absorption coefficient 0.737 mm-1 
F(000) 552 
Crystal size 0.190 x 0.100 x 0.020 mm3 
Theta range for data collection 2.887 to 66.752°. 
Index ranges -6<=h<=6, -36<=k<=36, -8<=l<=8 
Reflections collected 15694 
Independent reflections 2226 [R(int) = 0.1016] 
Completeness to theta = 67.679° 97.4 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7528 and 0.6178 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2226 / 0 / 182 
Goodness-of-fit on F2 1.163 
Final R indices [I>2sigma(I)] R1 = 0.0706, wR2 = 0.1753 
R indices (all data) R1 = 0.1047, wR2 = 0.1905 
Extinction coefficient n/a 




Table 2.  Atomic coordinates ( x 104) and equivalent  isotropic displacement 
parameters (Å2x 103) for zhu1_0m.  U(eq) is defined as one third of  the trace of the 
orthogonalized Uij tensor. 
_____________________________________________________________________ 
 x y z U(eq) 
_____________________________________________________________________  
O(1) 8357(5) 7468(1) 9646(3) 26(1) 
O(2) 1200(5) 6651(1) 6544(4) 30(1) 
N(1) 2912(6) 7502(1) 7016(4) 22(1) 
C(1) 4727(7) 7256(1) 7856(5) 22(1) 
C(2) 6544(7) 7578(1) 8734(5) 22(1) 
C(3) 5563(7) 8009(1) 8298(5) 22(1) 
C(4) 3334(7) 7948(1) 7284(5) 22(1) 
C(5) 1909(7) 8300(1) 6754(5) 23(1) 
C(6) 2701(7) 8718(1) 7220(5) 24(1) 
C(7) 4948(7) 8778(1) 8193(5) 25(1) 
C(8) 6377(7) 8426(1) 8736(5) 23(1) 
C(9) 1162(8) 9115(1) 6726(5) 28(1) 
C(10) 4971(7) 6823(1) 7973(5) 22(1) 
C(11) 3142(7) 6516(1) 7262(5) 23(1) 
C(12) 3589(7) 6037(1) 7398(5) 24(1) 
C(13) 5742(8) 5858(2) 8155(6) 32(1) 
C(14) 6046(9) 5412(2) 8252(7) 39(1) 
C(15) 4233(9) 5131(2) 7610(6) 40(1) 
C(16) 2089(9) 5306(2) 6845(6) 37(1) 





 Table 3.   Bond lengths [Å] and angles [°] for  zhu1_0m. 
_____________________________________________________  
O(1)-C(2)  1.222(5) 
O(2)-C(11)  1.239(5) 
N(1)-C(1)  1.372(5) 
N(1)-C(4)  1.395(5) 
N(1)-H(1)  0.8800 
C(1)-C(10)  1.336(6) 
C(1)-C(2)  1.524(5) 
C(2)-C(3)  1.455(6) 
C(3)-C(8)  1.383(6) 
C(3)-C(4)  1.415(5) 
C(4)-C(5)  1.379(6) 
C(5)-C(6)  1.390(6) 
C(5)-H(5)  0.9500 
C(6)-C(7)  1.409(5) 
C(6)-C(9)  1.515(6) 
C(7)-C(8)  1.382(6) 
C(7)-H(7)  0.9500 
C(8)-H(8)  0.9500 
C(9)-H(9A)  0.9800 
C(9)-H(9B)  0.9800 
C(9)-H(9C)  0.9800 
C(10)-C(11)  1.455(5) 
C(10)-H(10)  0.9500 
C(11)-C(12)  1.488(6) 
C(12)-C(13)  1.397(6) 
C(12)-C(17)  1.405(6) 
C(13)-C(14)  1.378(6) 
C(13)-H(13)  0.9500 
C(14)-C(15)  1.382(7) 
C(14)-H(14)  0.9500 
C(15)-C(16)  1.389(7) 
C(15)-H(15)  0.9500 
C(16)-C(17)  1.375(6) 
C(16)-H(16)  0.9500 







































































Table 4.   Anisotropic displacement parameters (Å2x 103) for zhu1_0m.  The 
anisotropic displacement factor exponent takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k 
a* b* U12 ] 
_____________________________________________________________________ 
 U11 U22  U33 U23 U13 U12 
_____________________________________________________________________ 
O(1) 22(2)  39(2) 17(1)  -1(1) -5(1)  1(1) 
O(2) 24(2)  38(2) 27(2)  -3(1) -8(1)  0(1) 
N(1) 15(2)  32(2) 16(2)  1(1) -4(1)  1(1) 
C(1) 17(2)  37(3) 11(2)  -1(2) 0(1)  -1(2) 
C(2) 20(2)  36(2) 10(2)  -1(2) 1(2)  -1(2) 
C(3) 20(2)  35(2) 11(2)  2(2) 2(1)  0(2) 
C(4) 21(2)  34(2) 9(2)  -1(2) 2(1)  -2(2) 
C(5) 21(2)  34(2) 15(2)  1(2) 2(2)  2(2) 
C(6) 21(2)  40(3) 11(2)  2(2) 2(2)  1(2) 
C(7) 27(2)  31(2) 17(2)  1(2) 2(2)  -1(2) 
C(8) 19(2)  37(3) 12(2)  -2(2) 1(2)  -2(2) 
C(9) 23(2)  38(3) 21(2)  2(2) -3(2)  3(2) 
C(10) 16(2)  35(3) 16(2)  0(2) -2(2)  -2(2) 
C(11) 15(2)  44(3) 10(2)  -1(2) 0(1)  -1(2) 
C(12) 22(2)  37(2) 12(2)  -1(2) 1(2)  -4(2) 
C(13) 28(2)  36(3) 32(2)  1(2) -2(2)  -3(2) 
C(14) 31(3)  37(3) 48(3)  2(2) 0(2)  5(2) 
C(15) 51(3)  34(3) 36(3)  -3(2) 1(2)  0(2) 
C(16) 47(3)  42(3) 22(2)  -4(2) -3(2)  -13(2) 





Table 5.   Hydrogen coordinates (x 104) and isotropic  displacement parameters (Å2x 
10 3) for zhu1_0m. 
_____________________________________________________________________ 
 x  y  z  U(eq) 
_____________________________________________________________________ 
  
H(1) 1647 7393 6391 26 
H(5) 408 8258 6081 28 
H(7) 5490 9066 8482 30 
H(8) 7886 8469 9397 27 
H(9A) 1697 9246 5616 41 
H(9B) 1329 9329 7708 41 
H(9C) -534 9026 6534 41 
H(10) 6416 6708 8552 27 
H(13) 7007 6046 8608 39 
H(14) 7524 5295 8767 47 
H(15) 4449 4824 7692 48 
H(16) 837 5116 6389 45 













Table 6.  Hydrogen bonds for zhu1_0m  [Å and °]. 
_____________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
_____________________________________________________________________ 
 N(1)-H(1)...O(1)#1 0.88 2.21 2.980(4) 146.5 
 N(1)-H(1)...O(2) 0.88 2.29 2.787(4) 115.8 
_____________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 x-1,-y+3/2,z-1/2       
